var title_f17_60_18368="Subtle buckle fx";
var content_f17_60_18368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subtle distal radial buckle fracture in 10-year-old",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 525px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although the anteroposterior view of the radius appears relatively normal, a subtle buckle fracture is present on the lateral view (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18368=[""].join("\n");
var outline_f17_60_18368=null;
var title_f17_60_18369="Retrograde urethrogram with severe stricture";
var content_f17_60_18369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Retrograde urethrogram with severe stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18369=[""].join("\n");
var outline_f17_60_18369=null;
var title_f17_60_18370="Endosc eosinophil gastroent";
var content_f17_60_18370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic gastroenteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic photo of a patient with eosinophilic gastroenteritis involving the mucosa showing nodularity and polypoid mucosa of the antrum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nirmala Gonsalves, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18370=[""].join("\n");
var outline_f17_60_18370=null;
var title_f17_60_18371="Patterns of left ventricular remodeling";
var content_f17_60_18371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Patterns of left ventricular remodeling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 513px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIBAeADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDEsdPtruW+kuYy7i5dcl26DHvVr+xdP/AOff/wAfb/GjRv8Al+/6+pP6Vo0AZ39i6f8A8+//AI+3+NH9i6f/AM+//j7f41o0UAZ39i6f/wA+/wD4+3+NH9i6f/z7/wDj7f41o0UAZ39i6f8A8+//AI+3+NH9i6f/AM+//j7f41o0UAZ39i6f/wA+/wD4+3+NH9i6f/z7/wDj7f41o0UAZ39i6f8A8+//AI+3+NH9i6f/AM+//j7f41o1lXXiDS7TxDZaHcXiJq17G8tvblWzIi8sQcY4x3NAEn9i6f8A8+//AI+3+NH9i6f/AM+//j7f41o1znifxpovhrUdO0/U55vt2oE/Z7e3t3mdlGNzEIDtUZGScD8jQBpf2Lp//Pv/AOPt/jR/Yun/APPv/wCPt/jS6FrOna9py32j3cV3ZszIJYzwWUlWH4EEVoUAZ39i6f8A8+//AI+3+NH9i6f/AM+//j7f41o0UAZ39i6f/wA+/wD4+3+NH9i6f/z7/wDj7f40trrOnXWsXulW93FJqNkqPcQA/NErjKk/UUa3q1vo1olzdpcvG8qRAW8DzNljgEqoJA9T0FACf2Lp/wDz7/8Aj7f40f2Lp/8Az7/+Pt/jWjRQBnf2Lp//AD7/APj7f40f2Lp//Pv/AOPt/jUGgeI9N1+41WDTJmkk0u7ayugyFdkqgEgZ69RyK2KAM7+xdP8A+ff/AMfb/Gj+xdP/AOff/wAfb/GtGigDO/sXT/8An3/8fb/Gj+xdP/59/wDx9v8AGtGigDO/sXT/APn3/wDH2/xo/sXT/wDn3/8AH2/xrRooAzv7F0//AJ9//H2/xo/sXT/+ff8A8fb/ABrRooAzv7F0/wD59/8Ax9v8aP7F0/8A59//AB9v8a0aKAM7+xdP/wCff/x9v8aP7F0//n3/APH2/wAa0aKAM7+xdP8A+ff/AMfb/Gj+xdP/AOff/wAfb/GtGigDO/sXT/8An3/8fb/Gj+xdP/59/wDx9v8AGtGigDO8Pf8AIHt+ScBhyc/xGtGs7w9/yB7f/gX/AKEa0aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7Rv+X7/r6k/pWjWdo3/L9/19Sf0rRoAKKKKACiiigAooooAKKKKACvF/ifLfaN8bPB/iKPQdc1TTbOwuYpm0uxe5KM4IUHbwOvc17RRQB81fFaTWfFXiPS9TutM1q18KXGmvHFBd6XdyNa3QldWaSGCRHVyoBVmyMEcc5qfw54GuNV8deAbzXLTX72OLR5lur66S4tW8yOTEPmAP8hKgfKT8w5INfR1FAHh/7M2j22habf6fdaTrFh4gglmW6N2k6wtH5pMezcfLJxjleT1OepzvGfh7xU/xJvvDGnRaq3hjxJf2mpT38W/y7OOMObiLzBwhdkQgZHUDnNfQNFAHyt8RdH8SzePfEsmptrEFwblJNFvbLTby7ZIVAKpbtFKsSHswdepJzzmrHjXwp4gv9K+I2tx2XiR9etNUtZtE8k3C8FoxI0USna3BbJAOMdeK+oaKAPA5tAtdP+P3iW91DR9bY39vby6XdW4uGgMwjYSbmQ7eD/C/A7AZGcOy8H65Z/Bbw9fxweJn8T3F7areQSyXDyRxLcMT+6P3F24J4HBya+mKKAPA/sMQ+Kmuy+OdK8T32oNqcLaFcWaXD28Vvldu1kIRcHl93GM++eeebxMkM3h7+yPE7ahF43W+a4S1laH7EZOD5g42Y5x0xX07RQB83azYavp2hePTL4Zvr6G+8Yb8PBcbVtiozcBIiryoMdFbBJ64BrG0/QvFkPw/1/S7a28RCEeIrN7LZaXNu4tzje0aOWdEHfLHHfFfVVFAHNnQotC8Eajpujm8lxbztGZZ3nmZ2DH7zEsTk8c14N4Q+Hd7c6l4AXVrPxMkGqaVcpr7SXV2nzqMxJKdw8vnGF4BwODzX07RQB8tLZa9N8LPhxpPiLw9qk0rG9jurq6s7yeSzxKwiDQQvG5LKFClzgAcVnX2m+Jm+Gfg2LWY9ea4spb3fYX+nXksFwPMxEJvKYSKwX7mcjBOCMc/W1FAHyX4y0/X5LTw1cS6Hqz3EWkrGugXNtfTQLIZGOY54n3LLjaP3hyo25J7fU2giUaHpwuYXgnFtGJInfe0bbRlS3cg8Z71eooAKKKKACiiigAooooAKKKKACiiigDO8Pf8ge3/AOBf+hGtGs7w9/yB7f8A4F/6Ea0aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMPT/t/m332X7L5f2p/9Zuznj0q3/wATb/pw/wDH6NG/5fv+vqT+laNAGd/xNv8Apw/8fo/4m3/Th/4/WjRQBnf8Tb/pw/8AH6P+Jt/04f8Aj9aNFAGd/wATb/pw/wDH6P8Aibf9OH/j9aNFAGd/xNv+nD/x+j/ibf8ATh/4/WjRQBnf8Tb/AKcP/H6P+Jt/04f+P1o0yeaK3gkmuJEihjUu8jsFVVAySSegAoAo/wDE2/6cP/H6P+Jt/wBOH/j9W7K7t760hurG4iubWZBJFNC4dHU8hlYcEH1FTUAZ3/E2/wCnD/x+j/ibf9OH/j9aNFAGd/xNv+nD/wAfo/4m3/Th/wCP1o0UAZ3/ABNv+nD/AMfqCG51WW6uIAtiDDtyfn5yM1sVnWP/ACGNS/7Zf+g0AH/E2/6cP/H6P+Jt/wBOH/j9aNFAGd/xNv8Apw/8fo/4m3/Th/4/WjRQBnf8Tb/pw/8AH6P+Jt/04f8Aj9aNFAGd/wATb/pw/wDH6P8Aibf9OH/j9QxeJ9Al1s6NFrelvrAJU2K3cZnBA3EeXndwAT06Vr0AZ3/E2/6cP/H6P+Jt/wBOH/j9aNFAGd/xNv8Apw/8fo/4m3/Th/4/WjRQBnf8Tb/pw/8AH6P+Jt/04f8Aj9O1/WLHw/o13qurz/Z7C0QyTS7GfavrhQSfwFWbO5ivLSC5tm3wTIskbYI3KRkHB56GgCp/xNv+nD/x+j/ibf8ATh/4/WjRQBnf8Tb/AKcP/H6P+Jt/04f+P1o0UAZ3/E2/6cP/AB+j/ibf9OH/AI/WjRQBm+HM/wBi227G7DZx0zuNaVZ3h7/kD2//AAL/ANCNaNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGdo3/AC/f9fUn9K0aztG/5fv+vqT+laNABRRRQAUUUUAFfK/xM8GeLJPEvxN17w9YahL9pMVi9oIHK39tJbqGeIY+do3VT8uf4h7H6oooA+frzWPiPpcEVnpNpqkUtraaXHpNlHpoktrsFFFz9pmMZMRU5GN8eMd+tP1XUvitH4d8daza6hqPnWmqS2Wk6WuiI0rQ/aYds6NszInlGRR8pBGW3EgY9+ooA8MudW+JFjrtysU2s3lla+JbWzjEmmREXFhIpMjsyRD5VIA3rgDPOeMZeo+IfiBqXia8sBpniL/hH7uDVLae3vbEMYysDmFleO2RQrNhVxLLu7kHGfoeigDk/hLaXFj8MPCtrfW8ttdQ6bAksMyFHjYIAVZTyCPQ11lFFABRRRQAUUUUAFZ1j/yGNS/7Zf8AoNaNZ1j/AMhjUv8Atl/6DQBo0UUUAFFFFABRRRQB47rOieKJPif4t1XTtFv47a98PPptlfJc26YuFDMrD97vUE4AOMg9QBzXPR+E/ina2csem6jqaTXHhm3SZrzVfPxqSzL5qoWdtjGIMN6jbk9c8j6DooA8W1nwp4k1q58LWmkHxp4c0kXNz/a0kmvrLchTCgRg5nlyu4EADodx2rnJp23hv4lW3jue6uNR1W5sor93tjFMptp7UrhIpQ10uz3ZYGcHnc3SvdaKAPnfRPD/AMURcay12Nd020vNHMUcVvqK3b293564MX2i8fJ8vdl98eRnADAZkm8OfFKTw5p8MQvbdItSkN1CmpyyXdzb7FEbkte/JyGJjS5AOQexB+hKKAPmzxJ4J+I2p+HW03UDr+twPoklrAHvobVlu/PJD3Ua3BWTMe0A75B0JAJOPoLw5bS2fh7S7W5TZPDaxRyLkHDBACMjjqK0aKACiiigAooooAKKKKAM7w9/yB7f/gX/AKEa0azvD3/IHt/+Bf8AoRrRoAKKKKAMPR7N7rSLG4mvr4ySwJI2JcDJUE9qt/2X/wBP1/8A9/v/AK1Hhz/kXtL/AOvWL/0AVo0AZ39l/wDT9f8A/f7/AOtR/Zf/AE/X/wD3+/8ArVo0UAYdtZvJqF7C1/fbItm3976jJ7Vb/sv/AKfr/wD7/f8A1qLH/kMal/2y/wDQa0aAM7+y/wDp+v8A/v8Af/Wo/sv/AKfr/wD7/f8A1q0aKAM7+y/+n6//AO/3/wBaj+y/+n6//wC/3/1q0aKAM7+y/wDp+v8A/v8Af/Wo/sv/AKfr/wD7/f8A1q0aKAM7+y/+n6//AO/3/wBaj+y/+n6//wC/3/1q0aKAM7+y/wDp+v8A/v8Af/Wo/sv/AKfr/wD7/f8A1q0aKAOf0nTt/wBs/wBMvVxcuOJcZ6c9Kv8A9l/9P1//AN/v/rUaN/y/f9fUn9K0aAM7+y/+n6//AO/3/wBaj+y/+n6//wC/3/1q0aKAM7+y/wDp+v8A/v8Af/Wo/sv/AKfr/wD7/f8A1q0aKAM7+y/+n6//AO/3/wBaj+y/+n6//wC/3/1q0aKAM7+y/wDp+v8A/v8Af/Wo/sv/AKfr/wD7/f8A1q0aKAM7+y/+n6//AO/3/wBaj+y/+n6//wC/3/1q0aKAM7+y/wDp+v8A/v8Af/Wo/sv/AKfr/wD7/f8A1q0aKAM7+y/+n6//AO/3/wBaj+y/+n6//wC/3/1q0aKAM7+y/wDp+v8A/v8Af/Wo/sv/AKfr/wD7/f8A1q0aKAM7+y/+n6//AO/3/wBaqFnp2dV1Bftl6Nvl8iXk/L34roKzrH/kMal/2y/9BoAP7L/6fr//AL/f/Wo/sv8A6fr/AP7/AH/1q0aKAM7+y/8Ap+v/APv9/wDWo/sv/p+v/wDv9/8AWrRooAzv7L/6fr//AL/f/Wo/sv8A6fr/AP7/AH/1q0aKAM7+y/8Ap+v/APv9/wDWo/sv/p+v/wDv9/8AWrRooAzv7L/6fr//AL/f/Wo/sv8A6fr/AP7/AH/1q0aKAM7+y/8Ap+v/APv9/wDWo/sv/p+v/wDv9/8AWrRooAzv7L/6fr//AL/f/Wo/sv8A6fr/AP7/AH/1q0aKAM7+y/8Ap+v/APv9/wDWo/sv/p+v/wDv9/8AWrRooAzv7L/6fr//AL/f/Wo/sv8A6fr/AP7/AH/1q0aKAM7+y/8Ap+v/APv9/wDWo/sv/p+v/wDv9/8AWrRooAzfDg26NbDJOAwyev3jWlWd4e/5A9v/AMC/9CNaNABRRRQBneHP+Re0v/r1i/8AQBWjWd4c/wCRe0v/AK9Yv/QBWjQAUUUUAZ1j/wAhjUv+2X/oNaNZ1j/yGNS/7Zf+g1o0AFFFFABRRRQAUUUUAFFFFABRRRQBnaN/y/f9fUn9K0aztG/5fv8Ar6k/pWjQAUUUUAFFFZfiPWrfQtMe7ucuc7IolPzSOeij/HsATSbtqxxi5Oy3LGq6nZ6TaNc6hcJBCOMt1Y+gHUn2HNcFqvxBupyyaNaLBH2nuhlj9EB4/E/hXJ6jeXWq37XuoyeZOeFUfciX+6g7D36nvUFcs67ekT2aGAhFXqass32oajqBJv8AUbucHqnmFE/75XA/Ss42NoTk20BJ5JKAmrFFYtt7ndGKirRViS0uLqyObG9u7YjtFMwX/vk/KfxFdTo/j3ULRlTWIVvbfoZoVCSr7lfut+GPoa5KinGco7MzqUKdRe8j3HS9RtNVs0utPnSeBujKeh9COoPsat14bpOo3mjX32zTXAc482Fj+7mHow9fRuo9xxXr/h7WrXXdOW7tCRzskib70Tjqp/zyOa66dRT9TxsThZUXdao06KKK1OQKKKKACs6x/wCQxqX/AGy/9BrRrOsf+QxqX/bL/wBBoA0aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7w9/wAge3/4F/6Ea0azvD3/ACB7f/gX/oRrRoAKKKKAM7w5/wAi9pf/AF6xf+gCtGs7w5/yL2l/9esX/oArRoAKKKKAM6x/5DGpf9sv/Qa0azrH/kMal/2y/wDQa0aACiiigAooooAKKKKACiiigAooooAztG/5fv8Ar6k/pWjWdo3/AC/f9fUn9K0aACiiigArxfxRq765rk1wW/0S3ZobVO20HDP9WI/ICvVvEl42n+HtSu48+ZDbyOmP7wU4/XFeJQRiGCOMdEUKPwFc+Ilokenl1NNubH0UVf0DSjrmtQafuZIWBlnZeojXGQPckgfiT2rmSu7I9SUlBOT2Q3SNJ1LWWP8AZloZIgSDPI2yIH03ck/8BBroF+H+rlMve2Cv/dCuw/Pj+Vel28EVtBHBbxrFDGoVEQYCgdABUldcaEVuePPMKjfu6I8V1nQdW0VDJf2ga2Xk3FsxkRfduAy/UjHvWaCCMjkV72QGBBGQe1eP+M9FTQtcCWq7bG7UywoOkbAjeg9uQR9SO1ZVaXKro68JjHVfJPcxK1/CGqNo/iK3lLbbW6Zbe4XtycI31DED6E1kVHcoZLeVFOGKkA+h7VjF8ruds4KcXF9T6Aoqno139v0exvOP9Igjl4/2lB/rVyvRPmWrOzCiiigQVnWP/IY1L/tl/wCg1o1nWP8AyGNS/wC2X/oNAGjRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBneHv+QPb/wDAv/QjWjWd4e/5A9v/AMC/9CNaNABRRRQBneHP+Re0v/r1i/8AQBWjWd4c/wCRe0v/AK9Yv/QBWjQAUUUUAZ1j/wAhjUv+2X/oNaNZ1j/yGNS/7Zf+g1o0AFQagxWxuWUkMI2IIPIODU9FAHyJ4G8TeN7ST4a22ravqt9put6kl5DdtdOXdRuSW1lYn5xkKwBOMMfw7eD41eI3tpJvsWkyztpup3k1hHFIJtHe2VjGt0d/zByoH3YzzxX0JRQB4UnxH8dxw+Dkv4vDEM/iOzvNQjeGCeZY4YrSOaMMDIh3li4bBIA24Jwcx6H8Y9Zlign1mPTobW68MvriSWtlLK1vIsvllWTzf3i8buCmOhPBaveaKAPlvVPiNqPji3istTjsium+JdFkt7i1RUEqTF2+ZVmmUEbeznrg4IIr6koooAKKKKAM7Rv+X7/r6k/pWjWdo3/L9/19Sf0rRoAKKKKAMPxwhk8H6yFySLWRuPZSf6V5BXu9zClzbSwSjMcqFGHqCMGvBYongDW83+ut3aGT/eUlT/KuXELZnrZbL3ZRHV2HwsUHW9SYj5hbxgH6s2f5CuPrU8Lauuh6/DdznFpKpguD/cUkEP8AgRz7E1lTaUk2dmJg50pRW57RRSKQwBUggjIIpa7z50K4X4sqv2DSX/jF2V/4CYnJ/ULXdV5P8QdWXU/EC20DbrbTwyEjo0rY3f8AfIAH1LVlWdos68FByrJroc3RRTZ5BFC8jdEUsfwriPePX/ARJ8HaRkYxAqj6DgGt+s3w1Ztp/h7TbSQYkhto0f8A3goz+ua0q9GOx8zUd5truFFFFMgKzrH/AJDGpf8AbL/0GtGs6x/5DGpf9sv/AEGgDRooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzvD3/ACB7f/gX/oRrRrO8Pf8AIHt/+Bf+hGtGgAooooAzvDn/ACL2l/8AXrF/6AK0azvDn/IvaX/16xf+gCtGgAooooAzrH/kMal/2y/9BrRrOsf+QxqX/bL/ANBrRoAKKKKACiiigAooooAKKKKACiiigDO0b/l+/wCvqT+laNZ2jf8AL9/19Sf0rRoAKKKKACvKfiLpjaf4g+3Iv+i6hjLdlmUYI/FQCPcNXq1UtY0221bTprK9TdDKMHHBU9QQexB5FRUhzqxvhq3sZ83Q8QoIBGDyKsarp91ouomw1EfPyYZgMLOvqPf1Hb6VXrgaadmfQxkpK62NbQ/EmraJEsFpLHPZr923uASEHorDkD2OQOwroU+I1wF/eaMm7vtu8j9UriKKtVZLRMxnhaU3eUTodY8ZaxqkZiiKabAwwwgctIfbeQMfgM+9c7GixoEQYUdBS0VMpOW5pTpwpq0FYK1fCmktrevwQFc2tuVnuT2wDlU/4ER+QNUdOsrrVb9bLToxJcNyzH7kS/3nPYe3U9q9g8N6JbaDpq2ltl2J3yyt96Vz1Y/4dgAK1pU+Z3exzYzEqlHlW7NWiiiuw8IKKKKACs6x/wCQxqX/AGy/9BrRrOsf+QxqX/bL/wBBoA0aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7w9/wAge3/4F/6Ea0azvD3/ACB7f/gX/oRrRoAKKKKAM7w5/wAi9pf/AF6xf+gCtGs7w5/yL2l/9esX/oArRoAKKKKAM6x/5DGpf9sv/Qa0azrH/kMal/2y/wDQa0aACiiigAooooAKKKKACiiigAooooAztG/5fv8Ar6k/pWjWdo3/AC/f9fUn9K0aACiiigAooooApatplnq9k9rqEKzQtzzwVPYqeoPuK811nwRqunMzaf8A8TK17AELMo9wcBvqMH2r1eionTU9zejiZ0fh2PAZ5BbSeXdpJay/3LhDGfybFHmx4z5iY9civfJI0lQpIiuh6qwyDVAaHpIfeNLsQ+c7vs6Zz+VYvD9md6zJW1ieJ2xa8fy7GKW7kHG23QyEfXHT8a6jR/A+qX7K+osNNtupUEPMw/DKr9efpXqcaJGgSNVRR0VRgCnVUaEVuY1MxnLSCsUNF0iy0azFtp8Iijzlj1Z2/vMepNX6KK32OBtyd2FFFFAgooooAKzrH/kMal/2y/8AQa0azrH/AJDGpf8AbL/0GgDRooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzvD3/IHt/8AgX/oRrRrO8Pf8ge3/wCBf+hGtGgAooooAzvDn/IvaX/16xf+gCtGs7w5/wAi9pf/AF6xf+gCtGgAooooAxVmuYtZ1EW9r54IjyfMC4+X3qz9r1D/AKBv/kdaLH/kMal/2y/9BrRoAzvteof9A3/yOtH2vUP+gb/5HWtGigDO+16h/wBA3/yOtH2vUP8AoG/+R1rRooAzvteof9A3/wAjrR9r1D/oG/8Akda0aKAM77XqH/QN/wDI60fa9Q/6Bv8A5HWtGigDO+16h/0Df/I60fa9Q/6Bv/kda0aKAOf0m5vh9s26fuzcuT+/UYPHFX/teof9A3/yOtGjf8v3/X1J/StGgDO+16h/0Df/ACOtH2vUP+gb/wCR1rRooAzvteof9A3/AMjrR9r1D/oG/wDkda0aKAM77XqH/QN/8jrR9r1D/oG/+R1rRooAzvteof8AQN/8jrR9r1D/AKBv/kda0aKAM77XqH/QN/8AI60fa9Q/6Bv/AJHWtGigDO+16h/0Df8AyOtH2vUP+gb/AOR1rRooAzvteof9A3/yOtH2vUP+gb/5HWtGigDO+16h/wBA3/yOtH2vUP8AoG/+R1rRooAzvteof9A3/wAjrVGzub4arqBGn5Y+XkecvHy1v1nWP/IY1L/tl/6DQAfa9Q/6Bv8A5HWj7XqH/QN/8jrWjRQBnfa9Q/6Bv/kdaPteof8AQN/8jrWjRQBnfa9Q/wCgb/5HWj7XqH/QN/8AI61o0UAZ32vUP+gb/wCR1o+16h/0Df8AyOtaNFAGd9r1D/oG/wDkdaPteof9A3/yOtW7i6t7bH2ieKLPTe4X+dU/7f0f/oLaf/4Ep/jSuNRb2Qv2vUP+gb/5HWj7XqH/AEDf/I61bt7q3uc/Z54pcddjhv5VNTFaxnfa9Q/6Bv8A5HWj7XqH/QN/8jrWjRQBnfa9Q/6Bv/kdaPteof8AQN/8jrWjRQBnfa9Q/wCgb/5HWj7XqH/QN/8AI61o0UAZ32vUP+gb/wCR1o+16h/0Df8AyOtaNFAGb4cJOjWxYYJDZHp8xrSrO8Pf8ge3/wCBf+hGtGgAooooAzvDn/IvaX/16xf+gCtGs7w5/wAi9pf/AF6xf+gCrtxIYreWRUaRkUsEXq2B0HvQBJRXnnhv4v8AhXV7xdOv7ifQNZztbT9YiNtIG9AW+U89MHJ9K9DByMjpQBnWP/IY1L/tl/6DWjWdY/8AIY1L/tl/6DWjQAUUUUAFFFFABRRRQAUUUUAFFFFAGdo3/L9/19Sf0rRrO0b/AJfv+vqT+laNABRRRQAUUUUAFFFFABRRTPNTzBHvXef4c8/lQA+iiigAooooAKKKKACiiigArOsf+QxqX/bL/wBBrRrOsf8AkMal/wBsv/QaANGiiigAooooAKhu7mCztpLi7mjhgjGWkkbAA9zVHxDrdnoNgbm9Y8nbHEnLyt/dUf5xXket6re69dCfUmARDmK2Q/u4v/im/wBo/his6lRQOrD4WVbXZHXax8QixMeg2wden2m5BVT/ALqcMfx2/jXI32rarqBJvtTu5Af4I38pPptTGfxzVOiuSVSUj2KeGp0/hRCtpbqSRBHk9TtGT+NSeWn9xfyp1FQbkLWluxBMEWR0O0ZFadhq+q6cR9h1K6RR/wAs5X81Pphs4/DFUqKabWwpRUlaSudzo/xCdWWPXLQBf+fm1BK/ihyw/AtXdaffWuo2q3FhcRXEDdHjbIz6fX2rwypbG5utNu/tWmXDW1x/EV5V/Z16MP19CK2hXa+I4K2XwlrT0f4Hu9Fcr4S8Xwa0RaXaLa6mBnyt2VlA6lD39x1HuOa6qupSUldHkzpypvlktQooopkBRRRQBneHv+QPb/8AAv8A0I1o1neHv+QPb/8AAv8A0I1o0AFFFFAGd4c/5F7S/wDr1i/9AFWdRLrp9yY3EbiJirkgBTg4OTwKreHP+Re0v/r1i/8AQBVDx7rp8OeFr3URpd/qpRdn2Wxt/PkbdxkpkZUZyfagDxP4ZeHfhl4w06xu/EmrR6/4o1JGD22q6yJ7iNsnKIilccDIwM46GvoPS7GDS9MtLCzUpa2sKQRKSSQiqFAyevAFfNnwz8U6ZrGt+C7fQvhza6brjTA6jqLaLFbwhBExcwODuDcqR7Z45r6coAzrH/kMal/2y/8AQa0azrH/AJDGpf8AbL/0GtGgAooooAKKKKACiiigAooooAKKKKAM7Rv+X7/r6k/pWjWdo3/L9/19Sf0rRoAKKKKACiis/XdWttF02W9vGPlpwqry0jHoqjuTQ3YaTk7In1G/tdNtHur+dIIE6u5/Qep9hXnmseP7y5LR6LbrbQ/8/Fwu5291ToP+BZ+lc1rGpXmt332vUW5X/UwKcpAPQep9W6n2HFVK5J1m9InsUMBGKvU1ZLe3V5ftnUL67uj6SSkL/wB8jCj8qpfYbQDH2WDHp5YqxRWDbe53pKOiHWks9kQbC6urUjtDMyj/AL5zg/iK6XSvHWrWRC36R6jB3YARzAfUfK35D61zFFVGco7MipRp1PiR7PoOv6frkJewmy6f6yFxtkj/AN5f69D2NateCRPLb3MdzaTPBdRHMcqdR7H1B7g8GvWPBfiRdesmS4VYtRt8CeNehz0df9k4/A5HueqnV59HueRisG6PvR1R0dFFFbHCFFFFABWdY/8AIY1L/tl/6DWjWdY/8hjUv+2X/oNAGjRRRQAVT1fUrbSdOmvb19sMQycclj0AA7knAA96uV5N4/1dtU1xrSNv9CsG247PN/E3/Ac7R77qipPkVzfDUHWny9DG1bUrrWtQa+vzhuRFCDlYE/uj1Pqe/wBAKq0UVwNtu7PoYxUVyrYKKKKBhRRRQAUUUUAFFFFACMudpDMjoQyOhwyMOhB7GvUPAnidtYiey1AqNSgXcWAwJk6bwOx7EfTsa8wp8FzNY3cF7aHFxbP5iDON3qp9iMj8a0pzcGc+JoKtC3Xoe80VX068i1Cwt7y2bdDPGsiH2IzViu4+eatowooooAzvD3/IHt/+Bf8AoRrRrO8Pf8ge3/4F/wChGtGgAooooAzvDn/IvaX/ANesX/oAqxqkE1zpl3BbTGCeWF0jlBIKMVIDceh5qv4c/wCRe0v/AK9Yv/QBUmtOI9Gv3ad7YLbyEzIu5o/lPzAdyOuKAPmr4W+AfFFh4u0ixuvC76Vaabfw391qLzq6yvFbNE/lnOW812LH079K+oq+XfgXbQXGr+GtQl0Dx7PdyZdtXuJ3NjIxVv3hBP3T/MjrX1FQBnWP/IY1L/tl/wCg1o1nWP8AyGNS/wC2X/oNaNABRRRQAUUUUAFFFFABRRRQAUUUUAZ2jf8AL9/19Sf0rRrO0b/l+/6+pP6Vo0AFFFFABXj/AI11c6zr8gRs2VkzQwgdGfo7/n8o9h716T4t1BtK8N6hdxHEyR7Yj6Ox2p/48RXjEMYiiSNeigDmuevKy5T08upJt1H0HUUUkjbFzhmJIAVRksScAAepNcp6wtNMsYbb5ibvTIzXoXhvwHAIEuPEK/aLlhn7Lu/dRexx98+pPHoO9dWNC0kQ+UNLsBF/cFum38sVvGg2tTgqZhTi7RVzxSivQ/EngK1lhe40BVs7tRkQA/uZfbH8J9xj3BrztGLA7lZHUlWRhyrA4IPuCCKznTcNzpo14VleItWtJ1J9F1a21JPuxHbMP70R+8Pw+8Pdaq0EAggjINSnZ3RrKKknF9T3tGV0VkIZWGQR0Ipa5r4dXhu/CVmrkmS23WzZ5+4cL/47trpa9BO6ufMzhyScX0CiiimSFZ1j/wAhjUv+2X/oNaNZ1j/yGNS/7Zf+g0AaNFFFAFPWL1dO0m9vXxtt4Xlwe+0E4rwyAMIl807pD8zt6seSfzJr1f4lzmHwfdqpw0zxQ/g0ig/pmvK65cQ9Uj2MtjaDl3YUUUVznohRRTZmZImKKXfoqj+JjwB+JoAsWNrdajd/ZdOtnuZ8ZYLgKg9WY8Afqe2a6eH4f6u6ZmvbGF/7qq8g/P5f5V3PhfRotC0iK0jw0pG+eTHMkh6t/h6AAVrV1xoJL3jx62YTcrU9EeQan4R1zTkaT7NFewjkm1clwP8AcIBP4ZrBjdZF3Icjp9D6H0Ne+15t8TNHitLm31a2QJ9ok8i5CjhmwSr/AF4Kn1yPSoqUUleJthca5y5J9TjKKKK5z0gooooA9K+Ft35ugTWbH5rO4ZF/3G+cf+hEfhXZV5n8LJvL1zUoO01ukn4oxB/9DH5V6ZXdSd4o+fxkOWtJBRRRWhzGd4e/5A9v/wAC/wDQjWjWd4e/5A9v/wAC/wDQjWjQAUUUUAZ3hz/kXtL/AOvWL/0AVY1J4o9OunuZWhgWJzJKpwUUA5Ye4HNV/Dn/ACL2l/8AXrF/6AKsao1sumXbaht+xiFzPuBI8vad2QOemaAPmj4TRw6Z4q8NSNN8RbLw9eyeXo8moanHJZ3RKMyq8KqNgYAkDJ7V9QV8tfDG50uTxT4dkml8VXGg2uoraaNZ6lPH5ds0tu8kEhQDLAxg7eflBHWvqWgDOsf+QxqX/bL/ANBrRrOsf+QxqX/bL/0GtGgAorG8X+JNO8J6Dcavq7utrEVULGm95HYgKir3YkgD/Cqln4utBp1xe+ILW58NQwsgZtZeGFSGGVIkWRk9RjduBHIGRkA6SisG48ZeGLa1trm48R6NFbXKNLBK99EqSopwWUlsMAeCRUmoeLPDumx2kmo6/pNol2gkt2nvI4xMp6MhJ+Ye4oA2qKx18T6A2qXGmrrmlnUbdWea1F3H5sSqMsWTOQAOTkcVi658TPCWlaBqWrJrmn6jFYQieWGwu4ZpSpIC4XeOpYAZIzmgDsqK5qw8deFr2z0+4TxBpKC/iWWCOS9iDuC2zAG7kh/kOM/MCOtMtfHnh46Nb6lqeqafpMFxJJHH9t1C2G5kYqwDJIyHp0DEjvg8UAdRRTY3WRFeNgyMAVZTkEHuKdQBnaN/y/f9fUn9K0aztG/5fv8Ar6k/pWjQAUUUUAcd8U3I8O26DpJdxg/gGb+aivNK9N+KMRfwyso6QXMTt9Cdn/s9eZVx1/iPby/+F8wra8FWy3Xi/TlkGViElxj1KrgfkWB/CsWrekagdI1ez1EKzpA58xF6tGwIbHuM5/Cs4NKSbOqsnKnJR3se40VBY3dvfWsVzZypNBKu5HU5BFT16B801bRhXi/iyJIPF2sxx42ecr4HYtGjH9ST+Nev6lfW+m2M13eSCK3hXczH+XuT0ArxC5upL+9ur6ddkl1KZSn90HhV/BQB+Fc+IaskellsXzOXQjooorlPXPQ/hO5/s3VI+wvNw/GJP8P1rua4v4VQlNCvJyOJ7xyp9lVU/mprtK76fwo+exX8aVgoooqznCs6x/5DGpf9sv8A0GtGs6x/5DGpf9sv/QaANGiiigDj/il/yLUf/X1F/M15nXrHxEtjc+EL8qCWgC3Ax6IwY/oDXlFcmI+I9rLnek15iUUUVgd4VY03YNY0sy48sXsGc9P9YuP1xVemyoJI2QkrkdQcEH1FCdncUldNHv1Fct4M8VQ6xbpaXjrFq0a4kjPAlx/GnqD1I6j9T1NeimpK6PmqlOVOXLLcK434qSKvh+2jJ+eS7QKPoGY/oDXXzSxwRPLM6xxICzO5wFA7knpXkHi/XV8Qauklvn+z7YFICRjzGP3pMenAA9snvWdWSUTowVJzqprZGLRRRXEe8FFFFAHSfDltvjFP9qzmX/x+M/0r1ivKvhnGZPFs0mMrDZMD7F3TH/oBr1Wuyh8B4eYfxvkFFFFbHEZ3h7/kD2//AAL/ANCNaNZ3h7/kD2//AAL/ANCNaNABRRRQBneHP+Re0v8A69Yv/QBVnURA2n3QvE32xiYSrjO5MHI/LNVvDn/IvaX/ANesX/oAq1f2sd9YXNpMWEU8bROVODhgQcH15oA+UfBur/Dbw74osdam1jxhcWELCWxgvbFvIh2x7FcsBlwkfA9AO9fWNvNFc28U9vIskMqh0dTkMpGQQfTFeJQfB3xLdWllpGt+MIZ9B0m2nttNSOxAlAkheFTIcjO1HPAPOOa9i0DTU0fQtN0yOQyJZW0dsrkYLBFCg4/CgBtj/wAhjUv+2X/oNaNZ1j/yGNS/7Zf+g1o0Ac38QfCdv408NS6Vc3Etq/mJPBcRAFoZUbcjYPB5HIPUZ6dawNd8Ca3r8elXGreJbaTVdKv4r6zkj0zZbKUUgh4fNLMWyST5gxxtC859DooA8f0n4KRWF5Z3R1szSpFqK3CtaYSSS7GGZF3/ACKv935s8881b8KfCu+8JXumX2heILY3ltpaaVOb3TmmSVEcuGRVmUxnnkbmHfGa9VooA8b0z4IQadqks8erJcWoluprYXMdy81sbhCr7SLlYu/JMWWAwexDf+FGxPp9taTa8xWHw4/h8sloFLZl8wS/fOMHjZ/48K9mooA82sPhfHJ4q0LXPEd3p+rSaVpQ01IG00KhZZN6TLvkfawGBxnnJBGcDL8N/CG78MX+l6loniG3/tSyhubZnvNOM0LxTTtNxGJVKOC2Nwbkdu1eu0UANjDCNRIQz4+YqMAn2GTj86dRRQBnaN/y/f8AX1J/StGs7Rv+X7/r6k/pWjQAUUUUAUdb09NV0i8sZDhbiJkDf3SRwfwOD+FeIJ5gDJOuyeNjHKn911OGH5g177XmnxI0N7W8bWrZCbaUAXagfcYDAk+mMA+mAfWsK8Lq6PQy+soScH1/M46ilpK5D2Sxpt9e6VK0ml3ctqXOXRcMjn1KnIz7jB962f8AhNPEO3H2iz6Y3fZuf/QsfpXPUVSnJbMzlRpzd5RTJ9QvLzU5kl1O7mu3Q5QPgIh9QoAAPvjPvUFFFS23uWkoqyCmzOUjZlUu3RVAyWPYD3J4p9dT8PtAfUr+LVrlCLC3bdBn/ltIP4v91ex7n6VUIuTsiKtVUouUjvvDGm/2RoFjYsQZIox5hHdzyx/76JrUoor0EraHzcm5NthRRRQIKzrH/kMal/2y/wDQa0azrH/kMal/2y/9BoA0aKKKAGyxpLE8cihkcFWB6EHqK8Ku7KTS7+606XJa1kMYJ/iTqjfipH45r3evPvijpDDydagXIiXybrH9zOVf/gJJB9m9qxrRvG/Y7sBV5KnK9mcJRS0lcZ7YUUUUANkjSQDeM4OQe4PqD2NaVvrmtW0YSDWL1UAxhyspx9XUn9az6KabWxMoRl8SuS31zd6iR/aV5c3YByFlkygPrtGFz+FRUUUm29xpJKyCiiigYUUVPp9hPq2owadaErLOfmcD/VRj7z/gOnuRQld2Qm1FXZ33wqsDHpd3qLj5ryXah/6ZplR/49vP0Irt6hs7aKztIba2QJBCgjRR2UDAFTV6EY8qsfN1qntJufcKKKKozM7w9/yB7f8A4F/6Ea0azvD3/IHt/wDgX/oRrRoAKKKKAM7w5/yL2l/9esX/AKAKt3gc2c4iVmkMbbVV9hJxwA3Y+9VPDn/IvaX/ANesX/oAqTW1uH0e+Syfy7t4HWFt23DlTt57c4oA8t+F+u/Ee2XR9D8U+C5fJTMdzrE+tQzSY+YhmQZLHoODXr9fK/w7+GGq+HfiF4Wun8LzfavMhvLvU5r0SLD/AKKyXEbBXILGb51PPUDp0+qKAM6x/wCQxqX/AGy/9BrRrOsf+QxqX/bL/wBBrRoAKKKKACiiigAooooAKKKKACiiigDO0b/l+/6+pP6Vo1naN/y/f9fUn9K0aACiiigApGVXUq4DKRggjIIpaKAPNfEvgaa0d7nw+nm255ayLYZP+uZPUf7J/A9q4zePNeJwyTJw8bqVdfqp5Fe+1n6ro2nasgXUrOG4wMKzL8y/Ruo/A1hOgnqj0aOYSgrVNfzPE6K9Guvh3p7kmzvr62/2CyyL/wCPAt+tUj8OZe2s8e9qP/iqxdCZ2LHUX1OGprOBIkahnlc4SNFLOx9Ao5NejW3w6sVbN5qF9OP7ilY1P5Dd+tdNpGh6bo6EabZRQFuGcDLt9WPJ/E1UaD6kVMxpx+FXOD8N+Brm+dLjXlNvaDkWgb55P98j7o/2Rz6kdK9MjRI41SNVRFAVVUYAA7AU6iumMFBWR5davOs7yCiiiqMQooooAKzrH/kMal/2y/8AQa0azrH/AJDGpf8AbL/0GgDRooooAKbIiSxtHIodHBVlYZBB6g06igDx3xZ4dk8O3e6IM+kytiGQ8+ST/wAs2Pp6H8OvXFr3e7t4by2kt7qNJYJVKujjIYHsa8r8T+ELrRme409ZbvTeu0AtLAPQjqy+/Ud89a5KtK2sT2cLjFNclTf8znKKSN1kQPGwZT0IOaWsD0AooooAKKKKACiik3M00cEMbzXEpxHDGMs59h/WgAdtu0KrO7EKiIMs7HoAO5Ner+BvDn9h2LTXYVtSucGZgchB2jU+g/U5PpVXwT4S/soi/wBUCSamwwqjlbdT2X1Y92/AcdewrrpUuXV7njYzF+09yG35hRRRW554UUUUAZ3h7/kD2/8AwL/0I1o1neHv+QPb/wDAv/QjWjQAUUUUAZ3hz/kAacv923RfyUD+lZfj7wfofjTRFsfEmntqFrbyfaY4VmeImQKwGCrA9GI5OOa1PDv/ACA7H/rkKl1mdLXSL64maVYooJHZojhwApJK+/pQB86+A9H8K6H8QfDp/wCFWa14dvri4aO0vbzUXZFcRsT8pchjtB4r6Wr538LaBpVld/DnxRqmq+L9YGr3I+xW+p6utylpK8TNG5UKMnaDnB4PBzX0RQBnWP8AyGNS/wC2X/oNaNZ1j/yGNS/7Zf8AoNaNABRRRQAUUUUAFFFFABRRRQAUUUUAZ2jf8v3/AF9Sf0rRrO0b/l+/6+pP6Vo0AFFFFABVPWr06bo9/fCIzG1gkn8ter7VJwPrirlIQGBDAEHgg96APO9LuNasPClt4y1vxTPd2kenvqd7YQ2cH2do/KMm2EhRINvGCztux0GeINQ+JGp6TY3Tat4bii1AWtteW1vBqPmLNHNOkJVnMa7HVnXIwynPDdcdBZ/DvwxZzI8Gny+VH5gjtXvJ3tovMBV9kDOYlyGYcKOp9aW0+Hvhm1tLi2jsJXjnECuZ7yeZgsLh4kVncsqKwBCKQvtQBjJ8QdRF/Jos2g26+JRqK6fHbJqBa2bNt9p8wzGIMFCBsjyycjABzmqWtfE7VdM1B9PHhG7utRtII5r63tDcXOzezBViaK3dWJVNw8wxdQOucdjqXg3QtSlu5ruzfz7q4jupJoriWKQSxoI0dHRg0ZCDblSOM56ms+f4b+F5kjV7G5ULD9nYx39whnj3FtsxWQGYbmY/vN3U+tAGanxA1BtX8o6DCul/2w2ii5N8fN83aSrGLy8BCQAfmyM9Disnwh468TyaH4bXU9JsL3UNZmuIbeVNQKAmNZXzIPIAQDYF+Xccc4J+U9lo2l+HNa0y31HTIfOs577+1o5N0i7rjOPMwSCOn3SMe1ZmjaV4Rs9d2aXDfPe6fqDxhFe7mitLiSEu2FJMcamOYnjCZYD72BQBn2HjO8/tB9K0nRVn1q5v71TFdarIYFEAi8xxI0bMo3SoFjVMck/LzXoOnSzz6fazXlt9kupIleW38wP5TkAsm4cNg5GR1xWFfeB9AvgTLaTRym5lvBNb3c0EqyyDEhWRHDKGAAKggHHSt3TrK307T7Wxso/KtbaJYYkyTtRQAoyeTgAdaALFFFFABRRRQAVnWP8AyGNS/wC2X/oNaNZ1j/yGNS/7Zf8AoNAGjRRRQAUUUUAFFFFAHMa/4L0vVpHuEV7K9bkz2+BuPqy9G+pGfeuO1DwPrlnk232fUYx08tvKk/75Y7f/AB6u58Q+J4dI1Gz02Cwv9U1W6R5Y7OxVN4jTAaRmkdERQSBlmGScDJpkXjHSIrCzuNbuE0Ca7do47XV5Y7eYsrbSACxDc9CpIIIIPNZypRludNLF1aeid15nlV1a3lmSLywvbfHd4G2/99AFf1qn9ttdxX7TCG9C4BFe2XHibQbbV00q51vS4dUdxGtnJdxrMzEAhQhO4khgcY7j1ok17QZNUl0qTVdMbUYVMslm1zGZUUDJYpnIAHOcVk8OujOtZk+sfxPE1vLZm2pcRM3orAn8hV+1sNQvCBZ6bfTZ6EQMq/8AfTYX9a9Vt/F/heTTnvbfxDorWETiJp0vYjEjkZClg2AcAnFUtQ+InhWxutGjm1vTzBq3m/ZrtbuLyD5eM5fdjknaMZ54prDrqxSzJ9I/ictp3gPWbxgb6WDToe4U+dL/APEj8zXd+HfDWm6AjfYoSZ3GJLiU7pH+p9PYYFRzeKNMe6tbbTdV0W5uJZlRon1BUcIWZCUADFm3KyheASCMgirdjr+j6hqdzp1hq2n3WoWufPtYblHliwcHcgOV5OORWsacY7HJVxVSrpJ6GnRRRVnOFFFFABRRRQBneHv+QPb/APAv/QjWjWd4e/5A9v8A8C/9CNaNABRRRQBneHf+QHY/9chUHiW91Cyhtf7P0ldTjlm8u6D3CQrBDsYmQ7uGGQq4/wBrPap/Dv8AyA7H/rkKj8U6rY6LoN5e6pfW1jbJGV864dVUMRgD5iAST0B60AeDfCbw1cweM9M1iD4ZNY6a7O0N6PE0V7b2QYHLxRDg56cZxmvo6vmL4T69caQ3gWzs/iXFqmm38ywDQIdNtVmgVkd8SlZCyAN6ZxkCvp2gDOsf+QxqX/bL/wBBrRrOsf8AkMal/wBsv/Qa0aACiiigAooooAKKKKACiiigAooooAztG/5fv+vqT+laNZ2jf8v3/X1J/StGgAooooAKp63539jX/wBm8zz/ALPJ5fl53btpxjHOc1cooA8O1fTfEtt4b8FP9v8AEKRXdmH1uVlv7uZLgQx+WDFbyxyoM+aG2EAtguGPNVNS0vxXcaJrVwNQ8XTXth4ctn054zcWhnuxJcZJhVyHk2rECrFiQRuGSMe+UUAeOaxp+vaRe63YWc/ii48PrcabLLKk9xcXJibzBceRJkydViLLGcgFtoGaqwHWc6f/AGoPGH/CIfb74xCH7Z9vMe2L7OJjH/pATd9pxuOceXur22igD5tt9P8AF1voWjWklx4g0exi0hPsgtNMvbiVbrzJd4dYJo9r48sjzw0Z9uc9jaWniC38XzyxQ6pHDc+JBLcSJE8aTQ/2OF3MBwU81VHUgOAM5Few0UAeDWNh4z0zwxpUunT+JptUvvC00t6LueaZo71TBt2iUkRy7XmAUYzt5BIzXV/Cy6jl8aeK7Wwn8Qvpdvaaf5UetSXTSLK32gyELcneuQEzwAcDHGK9JubeG7tpbe6ijmt5kMckUihldSMFSDwQQcYNVNF0XStCtmttE0yx063Zt7RWlukKlvUhQBmgDQooooAKKKKACs6x/wCQxqX/AGy/9BrRrOsf+QxqX/bL/wBBoA0aKKKACiiigAooqK6JW1mKkghCQR9KAOX8Q6PrMfiu08Q+HP7PuJxaNY3NnfSvCkke8OrLIqOVZTngqQQ3bANc5rnhXxbqV1eahJD4bmvdT0htIuoZZZhFbL5sjK8Z8smT5ZMMpCbiinI6VkeC/iFrun+BtDGraI1/cv4eGqwTLqBlmu0h8oSlwY8rIVkDgZfd0JU10d58SJZZV/4R7SYdStp9Uh0q0uXvDDHPI8DSu+fLYhEwqkgEk7uPlwQCjcfDe+/s7xDbQ3FnLJfXGlvbzzFg+y0EAYudpwx8pyMZ+91GTUV94A1y58Pax4aA0Qabdy31xFqbvI12GuHdwCgQAEF9jOJCSgxgdpLz4rXEIgsovD0s2vGW6intYmnnij+zuqMweCCR2B8xMExgckEqcAy3Pj/XNS0zWl0bw8bO7sdKiv5DqVyYHgMscp2mPymJdTH0IAIzkrwCAU9N+HWpG7hur20023mW+sbiUnV7zUWljg8zIL3A45kG1AOOcseMaEfg3W9N1yDVdNXS7iSLWL69+zzXDwqYbhAPvCNsOCMkbcHJ5qTw74x8R3L6Fpd1othNql9pY1EzLqTCLYGiUs37gEMfMJ2qpAIAzglhWi+KNyNHi1e50FItMvtOutR0x1vd0kywRmQLKvljyi6DIwXx0ODxQBb0zwNe2fhnQtP32IuLLXG1S4dCwWRDNK/B25L7XUcgdMZwBVr4c+HNZ8N2+n6XqNtoj2Gm2kltBfQO7XU+6RWBZSgEYIGXAZ9zYPGK5bxh4512TSI7V9KGm6m8mlX9qLTUi4nhlvY0aJ32JsJ+6wwykMeSM10Vv8Q5oJzFrukw2AttW/sm+mjvfNit3aFZYpAxRdyNvRDkKQzDg0Aeg0Vj+ENYl8QeHbLVpbNrNbxTLFEzlm8ok+WxyBgsu1sY4zjJxmtigAooooAKKKKAM7w9/wAge3/4F/6Ea0azvD3/ACB7f/gX/oRrRoAKKKKAM7w7/wAgOx/65Co/FGn6fqehXkGr6ZDqtoIzI1pLEJBIVGQAp75HHvUnh3/kB2P/AFyFTaxNBb6RfTXiM9tHA7yqvUoFJIHTnGaAPDvgza6lPdaFq+n/AA58I6Po08ZKXsEoa8iiKnHzEbi3QHJz1zXvlfJnwtt/DVp4v8Para+CbTTJp9Shgttup3E0scdxavNFJ8z7SduNwI/i7GvrOgDOsf8AkMal/wBsv/Qa0azrH/kMal/2y/8AQa0aACiiigAooooAKKKKACiiigAooooAztG/5fv+vqT+laNZ2jf8v3/X1J/StGgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs6x/5DGpf9sv/AEGtGs6x/wCQxqX/AGy/9BoA0aKKKACiiigApHUOjKwyrDBFLRQBg2vhXS9Ph08aXbJbzabYPp1i7s8iwwsE+UqW+cZjj6nPy9Rk1zqfDGwj8H+F/DsN3LBa6LdJdvJb7oHuHCSBiGjZTGWaQtlTx0r0CigDl5PAXh17KytVsp4RZNI0E1veTw3CmQ5kJmRxIS55bLHd3zV3S/Cui6WtytjYrGtzbx2kyl3cPFGGCKQxPQO3PU55zW3RQBgaD4Q0bQbiCfToLkTW9u1pE895NcGOFipMa+Y7YXKLgdscYyaybv4baAdO1WDTbdrO4vbK5so5WmlmjtVnB3+VEz7IwSckIFziu1ooA5LS/h9oFjYLbyW891KTbPJPcXc8sjNA4eLDO7Mqq43BAdvXjk0eK/A+n67ousabHsto9ZuobjUWZDKZgnlggAthCUiVQR064zzXW0UANjjSKNI4kVI0AVVUYCgdABTqKKACiiigAooooAzvD3/IHt/+Bf8AoRrRrO8Pf8ge3/4F/wChGtGgAooooAzvDv8AyA7H/rkKt3is9nOqeWGaNgPMGVzjv7VU8O/8gOx/65Crl2IWtZludvkFGEm44G3HOT9KAPlf4Qf2DoXxgtNKu9G06/1p2kFvf6HqbXVnbHYcnym/1fy8ZycZwAK+ra5bw1/wiGgaRpg8OrpVhp+qOqWZtgqLdMVLKAR94kBjzz1rqaAMVbC2u9Z1BriPeVEYHzEfw+xqz/Yun/8APv8A+Pt/jRY/8hjUv+2X/oNaNAGd/Yun/wDPv/4+3+NH9i6f/wA+/wD4+3+NaNFAGd/Yun/8+/8A4+3+NH9i6f8A8+//AI+3+NaNFAGd/Yun/wDPv/4+3+NH9i6f/wA+/wD4+3+NaNFAGd/Yun/8+/8A4+3+NH9i6f8A8+//AI+3+NaNFAGd/Yun/wDPv/4+3+NH9i6f/wA+/wD4+3+NaNFAHP6TpFi/2zdBnbcuo+dunHvV/wDsXT/+ff8A8fb/ABo0b/l+/wCvqT+laNAGd/Yun/8APv8A+Pt/jR/Yun/8+/8A4+3+NaNFAGd/Yun/APPv/wCPt/jR/Yun/wDPv/4+3+NaNFAGd/Yun/8APv8A+Pt/jR/Yun/8+/8A4+3+NaNFAGd/Yun/APPv/wCPt/jR/Yun/wDPv/4+3+NaNFAGd/Yun/8APv8A+Pt/jR/Yun/8+/8A4+3+NaNFAGd/Yun/APPv/wCPt/jR/Yun/wDPv/4+3+NaNFAGd/Yun/8APv8A+Pt/jR/Yun/8+/8A4+3+NaNFAGd/Yun/APPv/wCPt/jR/Yun/wDPv/4+3+NaNFAGd/Yun/8APv8A+Pt/jVCz0ixbVNQQwfKvl4G9uPl+tdBWdY/8hjUv+2X/AKDQAf2Lp/8Az7/+Pt/jR/Yun/8APv8A+Pt/jWjRQBnf2Lp//Pv/AOPt/jR/Yun/APPv/wCPt/jWjRQBnf2Lp/8Az7/+Pt/jR/Yun/8APv8A+Pt/jWjRQBnf2Lp//Pv/AOPt/jR/Yun/APPv/wCPt/jU2o6jZ6Zb+fqF1DbRdN0rhcn0Hqa5W++IenRkrYWt3eH+/sESfm2D+lS5KO7NKdGdT4Fc6T+xdP8A+ff/AMfb/Gj+xdP/AOff/wAfb/GuGm+IeoMf3Ol2sYz/AB3DOf0UVCPH+sbiTaaeV7D5wR+Of6VHtodzoWBrdvxO/wD7F0//AJ9//H2/xo/sXT/+ff8A8fb/ABrh4fiJeqR9o0m3kHcx3JU/kUP861rP4h6ZIQL22vbQ92aPzF/8cJP5gU1Vg+pEsHWj9k6L+xdP/wCff/x9v8aP7F0//n3/APH2/wAafperafqsZfTryC5Ufe8twSv1HUfjV6tDnaadmZ39i6f/AM+//j7f40f2Lp//AD7/APj7f41o0UCM7+xdP/59/wDx9v8AGj+xdP8A+ff/AMfb/GtGigDO/sXT/wDn3/8AH2/xo/sXT/8An3/8fb/GtGigDN8OKF0a2VeAAwH/AH0a0qzvD3/IHt/+Bf8AoRrRoAKKKKAM7w7/AMgOx/65CuD/AGg76Wx8CR4fVoLKe9iivLvS5WjmtocMS/yqSVLBVIx/FXeeHf8AkB2P/XIVNq7TJpV69rCs9wsDmOJhkSNtOFI7gnigD5e+B7eCLvVfB8U3iPxhfavbhZLbTbxnaxgmEZ+6NmAAM4wcfWvqyvlT4SeNtXvPE3h7R7fXrq8vH1CJriwSAQwwW5tWa4jMYACCOXCjpyOK+q6AM6x/5DGpf9sv/Qa0azrH/kMal/2y/wDQa0aACiiigAooooAKKKKACiiigAooooAztG/5fv8Ar6k/pWjWdo3/AC/f9fUn9K0aACiiigAoorH8SeILPQLUSXTF5pMiGBOXkPt6D1J4FJu2rKjFydo7mweK5vVPGuiWDtH9qN1OvBjtV8wg+hI+UfiRXm+ua3qWuu39oTGO2PS0hYiMD/aPVz9ePYVnKFRMABVHYcAVzyxH8p6dLLutR/cd1c/EaUsRZ6OdvZri4CH8lDfzqt/wsLU92f7Ostv93zmz+eP6VyFqJLwkWMFxd4OD9nhaQD6lQQKu/wBjawV3f2Rf4xn/AFX9Kj2lR7HR9Ww0dGl951UHxGmBAutHGO5hutx/JlH8617Lx/ok5AuWubFv+niI7f8AvpcqPxNeZXMVxaAm8s7y2UdWmt3RfzIxTI5EkXdG6uvqpyKPbTW4ngaM17unoz3i2uIbqBZrWaOaFxlZI2DKfoRUteD6fcXOmXP2jTLh7WYnLbPuv/vL0b8efcV6R4T8ZxapKllqaJa6g3CFT+7m/wB0nof9k/gTW0Kylozgr4KdJc0dUdhRRRWxxBRRRQAVnWP/ACGNS/7Zf+g1o1nWP/IY1L/tl/6DQBo0UUUAFFFQ3l1BZWs1zdSLFBEpd3booHegN9B8siQxPJK6pGgLMzHAUDqSa888Q+PpJi0Hh1QE6G9lXI/7Zqev+8ePY1geKPENz4jnKsHh0tTmO3PBkx0aT19l6D61k1y1K3SJ6+GwKXvVd+wku+e5a5upZLm5PWaZtzfQeg9hgUUUVz7npJW0QUUE4GSeKj8+HP8ArY/++hQBJRQCCMg5FFADfLHmrKpZJk5WWNirr9GHIrqdC8b6lppWPUw2o2g43gAToP5P+h9zXMUVUZuOxnUpQqq00e36Tqllq9oLnT7hJ4icHbwVPowPIPsau14TY3d1pt6LzTZjBcjg91kH91x3H6jtivVvCfia21+Blx5F/EB51uTkj/aU91Pr+eK66dVT06njYnByo+8tUdBRRRWpxhRRRQBneHv+QPb/APAv/QjWjWd4e/5A9v8A8C/9CNaNABRRRQBneHf+QHY/9chVHxv4t0nwVoTax4gmkhsVkWIskZc7m6cCr3h3/kB2P/XIVoEBhggEehoA8AT4s+HPE/xM8HWnga7kjlur2Qali1MJnj8piockfN8wzX0BTRGgOQqg+oFOoAzrH/kMal/2y/8AQa0azrH/AJDGpf8AbL/0GtGgAooooAKKKKACiiigAooooAKKKKAM7Rv+X7/r6k/pWjWdo3/L9/19Sf0rRoAKKKRmVFLOQqgZJJwAKAMrxNrlvoOmNdTjzJGOyGEHBlfsB/MnsK8duri5v7yS91CTzbuX7zDoo7Ko7KPT8TzVzxDrD6/q73uT9lTMdoh7R/3serYz9MDtVGOOa4uIba0jMt1O2yKMdz7+gAySewFcdWfO7I93CYdUYc0t/wAh1tBcXt5HZ2EJnu5OVQHAA7sx7KPX+Z4r0bQPAdjaKs2r7dQu+DtcfuUP+ynf6tn8K1vCfh638P2JRcS3kuDcXBHLt6D0Udh/XJrcranSUdXucOJxspvlp6L8xEVUUKihVAwABgAUtFFbHAFYWseE9G1Us89mkVwf+W8H7uTPuR1/HIrdopNJ7lRnKDvF2PHvEvhi+8Pq1wWN5pw6zquHiH+2o7f7Q49QKwnRJo8NhlOCCP0IP9a99IDAgjIPavKvHPhpNDmS+05dunTPtkiHSBz0I9FJ4x2JGODxzVaVtYnrYTG875Km5v8AgDxPJen+ytUk3XqKWhmbrOg9f9sd/Uc+tdvXgZMiPHLbyGO4iYSRSD+Fh0P/ANb0r2jw1qya3ottfIuxnBEif3HBwy/mD+GK0o1OZWZzY7Dqm+eOzNSiiitjgCs6x/5DGpf9sv8A0GtGs6x/5DGpf9sv/QaANGiiigAryv4ha2dU1M6Zbv8A6DZv+9x0lmHb6L/6F9K7nxjq50XQLi5ix9pbEUAPeRuB+A5J9ga8ciTy41XJYjqxOSx7k+5Nc9edlyo9LL6HM/aPpsOoopsjhE3EE9gFGSSegA9TXKeuLI6xgFjjJAAxkk9gB3PtXT6H4J1PUlWbUHOm2x5CEBp2H06J+OT7Cum8E+E002OPUNTRZNUcZVTyLcH+Ff8Aa9W/AcV2FdNOgt5HlYjHu/LS+85uw8FaDZgFrFLuQfx3Z80k+uG4H4AVr/2TpwXaLC024xjyV/wq7RXQopbHnSqTk7tmFd+EdAugfM0m0Qnq0KeU3/fSYNc7qfw7TaW0e/libtFdfvEPtu4YfU7q7+ipcIvdFwxFWG0jwvU7G90m5WDVbZrd2OEfO6OT/dboT7HB9qr17pqFlbahaSWt7Ck9vIMMjjIP/wBf3ryLxT4fm8O3qJuebT5jiCZ+WVv7jH19D3+o55qlLl1Wx62Gxiq+7LRmRT7ee4sruG8sZPKu4TlG7H1VvVT0I/rTKKxTsdrSasz2jw1rMGvaTFe24KEkpLETkxuOqn/PIwa1K8n+HWoGw8Sm1ZsW+oKRjPAlUZB/FQw/AV6xXfTlzRufPYqj7Go4rYKKKKs5zO8Pf8ge3/4F/wChGtGs7w9/yB7f/gX/AKEa0aACiiigDO8O/wDIDsf+uQrRrO8O/wDIDsf+uQrRoAKKKKAM6x/5DGpf9sv/AEGtGs6x/wCQxqX/AGy/9BrRoAKKKKACiiigAooooAKKKKACiiigDO0b/l+/6+pP6Vo1naN/y/f9fUn9K0aACuR+JuoNa+HhaRMVlvpBASOojwS/5gbf+BV11eZfFOYvrunQc4ht3kx7uwH/ALIazqu0WdOEhz1opnI9BgcCu9+F2kr9nm1mZcyTFobfI+7GpwT9WYH8AK4CRtkbN/dBNe0eE7cWnhjSYAMFLWIH67Rk/nmsKEbyuejmFRxpqK6mrRRRXWeKFFFFABRRRQAVT1ewi1TS7qxn/wBXPGYye4z0I9wefwq5RQNNp3R4DGJEDR3C7Z4maKQejqSrfqDXbfCu8MWo6hpxPySoLpB6MMI/846wPFsH2Xxdq0YGEeRZl/4Eik/+Pbqk8FTeR4x0s9BKZIT9DGzfzQVxQ92pY96t+9w7flf9T2Oiiiu08AKzrH/kMal/2y/9BrRrOsf+QxqX/bL/ANBoA0aKKKAPN/ircmTUtMsgfkiR7hh/tHCqfy3/AJ1xddH8RmLeMZM/w2kKj/vqQ/1rnK4arvNn0OEjy0YhXS/DvSxqPiFrqZd0GnqHGehlbO38gCfqVNc1Xp/wxtPI8MLcEYe8mec/TO1f/HVB/GnRjeRGNqclJ266HW0UUV2nghRRRQAUUUUAFUdb0yDWNLuLG6GY5VxuHVD1DD3BwR9KvUUbjTad0eCGOWCSWC6AFxA7RSgdNynBI9j1HsaSt3x5bi28Y3u0YE8UVwfqQU/9p1hV50lyto+lpT54KXcRp3tDHdxZ8y2dZ1x3Kndj8cY/Gve4pFliSSMhkcBlI7g14K6hlKnoRg17L4PlM/hTRpGOWazi3fXYM/rXRh3ujz8yjpGRr0UUV0nkmd4e/wCQPb/8C/8AQjWjWd4e/wCQPb/8C/8AQjWjQAUUUUAZ3h3/AJAdj/1yFaNZ3h3/AJAdj/1yFaNABRRRQBnWP/IY1L/tl/6DWjWdY/8AIY1L/tl/6DWjQAVxXij4iWGgeKo/D39la3qeqPZC/wDK021E22EuU3H5gR8wx+Irta8i+Jnwtv8AxT8QrXxLZ/2BcRw6aliLXV7eWVVcTPJ5i+W6nPzADn14oA9En8VaBb68miT61p0esP8AdsmuUEx4yPkznOOapxePfCMsF9NF4m0Z4bHBuXW8jIiycDcc8ZPH14rmR8PtUt9W8RRWuo6c2h6/ePe3XnWrNeQs0YQrHJu24GAVJHy5OPWsO8+E+vX/AIT0jQrrWdJjTQWt302e1tJYZJTFkDzmWUMMg8+WwO75s5xQB6LP448KQaZbajP4k0aOxuldoJ3vYwsoTAbYSfmIJAIHQkCqsfxE8KyeJbTQ49asmvLuzF7AwmTy5EJwArZwWPUKOSAT0Fcl4e+FMlhrfhy+vG0wxadPqE9xbxieVZmuUjXO6d3YtmMkknnPTqTU8G/CXU/DNx4dnh1HTZ3stIm0i7Elux3K85lEkZyMMMhee2aAO+bxtok1zp0Wlajp2p/a7hbctbahbny9ysynBcFshTgLlj1xgE1d0nxToGsapc6bpWtade6hbAtNb29wkjxgEAkgHPBIB9CQDXBaV8KWsPDngbTo7m0jm0G7W5u5oYihucJIvBHOfn6mtj4ZeD9Y8HW1rpVze6Vd6Np9vJBaPFZtHdPvkD5kYsV7HIUfMcE9KAO+ooooAztG/wCX7/r6k/pWjWdo3/L9/wBfUn9K0aACvKviXn/hL1znH2GLH/fyXP8AT9K9Vrzf4q2hj1DTL4D93Ir2zn0b76/pvrKsrwOzAtKsjiJxugkA7qR+le3+HpBNoGmSjo9rE3Bz1QV4nXqfw2vhdeFreAn97ZE2rD0C/c/8cK1jh3q0dmYxvBS7M6miiius8cKKKKACiiigAooooA8h8fMG8Y3mMfLFEpx64J/kRVTwt/yNejf9fB/9FvUGt3Qv/EGq3ancklwyoR3VAEBHsdmfxq/4HgNx4y04AZECy3DewCFP5uK4d6nzPoLcmHs+36HsNFFFdx8+FZ1j/wAhjUv+2X/oNaNZ1j/yGNS/7Zf+g0AaNFFFAHk3xGUr4wkz/FZwsP8AvqQf0rnK7P4qW+zVdMugPllikhY+6kMv6F/yrjK4aqtNn0OEfNRiFev+BSD4P0fBB/0ZB+leQV6P8LdQWXR5tNc/vrOQlR3Mbksp/Pcv/Aaug/esYZjFummujO1ooorrPFCiiigAooooAKKKhvLmGytJrm5cRwQoXdj0AAyaASueWfEWQSeMZQv/ACztIYz9d0jfyYVzlS3V3JqN/dX86lZLqQybT1VeiqfooA/Coq8+bvJs+low5Kai+gEgAk9BXsfgyMxeEdFVvvfY4iR6EoCR+teL3au9u8cQzLJ+7QerMcD9SK98tYVtraGBPuxoEH0AxW2HW7ODMn7sUS0UUV1Hkmd4e/5A9v8A8C/9CNaNZ3h7/kD2/wDwL/0I1o0AFFFFAGd4d/5Adj/1yFaNZ3h3/kB2P/XIVo0AFFFFAGdY/wDIY1L/ALZf+g1o1nWP/IY1L/tl/wCg1o0AFFFFABRRRQAUUUUAFFFFABRRRQBnaN/y/f8AX1J/StGs7Rv+X7/r6k/pWjQAVjeLtIOtaDc2keBccSQMe0inK/geh9ia2aKTV1YqMnFqS6HgMb70yVZWBIZWGCpHBBHqDxWx4V1r/hH9ZFxJn7DcAR3I/ugfdk/DJz7E+lb/AMQvDbwTTa3p6FomG68iUcjA/wBao+n3h7Z9a4lWV1DKQykZBHIIriadOR9BCcMTT8me9xukkavGyujAMrKcgg9wadXj3hfxNd+HgLcxtd6ZnPkg4eL12E8Ef7J/AjpXp2ia9putRltOukkZfvxH5ZE/3lPIrqhUUzxa+FnReu3c06KKK0OcKKKKACuV8feIRpOnG0tX/wCJldqViA6xr0Mh9MdvU496h8UeNrbTjJa6V5d5qA4ODmKE+rkdT/sjn1x1rzSR5Z7iW4upnnuZTuklfqx9PYDsBwKwq1UtFuehhMG5tTnt+YyNFjjVEGFUACu/+FenHZe6tIOJj9ng90U/M34tx/wCuP0XSbjXtSWxtNyIMG4nA4hT/wCKPYfj0Fe0WNrDY2cNraoI4IUCIo7ADAqKENeZnRmFdKPs1uyeiiiuo8cKzrH/AJDGpf8AbL/0GtGs6x/5DGpf9sv/AEGgDRooooA5j4iac2oeGJ3iUtPaMLpAOp253Ae5UsPxrypWDKGU5UjINe+HmvFPEekHQdamsgpFq+ZbU9vLJ5X/AICTj6bfWuavH7R6uXVd6b9UZ1XNG1OXRdXg1GBTIEBSaNeskZ6ge4wCPpjvVOiudOzuj05RUk4vY900+9t9RsoruylWa3lXcjr3/wAD7VYrxLRNYv8AQrhpdOdTE5zLbSE+W59R/db3H4g16DpHjvSbxVS9dtOuDwVueEz7Sfd/PB9q7IVVI8Ovgp03eOqOsopkM0U8YkgkSSM9GRgQfxFPrU4woorN1fXNM0dN2o3kUJPRCcu30Ucn8BQ3Yai5OyNKvKvHniMazcnTrF86dA+ZpAeJ5AeAPVVP5n6cs8T+L7rWke1sVkstObhmJxNMPTj7q+3U98dK5tVCqFUAKBgAdq5atW+kT1sJg3B+0qb9goopsriOMswJx2AySewA9a5z0jd8E6d/afim2DKTBZf6VIe24cRj/vrJ/wCAV7DXOeBdEfRdGH2lQL65bzp++044TP8Asjj65PeujrupR5YngYut7WpdbIKKKK0OUzvD3/IHt/8AgX/oRrRrO8Pf8ge3/wCBf+hGtGgAooooAzvDv/IDsf8ArkK0azvDv/IDsf8ArkK0aACiiigDOsf+QxqX/bL/ANBrRrOsf+QxqX/bL/0GtGgAooooAKKKKACiiigAooooAKKKKAM7Rv8Al+/6+pP6Vo1naN/y/f8AX1J/StGgAooooADzXm/izwRJbtJe+Hog0ZJaSxBxg9zHnp/u9PTHSvSKKmUFJWZrRrSoy5ongEcquzJhklQ4eN1Kuh9CDyKVo0Z1cjEi8q6nDL9CORXtes6DpmsqBqNpHK6/dkHyyL9HGCPzrjdR+HcyMW0nUQy9ortc/wDj6/1U1yyoSWx61PMKc9JaHO2fiTXbIBYdUkkQfwXKCX9T8361rR+P9aVcS22nSH1UOn6bjWXdeGNftSfM0t5VH8dvIsg/LIb9KzpLS9i4l03Uk/3rOXH57cUuapE09nh6muh0k3j7WnXEVvp0R9WV3/TcKxNT1rVtUQpf6jM0J6xQ4iQ+x28kexJqvHZ30pxDpupSdsrZyY/PbitKz8K6/eH5NO+zqf47qVUH5Llv0ovUkNQw9LXRGKiLGgSNQqjgADAFaOgaLe+IJwliPLtAcS3bDKL6hf7zfoO9dlo/w9toyJNauWvW/wCeCDy4h9ect+Jx7V28MUcMSxQoscaDCoowFHoAKuFDrI5q+YJK1LV9yloek2mi6elpYptjXlmblnY9WY9ya0KKK6krHktuTuwooooEFZ1j/wAhjUv+2X/oNaNZ1j/yGNS/7Zf+g0AaNFFFABWL4s0GPX9LMBYR3MZ8y3mx9x/f2PQj0/Ctqik1dWZUZODUo7ngs0U1tcy2t5EYbqE7ZIz29we4PY96bXr/AIo8NWmvwqZSYLyMERXKD5l9iP4l9j+GDzXlutaTqGhORqkGIc4W6iy0TfU/wn2b8Ca46lJx22Pdw+LjWVnoylS0gIIyORRWR1EccKQuXgBhc9WhYxk/iuKupqGpIMJqupgehu5D/M1WopptbCcU90TzXl9Ou2fUtRkX+613Jg/UZwaqxQxxEmNFUnqQOT9TT6KTbe4JJbIKKKksoLjULo22m28l3cDqsfRPdmPC/iaEr7A2krsikdY0LuwVQMkntXceAvC0jzxaxqsRRU+a1t3GCD/z0Ydj6Dt164xoeF/A8VjLHe6w6XV6vzJEo/cwn1GfvN7n8AK7WuqlRtrI8rFY3mXJT+8KKKK6DzAooooAzvD3/IHt/wDgX/oRrRrO8Pf8ge3/AOBf+hGtGgAooooAzvDv/IDsf+uQrRrO8O/8gOx/65CtGgAooooAzrH/AJDGpf8AbL/0GtGs6x/5DGpf9sv/AEGtGgAooooAKKKKACiiigAooooAKKKKAM7Rv+X7/r6k/pWjWdo3/L9/19Sf0rRoAKKKKACiiigDG8Q+JdN8PvZpqTXRlvHZIIrWzmupJCq7mwkSMeBznFX9Kv4dTsIru2S5SKTO1bm2kt5BgkcxyKrL07gZHI4Iri/ido15qWq+Gbq30zVdRtbKed7hNLvhaTqGiKqVczRHGSMgN09a5y78L3E+qrdX/gvU9a0+SzihsrXUtSimuNMmWaVpHeSSdyN4aNhJG7uAgXAwAAD2GivDrnwTrUmk6zZ2/htoPE0v2snxILyJTdI8u5Yw24yHcmE2yIFTHGRRpXw7uHsVtDoOow6dLq9lcT2eoSaeiGNFcSMsNoqxqPmUHqz8cccgHslzqtnbatZabPNtvb1JJII9rHese3ecgYGN69SM54qW7nkha3EVpPcCWURuYigEK4J3tuYZXgD5ctkjjGSPHYPh/JYeJdLu5vCVvqGlWWpah5FrGts32eGZomhdFkcKqKyyHaPmXdwtXdF8BXdlp/hS4OkQpq9tr011ezl4zItsXuivz55X96h2KeCxOM5oA9dorzL4V+HLjRLuEap4WNtrMVpLFfa+biJv7QkMqndhWLvuxuzIFKY2jg16bQAUUUUAFFFFABWdY/8AIY1L/tl/6DWjWdY/8hjUv+2X/oNAGjRRRQAUUUUAFIyq6lXAZSMEEZBFLRQByeqeA9HuyXtFk06U97YgIfqhyv5AGuZvfAOsQEm0uLO8Qf3t0Lfl8wP5ivUq5vSfGujavfC107+052MskHnDSroW++NmVx5xj8vhlYZ3YyMVnKlGXQ6aeMqw0T+886n8P67b587R7rA7xFJAf++WJ/SqhsdQUkHStVz7WMp/ULXulFQ8PHudCzKfVI8Oh0vVZziLSNRJ/wBu3aP/ANDxWla+DvEV0RmzgtF/vXM4J/JN38xXr9UtG1Wz1rT0vdMm861Z5Iw+1lyyOyMMEA8MrD8KFQiKWY1HskcjpXw7to2D6xeS3rdfKjHkxfjg7j+ePauzsrO2sLdbeyt4reBeiRKFA/AUWk8kzXAltJ7cRSmNDKUImXAO9drHC8kfNhsg8YwTYrWMVHY5KladX43cKKKKoyCiiigAooooAzvD3/IHt/8AgX/oRrRrO8Pf8ge3/wCBf+hGtGgAooooAzvDv/IDsf8ArkK0azvDv/IDsf8ArkK0aACiiigDOsf+QxqX/bL/ANBrRrOsf+QxqX/bL/0GtGgAooooAKKKKACiiigAooooAKKKKAM7Rv8Al+/6+pP6Vo1naN/y/f8AX1J/StGgAooooAKKKKAPPLr4saNaaLBq13Y6jbWNzL5FrLctbwLcSjduRTJKoXAQnc5VegDE8VFB8XdIvbW3m0nStY1My21xdulmsD+SkD7JNzGUIcEjGxmDcYJyK2n8B6eNB0nTba81C2k0qdrmyvYnTz4pG35PKFCCJGUgqQQelPtvBNsl0bq71TVb+7axn095rmVCzJM6uxwqAAgqAAAFA4xQBmxfFDSjZ3Nzdabq9miWkN9brNCha8ilkEcZiCu3LOVUK+0/MvGDmpz8RLNWa1l0fWI9bF2tmukFITcO7RmUEMJDFs2Kzbt+BtIODxUl78O9HvLOK2nmvtkWmw6ZGyyKrIsUiyRyAhf9YHRTnpx0qJvh1aO32p9a1ltb+2Lerq5eH7QrrG0QUL5XlbNjuu3y8fMT15oA5fTvi9aaRpUj+KTMdRm1HUVitXltIHhghuXRVZnlSMlRtXCszMQSN3JrR0zxyup65LKmoXo0i5udMFgtvDFki4hZ9sm9SdjcZx8w7Ec1o2fwzs7BYJNN17XbTUYmuWa/jkhaaYXEnmyK4aIoRv5B25HrV9PAenC8jupLzUZZ0ntLgvLMrs72yFELErk5BJY5yT3FAFDT/ihpNyiT3enatp1hLb3NzFe3UcflSLbjMuNjswIGT8ygEA4zWp4Z8Yx65qzadJo2raZcfY0vkF8IQJIXYqpHlyOQcg/KwBHcVVl+Hukto1jp7G5uLeyt7u3jillCiZbhWV1chc9GIBGMe9UPh54S13SdfvNW8R34nc2UVhbRfahclI0ZmyXEEI7gY2E9SWOeAD0KiiigAooooAKzrH/kMal/2y/9BrRrOsf+QxqX/bL/ANBoA0aKKKACiiigAooooAK8d8KeGNVsbS9sn0fxPZarLcag8OorrINhEZZZmik+zrddMOmR5Od3OM81peFPiLceXLb63purXM0mpala2l3HDCIrgwSTMsCAOG3eXHgFlCkqctnNat58UNDg037dbw399bixtr9jaxoxVLiURxIQWHzkknb2Ct3wCAcUng26OkadHb+ADZrbTWr6va/a7c/2yqLKHXAk2SYdkk3TFS+MGqHiD4e6jqM8br4Z1O10g2TRWWl2Fzp7Np83nzMWLThxFvDo26A5TG0ZCrj0DUvipo2k2dy+tWl9pl9BdJZtY3j28chdo/MUiQy+TtKgncZAMgjrgFdH+KGl659jTQtO1TUrm6gmnWG28g7RFKsTgyGUR8Fs5DFSOhJIBAOah+H17Hqc+sf2Sh1r/hJ7a7jvWljab7EFhWQ78jggSgrwW9DxVLw78OXtl0PTZfCMFpDZ63cT390n2dY722aO8EX3H3uqiWNCjqOHxgrux03hb4l3N7omjTav4c1RNQ1SSaG2jtlgZJ2jEjYX98SowmMuVGTnIXJGxZ/ECxudUitW0zVYLaS9bTRfyJF5AulB3QnbIWyGDJu27NwIDGgDjLjwTfW19O03hpNV8PLrc9x/Y0TwBJYWtYY4ZBG7LGQjRsAjEYzkDgV6j4Xtvsfh3Trb7B/ZvlQKos/O87yMD7m/+LHTNed698VVuvA2pX+k6fq2lXFxpF3faVeXkMJSZoUycAO+CM5w6gEAkZFb1v8AEaySOddU0rV7Ce2a0E63McWVjuXKRznZIw2blIP8S91FAHdUVlaDrltrh1E2UcwisruSyMrhdsrpgOUwTkBsrzjlW471q0AFFFFABRRRQBneHv8AkD2//Av/AEI1o1neHv8AkD2//Av/AEI1o0AFFFFAGd4d/wCQHY/9chWjWd4d/wCQHY/9chWjQAUUUUAZ1j/yGNS/7Zf+g1o1nWP/ACGNS/7Zf+g1o0AFFFFABRRRQAUUUUAFFFFABRRRQBnaN/y/f9fUn9K0aztG/wCX7/r6k/pWjQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWdY/8AIY1L/tl/6DWjWdY/8hjUv+2X/oNAGjRRRQAUUUUAFFFFAHL2fgnTrX+zPLmvD/Z+p3OqxbnX5pZ/O3q3y/dHnvgDB4XJPOeUX4aXUfgPXdKtZrW21XV9VGoPJHIxjhUXKSKiFlJ+WNOBtxuJ4ANep0UAcU3w8spFM8urau+s/bFvl1cvELlZFjMQwBGItuwlduzBBOQTzWlo/hOHTtYt9Vl1PU9Qv4rWW0Mt5IjF1kkWQkhVUAgoAAuFA4xXR0UAcfo3gKy0q80yaPU9Tnh0y4muLK2mMXlweasisgKxhiv7wkbmJGBzjgkXgHT4tbW+F/qZtFv31NdMMifZlumyTL9zf94ltpfbuOcV2FFAHlvhz4TonhCDSvE2r317MumTaaqRPGIrRZRiQw4iUkkADMm4j866PxP4OjvrPxJLYhJtQ1bSV0vyryTbbgJ5uwnapYczNkj0GMda6+igDJ8KaJB4c8OadpFqzPHaQiMyOSWkbqzn3ZiWPua1qKKACiiigAooooAzvD3/ACB7f/gX/oRrRrO8Pf8AIHt/+Bf+hGtGgAooooAy4dIMESxQ6hfJGowqhkwB/wB80/8As2X/AKCd/wD99J/8TWjRQBnf2bL/ANBO/wD++k/+Jo/s2X/oJ3//AH0n/wATWjRQBlpo5SWSRdRvg8mNx3Jzjp/DT/7Nl/6Cd/8A99J/8TWjRQBnf2bL/wBBO/8A++k/+Jo/s2X/AKCd/wD99J/8TWjRQBnf2bL/ANBO/wD++k/+Jo/s2X/oJ3//AH0n/wATWjRQBnf2bL/0E7//AL6T/wCJo/s2X/oJ3/8A30n/AMTWjRQBnf2bL/0E7/8A76T/AOJo/s2X/oJ3/wD30n/xNaNFAGd/Zsv/AEE7/wD76T/4mj+zZf8AoJ3/AP30n/xNaNFAGXDo5h3+XqN8u9i7fMnJPU/dp/8AZsv/AEE7/wD76T/4mtGigDO/s2X/AKCd/wD99J/8TR/Zsv8A0E7/AP76T/4mtGigDO/s2X/oJ3//AH0n/wATR/Zsv/QTv/8AvpP/AImtGigDO/s2X/oJ3/8A30n/AMTR/Zsv/QTv/wDvpP8A4mtGigDO/s2X/oJ3/wD30n/xNH9my/8AQTv/APvpP/ia0aKAM7+zZf8AoJ3/AP30n/xNH9my/wDQTv8A/vpP/ia0aKAM7+zZf+gnf/8AfSf/ABNH9my/9BO//wC+k/8Aia0aKAM7+zZf+gnf/wDfSf8AxNH9my/9BO//AO+k/wDia0aKAM7+zZf+gnf/APfSf/E0f2bL/wBBO/8A++k/+JrRooAzv7Nl/wCgnf8A/fSf/E0xNHKSySLqN8HkxuO5OcdP4a1KKAM7+zZf+gnf/wDfSf8AxNH9my/9BO//AO+k/wDia0aKAM7+zZf+gnf/APfSf/E0f2bL/wBBO/8A++k/+JrRooAzv7Nl/wCgnf8A/fSf/E0f2bL/ANBO/wD++k/+JrRooAzv7Nl/6Cd//wB9J/8AE0f2bL/0E7//AL6T/wCJrRooAzv7Nl/6Cd//AN9J/wDE0f2bL/0E7/8A76T/AOJrRooAzv7Nl/6Cd/8A99J/8TR/Zsv/AEE7/wD76T/4mtGigDO/s2X/AKCd/wD99J/8TR/Zsv8A0E7/AP76T/4mtGigDO/s2X/oJ3//AH0n/wATR/Zsv/QTv/8AvpP/AImtGigDO/s2X/oJ3/8A30n/AMTR/Zsv/QTv/wDvpP8A4mtGigDO/s2X/oJ3/wD30n/xNH9my/8AQTv/APvpP/ia0aKAILK2SztY4I2ZlQYBY5J5zzU9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The schematic demonstrates the relationship between left ventricular (LV) end-diastolic volume (LVEDV, represented here by the size of the inner circle) and LV mass (LV mass, represented here by the size of the shaded region) for various patterns of remodeling.",
"    <br>",
"     <br>",
"      Relative wall thickness (RWT) is the ratio of wall thickness to left ventricular diastolic dimension (RWT = 2 x [diastolic posterior wall thickness]/left ventricular internal diastolic dimension).&nbsp;&nbsp;",
"      <br>",
"       <br>",
"        With concentric remodeling, LVEDV is normal or reduced, LV mass is normal, and RWT is increased (and LV mass/LVEDV &nbsp;is increased).&nbsp;&nbsp;",
"        <br>",
"         <br>",
"          With concentric hypertrophy, LVEDV is normal or reduced, LV mass is increased, and RWT is increased (and LV mass/LVEDV is increased).&nbsp;&nbsp;",
"          <br>",
"           <br>",
"            With eccentric remodeling, LVEDV is increased, LV mass is normal to reduced, and RWT is normal to reduced (and LV mass/LVEDV is normal to reduced).&nbsp;&nbsp;",
"            <br>",
"             <br>",
"              With eccentric hypertrophy, LVEDV is increased, LV mass is increased and RWT is normal to reduced (ie, LV mass/LVEDV is normal to reduced).",
"              <div class=\"footnotes\">",
"              </div>",
"              <div class=\"reference\">",
"               Courtesy of William Gaasch, MD, Tufts University School of Medicine",
"              </div>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18371=[""].join("\n");
var outline_f17_60_18371=null;
var title_f17_60_18372="Benzoyl peroxide: Pediatric drug information";
var content_f17_60_18372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzoyl peroxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"    see \"Benzoyl peroxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/55/15221?source=see_link\">",
"    see \"Benzoyl peroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Clear Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      BenzEFoam Ultra&trade;;",
"     </li>",
"     <li>",
"      BenzEFoam&trade;;",
"     </li>",
"     <li>",
"      Benziq&trade;;",
"     </li>",
"     <li>",
"      BP Cleanser [OTC];",
"     </li>",
"     <li>",
"      BP Cleansing Lotion [OTC];",
"     </li>",
"     <li>",
"      BP Wash [OTC];",
"     </li>",
"     <li>",
"      BPO;",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; advantage&reg; 3-in-1 [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; continuous control&reg; [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; persa-gel&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Clearskin [OTC];",
"     </li>",
"     <li>",
"      Desquam-X&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Desquam-X&reg; 5 [OTC];",
"     </li>",
"     <li>",
"      Inova&reg;;",
"     </li>",
"     <li>",
"      Neutrogena&reg; On The Spot&reg; Acne Treatment [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Clinical Clearing Treatment [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum Face Wash [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum Spot Treatment [OTC];",
"     </li>",
"     <li>",
"      Pacnex&reg;;",
"     </li>",
"     <li>",
"      Pacnex&reg; HP;",
"     </li>",
"     <li>",
"      Pacnex&reg; LP;",
"     </li>",
"     <li>",
"      PanOxyl&reg; Bar [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg; [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg;-4 [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg;-8 [OTC];",
"     </li>",
"     <li>",
"      PR&trade; Wash;",
"     </li>",
"     <li>",
"      SE BPO;",
"     </li>",
"     <li>",
"      TL BPO MX;",
"     </li>",
"     <li>",
"      Zapzyt&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acetoxyl&reg;;",
"     </li>",
"     <li>",
"      Benoxyl&reg;;",
"     </li>",
"     <li>",
"      Benzac AC&reg;;",
"     </li>",
"     <li>",
"      Benzac W&reg; Gel;",
"     </li>",
"     <li>",
"      Benzac W&reg; Wash;",
"     </li>",
"     <li>",
"      Desquam-X&reg;;",
"     </li>",
"     <li>",
"      Oxyderm&trade;;",
"     </li>",
"     <li>",
"      PanOxyl&reg;;",
"     </li>",
"     <li>",
"      Solugel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"      see \"Benzoyl peroxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years, Adolescents, and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical formulations: Apply sparingly once daily; gradually increase to 2-3 times/day if needed. If excessive dryness or peeling occurs, reduce dose frequency or concentration. If excessive stinging or burning occurs, remove with mild soap and water; resume use the next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical cleansers: Wash once or twice daily; control amount of drying or peeling by modifying dose frequency or concentration",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical [emollient-based]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BenzEFoam Ultra&trade;: 9.8% (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BenzEFoam&trade;: 5.3% (60 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bar, topical [wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg; Bar: 10% (113 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cloth, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BPO: 3% (60s); 6% (60s); 9% (60s) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearskin: 10% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; On The Spot&reg; Acne Treatment: 2.5% (21 g) [vanishing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Maximum Spot Treatment: 10% (18.4 g) [vanishing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [cleanser]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; continuous control&reg;: 10% (141 g) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 2.5% (60 g); 5% (42.5 g, 60 g, 90 g); 10% (42.5 g, 60 g, 90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acne Clear Maximum Strength: 10% (42.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benziq&trade;: 5.25% (50 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BPO: 4% (42.5 g); 8% (42.5 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; persa-gel&reg; 10: 10% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zapzyt&reg;: 10% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [cleanser]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Cleanser: 4.25% (480 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TL BPO MX: 4.25% (480 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [emulsion-based/wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacnex&reg;: 7% (480 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [wash]: 5% (148 g, 237 g); 10% (148 g, 237 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Wash: 5.25% (175 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Maximum Face Wash: 10% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg;-4: 4% (170 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg;-8: 8% (170 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg;: 10% (156 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SE BPO: 7% (180 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [wash/water based]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benziq&trade;: 5.25% (175 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desquam-X&reg; 5: 5% (140 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desquam-X&reg; 10: 10% (140 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 5% (30 mL); 10% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Clinical Clearing Treatment: 5% (35.4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [cleanser]: 6% (170 g, 355 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; advantage&reg; 3-in-1: 5% (141 g) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [emulsion-based/wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PR&trade; Wash: 7% (473 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Cleansing Lotion: 4% (297 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inova&reg;: 4% (30s); 8% (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacnex&reg; HP: 7% (60s) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacnex&reg; LP: 4.25% (60s) [contains aloe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Gel, lotion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Shake lotion before using; cleanse skin before applying; for external use only. Avoid contact with eyes, eyelids, lips, and mucous membranes; rinse with water if accidental contact occurs",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild to moderate acne vulgaris (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benzoyl peroxide may be confused with benzyl alcohol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benoxyl&reg; may be confused with Brevoxyl&reg;, Peroxyl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benzac&reg; may be confused with Benza&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Brevoxyl&reg; may be confused with Benoxyl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fostex&reg; may be confused with pHisoHex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F140090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dermatologic: Contact dermatitis, dryness, erythema, irritation, peeling, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzoyl peroxide, benzoic acid, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; may bleach hair, carpeting, or colored fabrics; avoid contact with eyes, eyelids, lips, mucous membranes, open wounds, and highly inflamed or denuded skin; use a sunscreen and minimize exposure to sunlight or artificial light sources",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue if burning, swelling, irritation, or undue dryness occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13293362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; ~2% of the applied dose is expected to be absorbed systemically (Akhavan, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Releases free-radical oxygen which oxidizes bacterial proteins in the sebaceous follicles decreasing the number of anaerobic bacteria and irritating free fatty acids; exerts a keratolytic activity and a comedolytic effect",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~5% through the skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Major metabolite is benzoic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In the urine as benzoate",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F9729885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/55/15221?source=see_link\">",
"      see \"Benzoyl peroxide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if rash develops or if skin becomes red, itchy, or swollen. Avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing or wide-brimmed hat; use sunscreen with SPF &gt;15",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Granulation may indicate effectiveness; gels are more penetrating than creams and last longer than creams or lotions",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Winston MH and Shalita AR, &ldquo;Acne Vulgaris: Pathogenesis and Treatment,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):889-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/60/18372/abstract-text/ 1831256 /pubmed\" id=\" 1831256 \" target=\"_blank\">",
"        1831256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13018 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18372=[""].join("\n");
var outline_f17_60_18372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140054\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140055\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045521\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045518\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140045\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140033\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045524\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045523\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140091\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140090\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045527\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045517\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045516\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298844\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140040\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140041\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293362\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045515\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045526\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729885\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045528\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=related_link\">",
"      Benzoyl peroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/55/15221?source=related_link\">",
"      Benzoyl peroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_60_18373="TB chest radiograph 3";
var content_f17_60_18373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Imaging of cavitary lesions in tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph (A) and computed tomography (CT) scan (B), the latter of which more clearly demonstrates two cavitary lesions. A repeated CT scan (C) showed improvement after&nbsp;one month of treatment in a young woman with primary multidrug-resistant tuberculosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gorbach SL, Bartlett JG, et al. Infectious Diseases. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18373=[""].join("\n");
var outline_f17_60_18373=null;
var title_f17_60_18374="Asthma treatment in children";
var content_f17_60_18374=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Asthma treatment in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/60/18374/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18374/contributors\" id=\"au7312\">",
"       Gregory Sawicki, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18374/contributors\" id=\"au7511\">",
"       Kenan Haver, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/60/18374/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18374/contributors\" id=\"se5673\">",
"       Robert A Wood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/60/18374/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18374/contributors\" id=\"de2295\">",
"       Elizabeth TePas, MD, MS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/60/18374?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ASTHMA TREATMENT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The optimal treatment of asthma depends upon a number of factors, including the child's age and the severity and frequency of asthma attacks. For most children, asthma treatment can control symptoms, allowing the child to participate fully in activities and sports.",
"    </p>",
"    <p>",
"     Successful treatment of asthma involves three components:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Controlling and avoiding asthma triggers",
"      </li>",
"      <li>",
"       Regularly monitoring asthma symptoms and lung function",
"      </li>",
"      <li>",
"       Understanding how to use medications to treat asthma",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This article discusses the treatment of asthma in children younger than 12 years. Children with asthma who are 12 years and older are treated with medications and doses similar to that of adults.",
"    </p>",
"    <p>",
"     Separate articles discuss the symptoms and diagnosis of asthma and use of asthma dose inhalers in children. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"      \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A number of topics about asthma in adults are also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"      \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CONTROLLING ASTHMA TRIGGERS",
"     </span>",
"    </p>",
"    <p>",
"     The factors that set off or worsen asthma symptoms are called triggers. Identifying and avoiding asthma triggers are essential in preventing asthma flare-ups. Trigger avoidance is discussed in detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Common asthma triggers generally fall into several categories:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Respiratory infections",
"      </li>",
"      <li>",
"       Allergens (including dust, pollens, and furred animals)",
"      </li>",
"      <li>",
"       Irritants (such as tobacco smoke, aerosol sprays, some cleaning products)",
"      </li>",
"      <li>",
"       Exercise",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     After identifying potential asthma triggers, the parent and healthcare provider should develop a plan to deal with the triggers. If possible, the child should completely avoid or limit exposure to the trigger (eg, eliminate exposure to cigarette smoke). Recommendations may be made about decreasing allergen exposure (eg, removing carpets from bedrooms, not allow pets to sleep in the child's room). Children who have persistent problems despite efforts to avoid triggers may benefit from seeing an asthma specialist.",
"    </p>",
"    <p>",
"     Exercise is an exception to the general rule about trigger avoidance. Exercise is encouraged for children with asthma. An asthma action plan should include steps to prevent and treat exercise-related symptoms. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Exercise-induced asthma'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      MONITORING ASTHMA SYMPTOMS AND LUNG FUNCTION",
"     </span>",
"    </p>",
"    <p>",
"     Successful management of asthma requires the parent",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     child to monitor their asthma regularly. This is primarily done by recording the frequency and severity of asthma symptoms (coughing, shortness of breath, and wheezing).",
"    </p>",
"    <p>",
"     In addition, a healthcare provider may recommend that the child measure his or her lung function with a test known as a peak flow (peak expiratory flow rate [PEFR]).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17143704\">",
"     <span class=\"h2\">",
"      Asthma questionnaires",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider may recommend keeping a daily asthma diary when symptoms are not well controlled or when starting a new treatment. In the diary, the child's peak flow readings, asthma symptoms (eg, coughing, wheezing), and medications are recorded (",
"     <a class=\"graphic graphic_figure graphicRef74684 \" href=\"UTD.htm?4/25/4498\">",
"      figure 1",
"     </a>",
"     ). A standardized questionnaire such as the Asthma Control Test (ACT) or Asthma Control Questionnaire (ACQ) may be recommended to help track asthma symptoms.",
"    </p>",
"    <p>",
"     A periodic diary may be recommended for children who have stable symptoms and whose medications have not changed recently. This type of diary can be completed before visiting the healthcare provider and helps the",
"     <span class=\"nowrap\">",
"      parent/child",
"     </span>",
"     and healthcare provider to determine if the asthma treatment plan needs to be adjusted (",
"     <a class=\"graphic graphic_form graphicRef54723 \" href=\"UTD.htm?14/58/15266\">",
"      form 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Lung function assessment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Peak expiratory flow rate (PEFR) measures the rate at which a person can exhale. This rate depends upon the degree of airway narrowing. PEFR monitoring can provide data that can be used to make treatment decisions. Children five years of age and older are usually capable of performing peak flow measurements. This is discussed in greater detail elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     .) Children over the age of six years may also have lung function testing (spirometry) performed during a visit with their healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Review of asthma treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Routine follow-up appointments with a healthcare provider are recommended to review asthma symptom control and treatment plans. Children with asthma should see a healthcare provider every one to six months to monitor the child's symptom severity and frequency and response to treatment. The medications used to treat asthma in children vary according to a child's age, the severity of asthma, and the level of asthma symptom control. If control has been adequate for at least three months, the asthma medication dose may be decreased. If control is not adequate, the medication schedule, delivery technique, and trigger avoidance will be reviewed, and the medication dose may be increased.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CATEGORIES OF ASTHMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Intermittent asthma",
"     </span>",
"     &nbsp;&mdash;&nbsp;A child is defined as having intermittent asthma if he or she has asthma with minimal symptoms and infrequent asthma flares. Specifically, children with intermittent asthma have the following characteristics (",
"     <a class=\"graphic graphic_table graphicRef51579 \" href=\"UTD.htm?14/35/14909\">",
"      table 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Symptoms of asthma occur two or fewer times per week",
"      </li>",
"      <li>",
"       Asthma does not interfere with daily activities",
"      </li>",
"      <li>",
"       Awakenings during the night due to asthma symptoms occur two or fewer times per month",
"      </li>",
"      <li>",
"       Asthma flares require oral glucocorticoids (also called corticosteroids or steroids) no more than once per year",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A child with asthma symptoms that are triggered only during exercise (exercise-induced bronchoconstriction) might fit into this category, even if the child exercises more than twice per week. However, symptoms during exercise may also indicate that the child&rsquo;s asthma is poorly controlled. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Persistent asthma",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with persistent asthma have symptoms regularly. There may be days when activities are limited due to asthma symptoms, and the child may be awakened from sleep. Lung function is usually normal between episodes, but becomes abnormal during an asthma attack. Persistent asthma can be mild, moderate, or severe.",
"    </p>",
"    <p>",
"     The criteria that are used to determine a child's asthma severity include the number of days per week that a child has one or more of the following (",
"     <a class=\"graphic graphic_table graphicRef51579 \" href=\"UTD.htm?14/35/14909\">",
"      table 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Symptoms such as cough, wheeze, and shortness of breath",
"      </li>",
"      <li>",
"       Awakenings during the night due to cough or wheeze",
"      </li>",
"      <li>",
"       Use of a bronchodilator (reliever medication)",
"      </li>",
"      <li>",
"       Symptoms that affect the child's ability to participate in normal activities",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The number of flares per year that require treatment with oral glucocorticoids (also called corticosteroids or steroids) are also taken into consideration when determining asthma severity.",
"    </p>",
"    <p>",
"     Consultation with an asthma specialist (a pulmonologist or allergist) is recommended for children who have moderate or severe persistent asthma, as well as those ages zero to four years who have any form of persistent asthma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      QUICK-RELIEF MEDICATIONS FOR ASTHMA",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Short-acting bronchodilators (also called beta-2 agonists) relieve asthma symptoms rapidly, by relaxing the muscles around narrowed airways. In the United States, albuterol (Ventolin&reg;, Proventil&reg;, ProAir&reg;, and others) is the most commonly used short-acting bronchodilator. These medications are sometimes referred to as \"quick-acting relievers\". Children with intermittent asthma, the mildest form of asthma, will require these symptom-relieving medications only occasionally.",
"    </p>",
"    <p>",
"     There is no benefit to using short-acting bronchodilators on a regular basis and there may be some harm. If asthma symptoms are occurring more than twice per week on a regular basis, the child should be evaluated by a healthcare provider. Other medications are more effective for persistent symptoms in this situation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Metered-dose inhaler versus nebulizer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Short-acting bronchodilators can be delivered with a nebulizer or through a metered-dose inhaler with an attached spacer (valved holding device) device and an infant- or child-sized mask. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link\">",
"      \"Delivery of inhaled medication in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nebulizers use compressed air to change a medication from liquid form to a fine spray that can be inhaled through a mask or mouthpiece (",
"       <a class=\"graphic graphic_picture graphicRef75577 \" href=\"UTD.htm?25/46/26341\">",
"        picture 1",
"       </a>",
"       ). When a facemask is used, it should be placed snugly over the face; moving the mask just 1 centimeter away from the face reduces the dose of an inhaled medication by up to 50 percent. Nebulizers may be preferred to metered-dose inhalers for children who are unable to use a handheld device. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link\">",
"        \"Use of medication nebulizers in children\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Metered-dose inhalers dispense liquid or fine powder medications, which mix with the air that is breathed into the lungs. The spacer and face mask help to ensure that the greatest amount of medication is delivered to the lungs (",
"       <a class=\"graphic graphic_picture graphicRef75577 \" href=\"UTD.htm?25/46/26341\">",
"        picture 1",
"       </a>",
"       ). It is preferable to have the child use the inhaler when he or she is awake and not crying. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"        \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Side effects of bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some children feel shaky, have an increased heart rate, or become hyperactive after using a short-acting bronchodilator. The side effects often decrease over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      CONTROLLER MEDICATIONS FOR ASTHMA",
"     </span>",
"    </p>",
"    <p>",
"     Children with persistent asthma need to take medication on a daily basis to keep their asthma under control, even if there are no symptoms of active asthma on a given day. Medications taken daily for asthma are called \"long-term controller\" medicines and function to decrease inflammation (or swelling) of the small airways over time. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"      \"Chronic asthma in children younger than 12 years: Controller medications\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some controller medicines are delivered by inhaler or nebulizer, while others are taken as a pill or granules. The doses and types of controller medications prescribed to children with asthma depend on a child's asthma severity and level of symptom control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Inhaled glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inhaled glucocorticoids work by reducing swelling and sensitivity of the bronchial tubes, thereby reducing their exaggerated reaction to asthma triggers. These medications are the preferred treatment for persistent asthma. Regular treatment with an inhaled glucocorticoid medication can reduce the frequency of symptoms (and the need for inhaled bronchodilators), improve quality of life, and decrease the risk of a serious asthma attack.",
"    </p>",
"    <p>",
"     Inhaled glucocorticoids may be taken by metered dose inhaler with a valved holding chamber (spacer) or by nebulizer. Chambers are available with different sized masks to fit younger children. These medications need to be taken on a daily basis to effectively control asthma symptoms. An inhaled bronchodilator is still used as needed to relieve symptoms and before exposure to asthma triggers. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Side effects of glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Unlike glucocorticoids that are taken by mouth, very little of the inhaled glucocorticoid is absorbed into the bloodstream, and there are few side effects. As the dose of inhaled glucocorticoids is increased, more of the medication is absorbed into the bloodstream, and the risk of side effects increases.",
"    </p>",
"    <p>",
"     The most common side effect of",
"     <strong>",
"      low-dose",
"     </strong>",
"     inhaled glucocorticoids is oral candidiasis (thrush). This can usually be prevented by taking inhaled glucocorticoids with a spacer with or without a face mask (which helps to deliver medication to the lungs rather than the mouth). The child should rinse his or her mouth or brush teeth and tongue immediately after inhalation. A hoarse voice and sore throat (without thrush) are less common side effects that are usually managed by changing to a different glucocorticoid preparation.",
"    </p>",
"    <p>",
"     The most common side effect from long-term use of",
"     <strong>",
"      moderate or high-dose",
"     </strong>",
"     inhaled glucocorticoids is temporary slowing of growth; the body adjusts to a normal growth rate within the first year of use. Other rare but possible side effects include cataracts, increased pressure in the eye (glaucoma), and increased bone loss (osteoporosis).",
"    </p>",
"    <p>",
"     Although the side effects of glucocorticoids are of concern to many parents, it is important to remember that untreated asthma itself can prevent the child from participating in activities, influence the way a child perceives his or her well-being, and place the child at risk for an asthma exacerbation.",
"    </p>",
"    <p>",
"     In addition, the risk of side effects is far less with inhaled glucocorticoids than with oral glucocorticoids (eg, prednisolone). The goal of treatment is to use the lowest possible dose while maintaining good asthma control and minimizing the risk of serious asthma attacks. This usually means that treatment will be adjusted frequently, depending upon how well symptoms are controlled.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Leukotriene modifiers",
"     </span>",
"     &nbsp;&mdash;&nbsp;A category of medications called leukotriene modifiers are sometimes used as an alternative to low-dose inhaled glucocorticoids in children who have mild persistent asthma. However, leukotriene modifiers are not quite as effective as inhaled glucocorticoids. The leukotriene modifier montelukast (Singulair&reg;) is taken by mouth once daily and is available as a chewable pill or granules that can be taken directly or mixed into certain soft foods.",
"    </p>",
"    <p>",
"     Leukotriene modifiers can be used in addition to inhaled glucocorticoids in children who have more severe",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     difficult-to-control asthma.",
"    </p>",
"    <p>",
"     There are worries that montelukast might be linked to an increase in side effects like mood changes and aggressive behavior. Parents should notify the child&rsquo;s healthcare provider if any changes in mood or behavior occur after starting this medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Long-acting bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Long-acting bronchodilators (also called long-acting beta agonists, or LABA) are bronchodilators that have a longer-lasting effect (at least 12 hours) compared with the short-acting beta agonists that are used as reliever medications (see",
"     <a class=\"local\" href=\"#H10\">",
"      'Quick-relief medications for asthma'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     These medications (LABA) are used as add-on therapy in children who have more severe",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     difficult-to-control asthma. They should be used only in combination with an inhaled glucocorticoid; they should not be used alone, because there are concerns that using LABA long-term can cause severe asthma episodes. An attempt should be made to taper off the medication that contains a LABA once the child's asthma is under control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Cromolyn",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inhaled cromolyn (sodium cromoglycate) may be recommended as an alternative to low-dose inhaled glucocorticoids for children with mild persistent asthma. This medicine is not a glucocorticoid and works by decreasing the activity of allergy cells. It is taken via metered-dose inhaler, dry powder inhaler, or by nebulization (availability of these formulations varies from one country to another; most formulations are no longer available in the United States). Cromolyn is generally less effective than inhaled glucocorticoids. It is also less convenient, as it must be taken three or four times per day. Cromolyn can be used to prevent asthma symptoms before exposure to a trigger or before exercising.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      EXERCISE-INDUCED ASTHMA",
"     </span>",
"    </p>",
"    <p>",
"     An article that discusses exercise-induced asthma is available separately. If exercise is a trigger for asthma, the child can take an extra dose of bronchodilator medication, leukotriene modifier, or cromolyn before exercise. The child should not use more than twice the amount of medication normally used. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      ASTHMA ATTACK TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The term \"asthma attack\" is somewhat confusing because it does not distinguish between a mild increase in symptoms and a life-threatening episode. Asthma symptoms may be aggravated by changes in air quality, the common cold, and new or continued exposure to triggers. These triggers can cause mild, moderate, or severe asthma symptoms to develop. Any of these changes could be considered an asthma \"attack.\"",
"    </p>",
"    <p>",
"     Some children will have periodic, mild asthma attacks that never require emergency care, while others may have severe and sudden asthma attacks that require a call for emergency medical attention.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Asthma action plan",
"     </span>",
"     &nbsp;&mdash;&nbsp;The child",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     parent will work with their healthcare provider to develop tailored guidelines (also called an action plan) to follow when symptoms increase. Asthma action plans are available for children up to age five (",
"     <a class=\"graphic graphic_form graphicRef78132 \" href=\"UTD.htm?38/14/39146\">",
"      form 2",
"     </a>",
"     ), for children five and older and adults (",
"     <a class=\"graphic graphic_form graphicRef53142 \" href=\"UTD.htm?36/38/37482\">",
"      form 3",
"     </a>",
"     ), and for school (",
"     <a class=\"graphic graphic_form graphicRef59053 graphicRef71869 graphicRef51794 \" href=\"UTD.htm?43/42/44714\">",
"      form 4A-C",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Asthma symptoms are divided into three zones, which are assigned colors similar to those of a traffic light. These zones can be used to make decisions about the need for treatment:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Green",
"     </span>",
"     &nbsp;&mdash;&nbsp;Green signals that the lungs are functioning well. When asthma symptoms are not present or are well controlled, patients should continue their regular medicines and activities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Yellow",
"     </span>",
"     &nbsp;&mdash;&nbsp;Yellow is a sign that the airways in the lungs are somewhat narrowed, making it difficult to move air in and out; this occurs when there is an increase in asthma symptom frequency or severity. A short-term change or increase in medication is generally required. Patients should change or increase their asthma medication according to the plan that was discussed with their provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Red",
"     </span>",
"     &nbsp;&mdash;&nbsp;Red is a sign that the airways are significantly narrowed and requires immediate treatment; this occurs with a significant increase in asthma symptoms. The quick-acting reliever inhaler should be used according to the plan discussed with the provider and the child should be evaluated by a medical professional.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Emergency care plan",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parents should work with their child's healthcare provider to formulate an emergency care plan that explains specifically what to do if asthma symptoms worsen. This may include more frequent use of a reliever medication.",
"    </p>",
"    <p>",
"     However, if asthma symptoms worsen or do not improve after use of a quick-acting reliever medication, the parent should immediately call for emergency medical assistance. Severe asthma attacks can be fatal if not treated promptly.",
"    </p>",
"    <p>",
"     In most areas of the United States, emergency medical assistance is available by calling 911. Parents should",
"     <strong>",
"      not",
"     </strong>",
"     attempt to drive to the hospital and should not ask someone else to drive. Calling 911 is safer than driving for two reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       From the moment EMS personnel arrive, they can begin evaluating and treating asthma. If a parent drives to the hospital, treatment cannot begin until the child arrives at the emergency department.",
"      </li>",
"      <li>",
"       If a dangerous complication of asthma occurs on the way to the hospital, EMS personnel may be able to treat the problem immediately.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Following an asthma attack, most children are given a 3- to 10-day course of an oral glucocorticoid medication (eg, prednisone, prednisolone). This treatment helps to decrease the swelling and mucus production in the lungs and reduces the risk of a second asthma attack.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Wear medical identification",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many children with medical conditions wear a bracelet, necklace, or similar alert tag at all times. If an accident occurs and the child cannot explain his or her condition, this will help responders provide appropriate care.",
"    </p>",
"    <p>",
"     The alert tag should include a list of major medical conditions and allergies, as well as the name and phone number of an emergency contact. One device, Medic Alert&reg; (",
"     <a class=\"external\" href=\"file://www.medicalert.com\">",
"      www.medicalert.com",
"     </a>",
"     ), provides a toll-free number that emergency medical workers can call to find out a person's medical history, list of medications, family emergency contact numbers, and healthcare provider names and numbers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child&rsquo;s healthcare provider is the best source of information for questions and concerns related to your child&rsquo;s medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H281\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21387155\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/2/16419?source=see_link\">",
"      Patient information: Avoiding asthma triggers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/4/33858?source=see_link\">",
"      Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/52/13122?source=see_link\">",
"      Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21387163\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=see_link\">",
"      Patient information: Exercise-induced asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"      Acute severe asthma exacerbations in children: Intensive care unit management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"      An overview of asthma management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20870?source=see_link\">",
"      Anticholinergic agents in the management of acute exacerbations of asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"      Approach to wheezing in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15319?source=see_link\">",
"      Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=see_link\">",
"      Natural history of asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34472?source=see_link\">",
"      Nocturnal asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"      Risk factors for asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=see_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link\">",
"      Use of medication nebulizers in children",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       What's Asthma All About?",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.whatsasthma.org/\">",
"        www.whatsasthma.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acaai.org/allergist\">",
"        www.acaai.org/allergist",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/60/18374/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/60/18374?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18374/abstract/2\">",
"      Bisgaard H, Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet 2006; 367:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18374/abstract/3\">",
"      Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18374/abstract/4\">",
"      Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119:64.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_60_18374=[""].join("\n");
var outline_f17_60_18374=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ASTHMA TREATMENT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CONTROLLING ASTHMA TRIGGERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           MONITORING ASTHMA SYMPTOMS AND LUNG FUNCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CATEGORIES OF ASTHMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           QUICK-RELIEF MEDICATIONS FOR ASTHMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           CONTROLLER MEDICATIONS FOR ASTHMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           EXERCISE-INDUCED ASTHMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           ASTHMA ATTACK TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/25/4498\" title=\"figure 1\">",
"           Asthma daily diary PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          FORMS",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?14/58/15266\" title=\"form 1\">",
"           Asthma self assess PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?38/14/39146\" title=\"form 2\">",
"           Child asthma action plan PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?36/38/37482\" title=\"form 3\">",
"           Asthma action plan PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?28/14/28905\" title=\"form 4A\">",
"           School action plan A",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?38/31/39416\" title=\"form 4B\">",
"           School action plan B",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?35/59/36794\" title=\"form 4C\">",
"           School action plan C",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/46/26341\" title=\"picture 1\">",
"           Nebulizer and spacer use PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?14/35/14909\" title=\"table 1\">",
"           Asthma severity 5 to 11 yrs",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_60_18375="Second-line antituberculous therapy";
var content_f17_60_18375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second-line antituberculous therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18375/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18375/contributors\">",
"     Richard H Drew, PharmD, MS, BCPS, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18375/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18375/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18375/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18375/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/60/18375/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, first-line treatment of tuberculosis consists of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    under specific situations),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    . In the setting of drug resistance or intolerance to first line agents, second-line agents may be used (",
"    <a class=\"graphic graphic_table graphicRef83653 \" href=\"UTD.htm?42/59/43964\">",
"     table 1",
"    </a>",
"    ). These include fluoroquinolones, injectable agents and less effective agents or drugs for which clinical data are sparse.",
"   </p>",
"   <p>",
"    The second-line antituberculous drugs are so classified because of relative lack of clinical data, unfavorable or poorly characterized pharmacokinetic profile,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased incidence and severity of adverse events (",
"    <a class=\"graphic graphic_table graphicRef66493 \" href=\"UTD.htm?13/8/13453\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Experience with some of these agents is increasing based upon the need for alternative therapies for treatment of drug resistant TB.",
"   </p>",
"   <p>",
"    This topic will review pharmacologic issues related to use of second-line antituberculous drugs, with the exception of the fluoroquinolones and aminoglycosides (other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ); these are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical approaches to treatment of tuberculosis and drug-resistant tuberculosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\", section on 'Clinical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major indications for the use of second-line therapy in the treatment of tuberculosis: resistance of the M. tuberculosis isolate to first-line agents,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patient intolerance (including hypersensitivity reactions) to first-line drugs.",
"   </p>",
"   <p>",
"    Second-line antituberculous agents should be used only in combination regimens. It is especially important to consult an expert in the treatment of tuberculosis before embarking upon a treatment course with any second-line antituberculous agents, and selection should be guided by in vitro susceptibility results.",
"   </p>",
"   <p>",
"    The clinical approach to use of second-line agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\", section on 'Clinical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPECIFIC DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Capreomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     Capreomycin",
"    </a>",
"    , a polypeptide antibiotic obtained from Streptomyces capreolus, is active against most drug resistant TB strains, at concentrations of 1 to 50",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (usually 10",
"    <span class=\"nowrap\">",
"     microgram/mL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    mechanism of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    is poorly understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The site of mutational change resulting in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    resistance is unknown. There is no cross-resistance between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    and capreomycin, but some isolates resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    are cross-resistant to capreomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average peak serum concentrations are approximately 30",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     Capreomycin",
"    </a>",
"    is not thought to penetrate into the cerebrospinal fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     Capreomycin",
"    </a>",
"    is a parenteral (IM or IV) drug, administered once daily at a dose of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in adults (maximum dose of 1 g). The dose should be reduced for individuals &gt;59 years of age to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 750 mg). Children may receive doses of 15 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum dose 1 g) as a single daily dose or given twice weekly.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     Capreomycin",
"    </a>",
"    is usually given five to seven times a week. Once the sputum culture is negative (usually after two to four months of therapy), the frequency can be reduced to two or three times a week (depending upon the activity of other agents).",
"   </p>",
"   <p>",
"    Patients with renal dysfunction are at increased risk of toxicity because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    is cleared almost entirely by the kidneys. In patients with significant reduction in estimated glomerular filtration rate (including patients undergoing hemodialysis), the dosing frequency should be reduced to two or three times weekly at a dose of 12 to 15",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auditory, vestibular, and renal toxicity (including potassium and magnesium wasting and proteinuria) have been associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    therapy. Capreomycin should be avoided in pregnancy because of the risks of fetal nephrotoxicity and congenital hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline audiogram, vestibular testing, Romberg testing, and serum creatinine, potassium and magnesium measurements should be performed. Assessments of renal function, auditory and vestibular symptoms should be performed monthly. An audiogram and vestibular testing should be repeated if there are symptoms of eighth nerve toxicity. In addition, serum potassium and magnesium concentrations should be measured at least at monthly intervals because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    can cause both hypokalemia and hypomagnesemia due to renal wasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant use of aminoglycosides or other nephrotoxins can potentiate the toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    . Capreomycin can interact with a variety of other drugs. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     \"Capreomycin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Streptomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    is an aminoglycoside antibiotic. Its use is limited by drug toxicity, the need for parenteral administration, and increased resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    acts by binding to the 30S ribosomal subunit, leading to misreading of the genetic code and inhibition of translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The initial steps required for peptide synthesis are uninterrupted, such as binding of mRNA and the association of the 50S ribosomal subunit, but elongation fails to occur due to disruption of the mechanisms for ensuring translational accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aminoglycosides penetrate the organism by disrupting the magnesium bridges between lipopolysaccharide moieties. They are transported across the cytoplasmic membrane in an energy-dependent manner. This step can be inhibited in vitro by divalent cations, increased osmolality, acidic pH, and an anaerobic environment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiologic activity of aminoglycosides is pH dependent. As a result, an antimicrobial effect may be reduced at the low pH found in lung and bronchial secretions. In one in vitro study the minimum inhibitory concentration (MIC) of aminoglycosides was increased almost fivefold at pH &lt;6.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid emergence of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    was quickly recognized when given as single-drug therapy. Approximately 1 in 10(6) tubercle bacilli is spontaneously resistant to streptomycin. Primary resistance to streptomycin is seen most often in populations of patients with high incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    resistance. Streptomycin resistance is related to mutational changes involving ribosomal binding protein or the ribosomal binding site [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular injection of 1 g yields peak serum concentrations of 25 to 45",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    is virtually excluded from the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    is administered parenterally at a dose in adults of 15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (maximum 1 g per day). The dose should be reduced for individuals &gt;59 years of age to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 750 mg); children may be given a dose of 20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 1 g per day).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    is initially given as a single daily dose five to seven times a week. Once the sputum culture has become negative (usually after two to four months of therapy), the frequency can be reduced to two or three times a week. In patients with significant reduction in estimated glomerular filtration rate (including patients undergoing hemodialysis), the dosing frequency should be reduced to two or three times weekly at a dose of 12 to 15",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    is associated with numerous side effects, most notably ototoxicity (vestibular or hearing disturbances), neurotoxicity (weakness, circumoral paresthesias) and nephrotoxicity. Risk factors for toxicity in patients include preexisting renal dysfunction, increasing age, concomitant use of other ototoxins or nephrotoxins, increasing amount of single doses, and cumulative doses above 100 g. Streptomycin is contraindicated in pregnancy due to risk of fetal hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    should receive an audiogram, vestibular testing, Romberg testing and assessment of renal function (ie, serum creatinine concentration) at baseline. Measurement of serum creatinine and questioning regarding signs of auditory or vestibular toxicity should be performed monthly. Serum drug concentrations should also be monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    can interact with a variety of drugs. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     \"Streptomycin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ethionamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     Ethionamide",
"    </a>",
"    is a derivative of isonicotinic acid. It is tuberculostatic at 0.6 to 2.5",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    against susceptible strains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     Ethionamide",
"    </a>",
"    may work by inhibition of the synthesis of oxygenated mycolic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    resistance is unknown, but some isolates are resistant to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and ethionamide and harbor mutations in the region of the inhA gene, which is involved in mycolic acid biosynthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     Ethionamide",
"    </a>",
"    is well absorbed after oral administration, yielding peak serum concentrations of 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    It is widely distributed and penetrates both normal and inflamed meninges to yield CSF concentrations equivalent to those in plasma. It is metabolized by the liver, with metabolites being excreted in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    for both adults and children is 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 1 g) PO in a single daily dose or two divided doses (either with meals or at bedtime in attempts to reduce GI intolerance). Single doses exceeding 500 mg are generally poorly tolerated. For patients with creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute,",
"    </span>",
"    the dose should be reduced to 250 to 500 mg per day. Ethionamide is not recommended for intermittent administration due to a lack of data to support such dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    are gastrointestinal including a metallic taste, nausea, vomiting, anorexia, and abdominal pain. Nausea may be sufficiently severe to necessitate bedtime administration with or without antiemetic therapy. This drug should not be taken on an empty stomach.",
"   </p>",
"   <p>",
"    Additional adverse reactions include neurotoxicity (peripheral neuritis, optic neuritis, anxiety, depression, and psychosis), hepatotoxicity, hypersensitivity reactions, and endocrine effects (hypothyroidism, gynecomastia, alopecia, and impotence). Pyridoxine (50 to 100 mg daily) may be useful in reducing CNS-related side effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     Ethionamide",
"    </a>",
"    is contraindicated in pregnant women due to teratogenicity observed in animal models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver function tests should be obtained at baseline and, if there is underlying liver disease, at monthly intervals. These studies should be repeated if symptoms occur. Serum thyroid-stimulating hormone should be measured at baseline and at monthly intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"     paraaminosalicylic acid",
"    </a>",
"    appears to increase the likelihood of adverse reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    . Seizures have been reported with concomitant administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    . In addition, there is an increased risk of hepatotoxicity when ethionamide is administered in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     \"Ethionamide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044339\">",
"    <span class=\"h2\">",
"     Cycloserine",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044346\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     Cycloserine",
"    </a>",
"    inhibits cell wall synthesis. Serum concentrations of 5 to 20",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    inhibit susceptible M. tuberculosis in vitro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044353\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    resistance in M. tuberculosis is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044360\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     Cycloserine",
"    </a>",
"    is readily absorbed orally and produces peak serum concentrations of 20 to 50",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"    It is widely distributed among tissues, including the central nervous system. Approximately two-thirds of the administered drug is excreted unchanged by the kidneys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044367\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose in adults and children is 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally per day (maximum 1 g). This is usually administered to adults as 500 mg every twelve hours. Therapy should begin with a low dose which can be increased as tolerated. There are no published data available to support the intermittent administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Dosing modifications are necessary in patients with renal impairment. Once daily or alternate daily dosing can be employed, depending upon the degree of renal dysfunction.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     Cycloserine",
"    </a>",
"    is not recommended in patients with creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    unless receiving concomitant hemodialysis. For such patients, the dose should be reduced to 500 mg three times weekly or 250 mg daily with serum concentration monitoring performed to guide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044381\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     Cycloserine",
"    </a>",
"    has been associated with dose-related CNS-related adverse events (such as psychosis, convulsions, depression and headaches). Cycloserine therapy is known to worsen underlying disease in patients with seizures disorders or significant mental health disorders. Pyridoxine may decrease the incidence or severity of neurotoxicity.",
"   </p>",
"   <p>",
"    Data on safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    in pregnancy are limited. Since cycloserine crosses the placenta, it should be avoided in pregnant women and used only when no suitable alternatives exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044388\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum drug level monitoring is often advocated for patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , especially in those with renal insufficiency, with a goal peak serum concentration of 20 to 35",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    Neuropsychiatric status should be assessed at least at monthly intervals and more frequently if symptoms develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044395\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     Cycloserine",
"    </a>",
"    can interact with a variety of other drugs. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     \"Cycloserine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Paraaminosalicylic acid",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"     Paraaminosalicylic acid",
"    </a>",
"    (PAS) inhibits the growth of tubercle bacilli by impairment of folate synthesis and inhibition of iron uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/15\">",
"     15",
"    </a>",
"    ]. PAS is bacteriostatic against M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of resistance to PAS is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral absorption of PAS is incomplete. Twice-daily dosing of 4 g of granules can maintain serum PAS concentrations above 1",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    which is considered to be the minimum inhibitory concentration (MIC) for PAS against M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 80 percent of PAS is excreted in the urine. Unless no alternative treatment options exist, its use is contraindicated in severe renal insufficiency because of metabolite accumulation (ie, acetylated form).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAS is dosed in adults at 8 to 12 g per day in two or three divided doses. Children may receive 200 to 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two to four divided doses. PAS is generally started at a low dose and increased according to patient tolerance.",
"   </p>",
"   <p>",
"    The delayed-release granules (the only formulation available in the United States) may improve gastrointestinal tolerability and should be sprinkled on yogurt or applesauce. Previously it was advised that granules be taken with an acidic beverage (orange or tomato juice) to enhance absorption but this is no longer thought to be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18375/abstract/18\">",
"     18",
"    </a>",
"    ]. The granules should not be chewed. No data on intermittent dosing are available.",
"   </p>",
"   <p>",
"    PAS can be obtained in the United States by contacting the",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     Centers for Disease Control and Prevention (CDC)",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects associated with PAS include gastrointestinal intolerance (which is often severe), hypersensitivity (manifested by fever, joint pain, and rash), malabsorption syndromes, hypothyroidism, hepatotoxicity, and coagulopathy.",
"   </p>",
"   <p>",
"    PAS has been used safely in pregnancy, although extensive studies have not been performed. Thus, PAS should be used in pregnancy only if there are no alternatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration is associated with a significant sodium load since PAS is supplied as a sodium salt; this may be a concern in patients with heart failure or hypertension. Hepatic enzymes and thyroid function should be measured at baseline. Thyroid function should be checked at three month intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAS can interact with a variety of other drugs. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"     \"Para-aminosalicylic acid: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044566\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the setting of drug resistance, clinical failure, or intolerance to first-line antituberculous agents, second-line agents may be used (",
"      <a class=\"graphic graphic_table graphicRef83653 \" href=\"UTD.htm?42/59/43964\">",
"       table 1",
"      </a>",
"      ). Second-line agents include fluoroquinolones, injectable agents, and other less effective agents or drugs for which clinical data are sparse. The second-line antituberculous drugs are so classified because of limited data, unfavorable or poorly characterized pharmacokinetic profiles,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased incidence and severity of adverse events (",
"      <a class=\"graphic graphic_table graphicRef66493 \" href=\"UTD.htm?13/8/13453\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Second-line antituberculous agents should be used only as part of a combination regimen. It is especially important to consult an expert in the treatment of tuberculosis before embarking upon a treatment course with any second-line antituberculous agent. Selection should be guided (whenever possible) by in vitro susceptibility results. The clinical approach to use of second-line agents is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link&amp;anchor=H14#H14\">",
"       \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\", section on 'Clinical approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"       Capreomycin",
"      </a>",
"      has been associated with auditory, vestibular, and renal toxicity (including potassium and magnesium wasting and proteinuria). Baseline audiogram, vestibular testing, Romberg testing, and measurements of serum creatinine, potassium, and magnesium concentrations should be performed. Assessments of renal function, auditory, and vestibular symptoms should be performed monthly. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Capreomycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      is limited by resistance and drug toxicity, most notably ototoxicity (vestibular or hearing disturbances), neurotoxicity (weakness, circumoral paresthesias), and nephrotoxicity. Baseline audiogram, vestibular testing, Romberg testing, and serum creatinine concentration should be performed. Measurement of serum creatinine and evaluation for signs of auditory or vestibular toxicity should be performed monthly. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Streptomycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      include a metallic taste, nausea, vomiting, anorexia, and abdominal pain. Additional adverse reactions include neurotoxicity (peripheral neuritis, optic neuritis, anxiety, depression, and psychosis), hepatotoxicity, hypersensitivity reactions, and endocrine effects (hypothyroidism, gynecomastia, alopecia, and impotence). Pyridoxine (50 to 100 mg daily) may be useful in reducing neurotoxicity. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Ethionamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"       Cycloserine",
"      </a>",
"      has been associated with psychosis, convulsions, depression, and headaches. It is known to worsen underlying disease in patients with seizures disorders or mental illness. Pyridoxine (50 to 100 mg daily) may decrease the incidence or severity of neurotoxicity. (See",
"      <a class=\"local\" href=\"#H4044339\">",
"       'Cycloserine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects associated with p-aminosalicylic acid include gastrointestinal intolerance (which is often severe), hypersensitivity (manifested by fever, joint pain, and rash), malabsorption syndromes, hypothyroidism, hepatotoxicity, and coagulopathy. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Paraaminosalicylic acid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/1\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/2\">",
"      Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/3\">",
"      Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10:621.",
"     </a>",
"    </li>",
"    <li>",
"     United States Pharmacopeial Dispensing Information. Drug Information for the Health Care Professional, Volume I. Micromedex, Englewood, CO 1999. p. 69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/5\">",
"      Fourmy D, Recht MI, Blanchard SC, Puglisi JD. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 1996; 274:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/6\">",
"      Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999; 43:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/7\">",
"      Nanavaty J, Mortensen JE, Shryock TR. The effects of environmental conditions on the in vitro activity of selected antimicrobial agents against Escherichia coli. Curr Microbiol 1998; 36:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/8\">",
"      Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/9\">",
"      Meier A, Sander P, Schaper KJ, et al. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/10\">",
"      Honor&eacute; N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994; 38:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/11\">",
"      ROBINSON GC, CAMBON KG. HEARING LOSS IN INFANTS OF TUBERCULOUS MOTHERS TREATED WITH STREPTOMYCIN DURING PREGNANCY. N Engl J Med 1964; 271:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/12\">",
"      CONWAY N, BIRT BD. STREPTOMYCIN IN PREGNANCY: EFFECT ON THE FOETAL EAR. Br Med J 1965; 2:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/13\">",
"      Qu&eacute;mard A, Lan&eacute;elle G, Lacave C. Mycolic acid synthesis: a target for ethionamide in mycobacteria? Antimicrob Agents Chemother 1992; 36:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/14\">",
"      Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 2002; 277:12824.",
"     </a>",
"    </li>",
"    <li>",
"     Winder FG. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the Mycobacteria, Academic Press Inc, New York 1982.",
"    </li>",
"    <li>",
"     Aminosalicylate sodium. In: Drug Facts and Comparisons, 4th ed, St. Louis 2000. p.750.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/17\">",
"      Peloquin CA, Berning SE, Huitt GA, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999; 159:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18375/abstract/18\">",
"      Peloquin CA, Henshaw TL, Huitt GA, et al. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 1994; 14:40.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 488 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18375=[""].join("\n");
var outline_f17_60_18375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4044566\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPECIFIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Capreomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Streptomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ethionamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044339\">",
"      Cycloserine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4044346\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4044353\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4044360\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4044367\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4044381\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4044388\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4044395\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Paraaminosalicylic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4044566\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/488|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/59/43964\" title=\"table 1\">",
"      Categories of antituberculous drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/8/13453\" title=\"table 2\">",
"      Second line TB drugs for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=related_link\">",
"      Capreomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=related_link\">",
"      Cycloserine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=related_link\">",
"      Ethionamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=related_link\">",
"      Para-aminosalicylic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=related_link\">",
"      Streptomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_60_18376="Diagnostic approach to short stature";
var content_f17_60_18376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to short stature",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18376/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18376/contributors\">",
"     Alan D Rogol, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18376/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18376/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18376/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/60/18376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child who is 2 standard deviations (SD) or more below the mean height for children of that sex and chronologic age (and ideally of the same racial-ethnic group) is said to have short stature. A single measurement of height is much less important in assessing growth than is the pattern of growth over a period of time; the key finding is slowed growth that progressively deviates from a previously defined growth channel (or percentile).",
"   </p>",
"   <p>",
"    Height measurements must be made with an appropriate apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/1\">",
"     1",
"    </a>",
"    ], and these measurements (along with those of weight and head circumference) plotted accurately on the appropriate growth chart.",
"   </p>",
"   <p>",
"    This topic will review the diagnostic approach to children with short stature, beginning with a brief review of normal growth and development. The causes of short stature are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal pattern of growth is evidence that the general health of a child or adolescent is good. On the other hand, children with almost any subacute or chronic illness may grow slower than normal. Because growth is one of the most important parameters in monitoring the health of children, a child's height and weight should be measured at each well child visit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Phases of growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statural growth is a continuous but not linear process. There are three phases of postnatal growth &mdash; infantile, childhood, and pubertal &mdash; each with its own distinctive pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/3\">",
"     3",
"    </a>",
"    ]. The phases are similar for boys and girls, but the timing and pace of growth differ, particularly during puberty.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The infantile phase is characterized by rapid but decelerating growth during the first two years of life; overall growth during this period is about 30 to 35 cm. Infants often cross percentile lines in the first 24 months as they grow toward their genetic potential and get further away from the excesses or constraints of the intrauterine environment.",
"     </li>",
"     <li>",
"      The childhood phase is characterized by growth at a relatively constant velocity of 5 to 7 cm per year in both sexes; there is often slight slowing later in childhood.",
"     </li>",
"     <li>",
"      The pubertal phase is characterized by a growth spurt of 8 to 14 cm per year due to the synergistic effects of increasing gonadal steroid and growth hormone secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prediction of height potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic growth and biologic maturation are influenced by many factors that act independently or in concert to modify a child's genetic potential for growth. No method accurately predicts adult height, and indeed there is wide variation in predicted adult height among the different methods. These limitations should be understood when making clinical decisions about management of children with short stature. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7821167\">",
"    <span class=\"h3\">",
"     Midparental height method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the precise contribution of heredity cannot be quantitated, an estimate of a child's adult height potential can be obtained by calculation of the midparental height, adjusted for the sex of the child (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?30/3/30769?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For girls, 13 cm (or 5 inches) is subtracted from the father's height and averaged with the mother's height.",
"     </li>",
"     <li>",
"      For boys, 13 cm (or 5 inches) is added to the mother's height and averaged with the father's height.",
"     </li>",
"     <li>",
"      For both girls and boys, 8.5 cm (2.4 inches) on either side of this calculated value (target height) represents the 3rd to 97th percentiles for anticipated adult height [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/5\">",
"       5",
"      </a>",
"      ]. The 13 cm (or 5 inches) represents the average difference in height of men and women; thus, the child grows, on average, to the midparental height percentile. In general, the rule of \"fives\" for length or height (a rule for estimating normal growth velocity in a given age group, as shown in the table (",
"      <a class=\"graphic graphic_figure graphicRef70382 \" href=\"UTD.htm?6/6/6253\">",
"       figure 1",
"      </a>",
"      )) should suffice to estimate normal growth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7821181\">",
"    <span class=\"h3\">",
"     Methods that incorporate bone age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult height also can be predicted from the child&rsquo;s present height and the bone age. Bone age is measured from a radiograph of the left hand and wrist, and is a surrogate for the child's biologic age. Although methods that incorporate bone age are generally more accurate in predicting adult height than the simple midparental height method, there is a wide variation in height prediction, and the same method may yield significantly different adult height predictions at different ages [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using the Bayley-Pinneau (BP) method, the bone age corresponds to a percentage of adult height, which is shown on a table derived decades ago from a population of normally-growing children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/7\">",
"     7",
"    </a>",
"    ]. To predict adult height, the present height is multiplied by 100 and divided by percent adult height.",
"   </p>",
"   <p>",
"    The Tanner-Whitehouse II (TWII), Roche-Wainer-Thissen (RWT), and Khamis-Roche (KR) methods use different algorithms to predict adult height from auxological and bone age data. RWT and KR incorporate mid-parental height, and TWII uses a different measure of bone age. Comparison of these methods reveals a wide range of adult height predictions. Overall, the TWII method tends to under-predict adult height, while the BP and RWT methods tend to over-predict adult height in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/6\">",
"     6",
"    </a>",
"    ]. The BP method is most likely to identify a short child as a candidate for growth hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523440\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a child suspected of having short stature is guided by answering the following questions. Although the causes and clinical presentation of short stature varies by age group, the same questions are relevant for children of any age:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the child short?",
"     </li>",
"     <li>",
"      Does the child have dysmorphic features or disproportionate short stature?",
"     </li>",
"     <li>",
"      Although the child is short, is his or her growth velocity impaired?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Is the child short?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child's length or height should be accurately measured and then plotted on an appropriate growth chart. Length is measured lying down and should be used for infants and children up to 24 months of age (",
"    <a class=\"graphic graphic_figure graphicRef67950 graphicRef80511 \" href=\"UTD.htm?38/48/39687\">",
"     figure 2A-B",
"    </a>",
"    ); height is measured standing and should be used for children 2 years and older (",
"    <a class=\"graphic graphic_figure graphicRef56127 \" href=\"UTD.htm?27/45/28371\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63399 graphicRef77249 \" href=\"UTD.htm?43/30/44519\">",
"     figure 4A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link\">",
"     \"Measurement of growth in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percentiles and z-scores can be calculated using a calculator for recumbent length (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34339?source=see_link\">",
"     calculator 2",
"    </a>",
"    ), or standing height for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=see_link\">",
"     calculator 3",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=see_link\">",
"     calculator 4",
"    </a>",
"    ). For the purposes of an endocrine evaluation, short stature is defined as a length or height more than 2 SD below the mean (ie, a z-score &lt; -2), which corresponds to a percentile of &lt;2.5.",
"   </p>",
"   <p>",
"    For children with delayed or accelerated growth, the child's height should be adjusted to the appropriate height percentile, based upon the child's skeletal (biologic) age rather than chronologic age. This permits more accurate determination of whether the child is growing appropriately for his or her genetic potential. As an example, if an eight year-old child is 117 cm tall and has a bone age of seven years, this corresponds to the 3rd percentile for chronological age, but to the 17th percentile for skeletal age, the child may have mild constitutional delay of growth. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Does the child have dysmorphic features or disproportionate short stature?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with the following disorders typically present with short stature. The presence of other characteristics, such as microcephaly, dysmorphic features, disproportionate skeletal growth, or complications during gestation, often suggest a specific cause and direct appropriate imaging and laboratory studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal abnormalities, including Down syndrome and Turner syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nonchromosomal dysmorphic syndromes, such as the Noonan and Russell-Silver syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"       \"Causes of short stature\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intrauterine growth restriction (multiple causes). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"       \"Overview of causes of and risk factors for fetal growth restriction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intrauterine infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"       \"Placental infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maternal exposures including toxins, smoking, or alcohol, and systemic illness such as preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link\">",
"       \"Infants of mothers with substance abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disproportionate short stature, as in skeletal dysplasias, rickets, or hypothyroidism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"       \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"       \"Overview of rickets in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"       \"Clinical features and detection of congenital hypothyroidism\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Although the child is short, is his or her growth velocity normal or impaired?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the presence of growth failure requires an accurate plot of the results of multiple measurements of length or height. The rule of \"fives\" noted above should be helpful (",
"    <a class=\"graphic graphic_figure graphicRef70382 \" href=\"UTD.htm?6/6/6253\">",
"     figure 1",
"    </a>",
"    ); children should grow at a rate of at least 5 cm per year from age four years until the onset of puberty (",
"    <a class=\"graphic graphic_figure graphicRef66909 graphicRef74573 \" href=\"UTD.htm?32/1/32792\">",
"     figure 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The two most common causes of short stature are familial (genetic) short stature and constitutional delay of growth. In familial short stature, growth velocity is within the normal range. In constitutional delay of growth, growth velocity tends to be slow between six months and three years of age, and then normalizes. They can be distinguished from one another, although some children have features of both (",
"    <a class=\"graphic graphic_table graphicRef51582 \" href=\"UTD.htm?24/15/24827\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the growth velocity is subnormal (below the 25th percentile for age) without alternative physiological explanations, such as genetic channeling down after birth or obvious constitutional delay of growth, the child should be thoroughly investigated for one of the many different disorders that can cause this pattern. (",
"    <a class=\"graphic graphic_table graphicRef74590 \" href=\"UTD.htm?35/38/36460\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with endocrine disorders, such as Cushing's syndrome, growth hormone deficiency, and hypothyroidism are usually overweight-for-height.",
"     </li>",
"     <li>",
"      If the child is underweight-for-height, one is more likely to find malnutrition, either primary or secondary to systemic illness [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/9\">",
"       9",
"      </a>",
"      ]. The malnutrition may be a result of anorexia, malabsorption, diarrhea, or excess energy expenditure. These children should be evaluated for the presence of gastrointestinal (eg, celiac or inflammatory bowel disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/9,10\">",
"       9,10",
"      </a>",
"      ], cardiac, pulmonary (eg, asthma or cystic fibrosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/11\">",
"       11",
"      </a>",
"      ], and renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/12\">",
"       12",
"      </a>",
"      ]. HIV infection should also be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H888170\">",
"    <span class=\"h2\">",
"     Gender bias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that sex differences exist in the evaluation and treatment of short stature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. More boys than girls are referred for evaluation and boys are referred earlier and for less severe height deficits than girls.",
"   </p>",
"   <p>",
"    In one retrospective review of 288 children referred to a single center for assessment of short stature, the male:female ratio was 1.9:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the time of referral, the height deficit was significantly greater for girls than boys relative to either their mid-parental heights (median deficit, 1.9 SD versus 1.3 SD) or the general population normative data based for age and sex (median height z score, -2.4 versus -1.9). In addition, organic disease was more common among girls (40 versus 15 percent) and normal height was more common among boys (40 versus 15 percent) who were referred for evaluation of short stature.",
"   </p>",
"   <p>",
"    Studies of growth hormone registries have shown preferential treatment of boys compared to girls with an approximate ratio of 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following possibilities have been proposed to explain gender differences in the evaluation and treatment of short stature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Under-appreciation of growth problems in girls may lead to a decrease in the number of girls evaluated and treated for short stature compared to boys.",
"     </li>",
"     <li>",
"      Increased societal pressure for tall stature in boys may lead to increased referral and growth hormone treatment of boys without organic causes of short stature compared to girls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings emphasize the need for accurate growth monitoring during the health care maintenance of all children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/2\">",
"     2",
"    </a>",
"    ] to ensure appropriate referral and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IDIOPATHIC SHORT STATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children whose stature falls below 2 SD of the mean for age and whose predicted adult height is &lt;63 inches for males and &lt;59 inches for girls, and for whom no endocrine, metabolic or other diagnosis can be made are considered to have idiopathic short stature. A more stringent definition is used when considering therapy with growth hormone (height below -2.25 SD of the mean in the United States). They have normal (often at the lower limit) growth velocity, no biochemical or other evidence for a specific growth-retarding condition, normal serum concentrations of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3, and normal serum growth hormone responses to drugs that stimulate growth hormone release [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Growth hormone deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As noted above, the two most common subgroups with these findings are genetic short stature (in which bone age is not delayed and the child is growing within the parental target range), constitutional delay of growth (in which bone age is delayed), or their combination. All other children who fulfill the above criteria are considered to have idiopathic short stature.",
"   </p>",
"   <p>",
"    Emerging evidence suggests that mutations in the Short Stature Homeobox (SHOX) gene are responsible for 1 to 4 percent of cases of apparent \"idiopathic\" short stature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Individuals with this mutation tend to have shorter forearms and lower legs, Madelung deformity of the forearm, cubitus valgus (increased carrying angle of the arm), high arched palate, and muscular hypertrophy, as compared to those with ISS but no SHOX mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Growth hormone therapy is now approved for children with idiopathic short stature, but its use remains controversial. Studies have shown that consumer preferences (family concern) and physician attitudes are important drivers of treatment decisions, independent of patient characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatment indications and efficacy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18248?source=see_link\">",
"     \"Growth hormone treatment for idiopathic short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ENDOCRINE CAUSES OF GROWTH FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure caused by endocrine disorders is uncommon, but often is easily treated (",
"    <a class=\"graphic graphic_table graphicRef74590 \" href=\"UTD.htm?35/38/36460\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function should always be evaluated, because growth failure may be the first or even the only manifestation of hypothyroidism. The evaluation should include measurements of both serum thyrotropin (TSH) and thyroxine; both primary and central hypothyroidism can cause growth failure, and measurement of serum TSH alone will not detect central hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cushing syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cushing syndrome is rare in children except when due to the toxicity of glucocorticoid therapy. It is initially a clinical diagnosis that is suggested by the clinical findings and then confirmed by biochemical and imaging tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted in a review of 59 patients with Cushing's syndrome who were between the ages of 4 and 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A corticotropin (ACTH)-secreting pituitary adenoma (Cushing's disease) is by far the most common cause, accounting for 50 cases.",
"     </li>",
"     <li>",
"      The two major findings are weight gain (90 percent) and growth retardation (83 percent); bone age was within normal limits at diagnosis in most patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Growth hormone deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;If growth hormone deficiency is congenital and complete, the diagnosis is relatively easy to confirm. Affected children present with severe postnatal growth failure, delayed bone age, and very low serum concentrations of growth hormone, IGF-I, and IGF-binding protein-3 (IGFBP-3, the major circulating binding protein for IGF-I) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children with less severe growth failure, whose height may still be within the normal range for age, the decision to undertake detailed testing should be based on strict auxological criteria. It is therefore mandatory to obtain accurate serial measurements of height. Any evidence of central nervous system disease or other anterior pituitary hormone deficiencies should lead to measurement of IGF-I and provocative testing of growth hormone (growth hormone stimulation tests). These provocative tests are not definitive, but can be a valuable diagnostic tool when combined with auxological data and measurements of IGF-I and IGFBP-3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The rare children with growth hormone insensitivity have high serum growth hormone concentrations but low serum IGF-I and IGF binding-protein-3 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/28\">",
"     28",
"    </a>",
"    ]. In its complete form, this condition is called Laron-type dwarfism (complete growth hormone insensitivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39270?source=see_link\">",
"     \"Growth hormone insensitivity syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/28\">",
"     28",
"    </a>",
"    ] concluded that \"the single most useful parameter in the assessment of the child with growth retardation is the clinical evaluation, with emphasis placed upon accurate serial measurements of height and determination of the height velocity. Additionally, a high index of suspicion is necessary in children with obvious predisposition to pituitary dysfunction, such as children with other pituitary disorders, brain tumors, septo-optic dysplasia, cranial irradiation, neonatal hypoglycemia, microphallus, and hereditary forms of growth hormone deficiency.\" (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ACCELERATED EARLY GROWTH BUT MARKED ACCELERATION OF EPIPHYSEAL MATURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions are associated with rapid childhood growth but more rapid advancement of bone age. As a result, height age is advanced compared with chronologic age, but it lags behind the markedly accelerated bone age. If their growth is not halted, these tall children will be short adults, because early epiphyseal closure stops linear growth. Virtually all children with this growth pattern have precocious sexual development and high serum sex steroid hormone concentrations (for age). Children with untreated chronic hyperthyroidism also may have this pattern of growth [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gonadotropin-dependent precocious puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin-dependent precocious puberty (GDPP), also known as central (or true) precocious puberty, refers to the early occurrence of normal puberty. Precocious puberty historically had been defined as sexual development in girls before the age of 8 years and in boys before the age of 9 years; however, current data for girls, particularly black girls, indicate that the age of onset of normal puberty is younger [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The hallmarks of precocious puberty are accelerated growth and advanced bone age, plus breast development in girls and penile enlargement and sexual hair growth in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/35\">",
"     35",
"    </a>",
"    ]. The pattern of secretion of pituitary gonadotropins and gonadal sex steroids is normal but early. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gonadotropin-independent precocious puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin-independent precocious puberty (GIPP), also known as pseudoprecocious puberty or peripheral precocious puberty, refers to sexual precocity due to adrenal or gonadal disorders (or rarely tumor production of human chorionic gonadotropin in boys). The clinical manifestations are similar to those of central precocious puberty, except that the sexual development may be that of the opposite sex, eg, androgen effects in girls with congenital adrenal hyperplasia. Any cause of sexual precocity (including exogenous) can awaken the hypothalamic-pituitary-gonadal axis and \"induce\" GDPP as well [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory studies are indicated to establish a diagnosis of idiopathic short stature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18376/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count, erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      Electrolytes, creatinine, bicarbonate, calcium, phosphate, alkaline phosphatase, albumin",
"     </li>",
"     <li>",
"      TSH, Free T4, and IGF-I, and IGFBP-3 (IGFBP-3 has higher sensitivity for predicting the diagnosis of growth hormone deficiency in children &lt;10 years of age)",
"     </li>",
"     <li>",
"      Tissue transglutaminase or other serological screen for celiac disease",
"     </li>",
"     <li>",
"      Karyotype (in all girls, to rule out Turner syndrome, and in boys with associated genital abnormalities).",
"     </li>",
"     <li>",
"      Bone age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing is appropriate if the history and physical examination suggest a particular diagnosis, such as precocious puberty, or an endocrine, skeletal, or syndromic cause of growth failure as described above. Patients with reduced height velocity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low IGF-I and IGFBP-3 and delayed bone age should be evaluated for growth hormone deficiency using provocative tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contrast-enhanced magnetic resonance imaging (MRI) of the brain is not necessary to establish the diagnosis of idiopathic short stature, but is appropriate for children with established growth hormone deficiency, or in those with signs or symptoms suggesting hypothalamic-pituitary dysfunction (eg, hypoglycemia, microphallus, cryptorchidism, septo-optic dysplasia, intracranial tumor, or history of cranial irradiation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=see_link\">",
"       \"Patient information: My child is short (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short stature is defined as height that is 2 standard deviations (SD) or more below the mean height for children of that sex and chronological age (and ideally of the same racial-ethnic group). The clinical significance of the short stature depends on many factors, including genetic potential and changes in stature over time (growth velocity). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Is the child short?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants undergo rapid but decelerating growth during the first two years of life. Overall growth during this period is about 30 to 35 cm, and crossing of percentile lines is common among healthy infants. Children between 4 and 10 years of age of both sexes typically grow at a relatively constant velocity of 5 to 7 cm per year. The pubertal phase of growth is characterized by a growth spurt of 8 to 14 cm per year. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Phases of growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An estimate of a child's adult height potential can be obtained by calculation of the midparental height, adjusted for the sex of the child (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?30/3/30769?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prediction of height potential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of a child with short stature requires accurate measurements of length or height, with calculation of percentiles or z-scores; multiple measurements over time are valuable to assess growth velocity. The history and examination should assess for associated dysmorphic features, anomalies, or evidence of systemic disease, and genetic height potential. Subnormal",
"      <span class=\"nowrap\">",
"       weight/height",
"      </span>",
"      or body mass index suggest nutritional causes of growth failure. (See",
"      <a class=\"local\" href=\"#H523440\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic short stature (ISS) is characterized by low-normal growth velocity, normal serum concentrations of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3, without biochemical or other evidence for a specific growth-retarding condition. Most children with ISS have genetic short stature (in which bone age is not delayed and the child is growing within the parental target range), constitutional delay of growth (in which bone age is delayed), or a combination of these mechanisms. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Idiopathic short stature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with growth failure (growth velocity below the 25th percentile for age) without an obvious physiological explanation should be further evaluated with TSH, Free T4, and IGF-I, IGFBP-3, tissue transglutaminase or other serologic screen for celiac disease, and bone age. All girls should have a karyotype to rule out Turner syndrome. Abnormal results may trigger additional testing to establish a diagnosis (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Endocrine causes of growth failure'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Children with advanced bone age often have normal or increased growth velocity during childhood, but stop growing earlier than their peers and ultimately have short stature. Providers should be alert to this possibility in children with precocious puberty or untreated hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Accelerated early growth but marked acceleration of epiphyseal maturation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rogol AD, Lawton EL. Body measurements. In: Pediatric Outpatient Procedures, Lohr JA (Ed), JB Lippincott, Philadelphia 1991. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/2\">",
"      Committee on Practice and Ambulatory Medicine and Bright Futures Steering Committee. Recommendations for preventive pediatric health care. Pediatrics 2007; 120:1376.  Available at:  file://pediatrics.aappublications.org/cgi/data/120/6/1376/DC1/1",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/3\">",
"      Karlberg J. A biologically-oriented mathematical model (ICP) for human growth. Acta Paediatr Scand Suppl 1989; 350:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/4\">",
"      Kerrigan JR, Rogol AD. The impact of gonadal steroid hormone action on growth hormone secretion during childhood and adolescence. Endocr Rev 1992; 13:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/5\">",
"      Tanner JM, Goldstein H, Whitehouse RH. Standards for children's height at ages 2-9 years allowing for heights of parents. Arch Dis Child 1970; 45:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/6\">",
"      Roemmich, JN, Blizzard, RM, Peddada, SD, et al. Longitudinal assessment of hormonal and physical alterations during normal puberty in boys. IV: Predictions of adult height by the Bayley Pinneau, Roche-Warner-Thissen &amp; Tanner-Whitehouse methods compared. Am J Hum Biol 1997; 9:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/7\">",
"      BAYLEY N, PINNEAU SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952; 40:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/8\">",
"      Topor LS, Feldman HA, Bauchner H, Cohen LE. Variation in methods of predicting adult height for children with idiopathic short stature. Pediatrics 2010; 126:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/9\">",
"      Damen GM, Boersma B, Wit JM, Heymans HS. Catch-up growth in 60 children with celiac disease. J Pediatr Gastroenterol Nutr 1994; 19:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/10\">",
"      Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/11\">",
"      Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986; 61:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/12\">",
"      Betts PR, Magrath G. Growth pattern and dietary intake of children with chronic renal insufficiency. Br Med J 1974; 2:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/13\">",
"      Grinspoon SK, Donovan DS Jr, Bilezikian JP. Aetiology and pathogenesis of hormonal and metabolic disorders in HIV infection. Baillieres Clin Endocrinol Metab 1994; 8:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/14\">",
"      Grimberg A, Kutikov JK, Cucchiara AJ. Sex differences in patients referred for evaluation of poor growth. J Pediatr 2005; 146:212.",
"     </a>",
"    </li>",
"    <li>",
"     August, GP, Lippe, BM, Blethen, SL. et al. Growth hormone treatment in the United States demographic and diagnostic features of 2331 children. In: National cooperative growth study (NCGS) advisory group, Growth Hormone: Science, Research, and the NCGS: 10 years of research, Gardiner-Caldwell SynerMedCalifon, NJ, 1996. p. 179.",
"    </li>",
"    <li>",
"     Chatelain P. Trends in the diagnosis and treatment of short stature as revealed by KIGS. In: Growth Hormone Therapy in KIGS: 10 Years' Experience, Ranke, MB, Wilton, P (Eds), Johann Ambrosius Barth Verlag, Heidelberg, 1999. p. 11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/17\">",
"      Grimberg A, Feemster KA, Pati S, et al. Medically underserved girls receive less evaluation for short stature. Pediatrics 2011; 127:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/18\">",
"      Wit JM, Clayton PE, Rogol AD, et al. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res 2008; 18:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/19\">",
"      Wit JM, Reiter EO, Ross JL, et al. Idiopathic short stature: management and growth hormone treatment. Growth Horm IGF Res 2008; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/20\">",
"      Rappold GA, Fukami M, Niesler B, et al. Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab 2002; 87:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/21\">",
"      Ross JL, Kowal K, Quigley CA, et al. The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Leri-Weill dyschondrosteosis and Turner syndrome. J Pediatr 2005; 147:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/22\">",
"      Franklin SL, Geffner ME. Growth hormone: the expansion of available products and indications. Endocrinol Metab Clin North Am 2009; 38:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/23\">",
"      Rappold G, Blum WF, Shavrikova EP, et al. Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet 2007; 44:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/24\">",
"      Cuttler L, Marinova D, Mercer MB, et al. Patient, physician, and consumer drivers: referrals for short stature and access to specialty drugs. Med Care 2009; 47:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/25\">",
"      Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994; 331:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/26\">",
"      Kanter AS, Diallo AO, Jane JA Jr, et al. Single-center experience with pediatric Cushing's disease. J Neurosurg 2005; 103:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/27\">",
"      Storr HL, Chan LF, Grossman AB, Savage MO. Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab 2007; 18:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/28\">",
"      Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/29\">",
"      Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994; 15:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/30\">",
"      Takamatsu J, Kobe N, Ito M, Ohsawa N. Body height and weight of patients with childhood onset and adult onset thyrotoxicosis. Endocr J 1999; 46 Suppl:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/31\">",
"      Conwell LS. Graves' disease--acceleration of linear growth. J Pediatr Endocrinol Metab 2009; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/32\">",
"      Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997; 99:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/33\">",
"      Biro FM, McMahon RP, Striegel-Moore R, et al. Impact of timing of pubertal maturation on growth in black and white female adolescents: The National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr 2001; 138:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/34\">",
"      Rogol AD. Early menarche and adult height: reprise of the hare and the tortoise? J Pediatr 2001; 138:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/35\">",
"      Kaplan SL, Grumbach MM. Clinical review 14: Pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990; 71:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/36\">",
"      Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr 1986; 108:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18376/abstract/37\">",
"      Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93:4210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5834 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18376=[""].join("\n");
var outline_f17_60_18376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL GROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Phases of growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prediction of height potential",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7821167\">",
"      - Midparental height method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7821181\">",
"      - Methods that incorporate bone age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523440\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Is the child short?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Does the child have dysmorphic features or disproportionate short stature?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Although the child is short, is his or her growth velocity normal or impaired?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H888170\">",
"      Gender bias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IDIOPATHIC SHORT STATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ENDOCRINE CAUSES OF GROWTH FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cushing syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACCELERATED EARLY GROWTH BUT MARKED ACCELERATION OF EPIPHYSEAL MATURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gonadotropin-dependent precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gonadotropin-independent precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5834|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/6/6253\" title=\"figure 1\">",
"      Normal growth rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/44/31426\" title=\"figure 2A\">",
"      WHO length for age boys 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/51/30514\" title=\"figure 2B\">",
"      WHO length for age girls 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/45/28371\" title=\"figure 3\">",
"      Height measurement technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/1/44050\" title=\"figure 4A\">",
"      CDC stature for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/10/29858\" title=\"figure 4B\">",
"      CDC stature for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4692\" title=\"figure 5A\">",
"      Height velocity in boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16387\" title=\"figure 5B\">",
"      Height velocity in girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5834|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/15/24827\" title=\"table 1\">",
"      Short stature v delay of growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/38/36460\" title=\"table 2\">",
"      Major causes of short stature",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?30/3/30769?source=related_link\" title=\"calculator 1\">",
"      Calculator: Mid-parental target height prediction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34339?source=related_link\" title=\"calculator 2\">",
"      Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=related_link\" title=\"calculator 3\">",
"      Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=related_link\" title=\"calculator 4\">",
"      Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39270?source=related_link\">",
"      Growth hormone insensitivity syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18248?source=related_link\">",
"      Growth hormone treatment for idiopathic short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=related_link\">",
"      Overview of causes of and risk factors for fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_60_18377="Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism";
var content_f17_60_18377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Linwah Yip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Shonni J Silverberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18377/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/60/18377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism is usually caused by a solitary benign adenoma (80 to 85 percent), but can also be due to double adenomata (2 to 5 percent), diffuse or nodular hyperplasia (10 to 15 percent), or parathyroid carcinoma (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/1\">",
"     1",
"    </a>",
"    ]. A four gland parathyroid exploration has traditionally been considered the gold standard for patients undergoing surgery for primary hyperparathyroidism. However, a more focused, minimally invasive approach to parathyroid surgery is being adopted at many centers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperative parathyroid localization studies are useful for identifying patients who are candidates for the minimally invasive approach. Localization studies, in conjunction with intraoperative parathyroid hormone testing, can help minimize the extent of surgical dissection, identify concurrent thyroid pathology, and in patients with recurrent or persistent hyperparathyroidism, can help detect ectopic parathyroid tissue. However, localization studies should not be used to diagnose or confirm the diagnosis of hyperparathyroidism or determine the need for surgery.",
"   </p>",
"   <p>",
"    The techniques and role of preoperative localization in patients with primary hyperparathyroidism will be reviewed here. Decision making regarding the role of surgical therapy and the details of surgical management in these patients and the role of surgery for secondary hyperparathyroidism in patients with end-stage renal disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of primary hyperparathyroidism\", section on 'Candidates for surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466865#H10466865\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Focused parathyroid exploration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMAGING MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative localization studies help plan the operative approach in patients who have biochemically confirmed diagnosis of primary hyperparathyroidism. Imaging studies have no role in the diagnosis of primary hyperparathyroidism. Imaging studies have a high false positive rate and are ordered when a decision has been made to operate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, a single-focus positive imaging result does not reliably exclude the presence of multiglandular parathyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sestamibi scintigraphy (technetium-99-sestamibi scanning) combined with sestamibi single photon emission computed tomography (SPECT) has the highest positive predictive value of the available imaging techniques and some prefer this as the localizing procedure of choice for initial surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. However, SPECT is not available at all centers and some use planar sestamibi as the initial localizing study. Additional complementary techniques are sometimes needed for patients with",
"    <span class=\"nowrap\">",
"     persistent/recurrent",
"    </span>",
"    disease or inconclusive results on sestamibi or SPECT scanning. Complementary imaging techniques that have been used successfully with sestamibi or SPECT include ultrasound, SPECT combined with computed tomography (MIBI-SPECT-CT fusion), four-dimensional computed tomography, and 11C-methionine positron emission tomography (PET) combined with CT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/5,7-13\">",
"     5,7-13",
"    </a>",
"    ]. The utility of these tests is discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2890373\">",
"    <span class=\"h2\">",
"     Sestamibi scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technetium-99m-methoxyisobutylisonitrile (99mTc-sestamibi or MIBI) was first used for cardiac scintigraphy and was noted to concentrate in parathyroid adenomas. 99mTc-sestamibi is taken up by the mitochondria in thyroid and parathyroid tissue; however, the radiotracer is retained by the mitochondria-rich oxyphil cells in parathyroid glands longer than in thyroid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/14\">",
"     14",
"    </a>",
"    ]. Planar images are typically obtained shortly after injection of 99mTc-sestamibi and again at approximately two hours to identify foci of retained radiotracer activity consistent with hyperfunctioning parathyroid tissue. Sestamibi scintigraphy alone provides limited anatomic detail.",
"   </p>",
"   <p>",
"    A negative 99mTc sestamibi scan does not preclude the diagnosis of primary hyperparathyroidism, since it occurs in 12 to 25 percent of patients with disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Sestamibi scanning is often unrevealing in patients with parathyroid hyperplasia, multiple parathyroid adenomas, and in those with coexisting thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/17-24\">",
"     17-24",
"    </a>",
"    ]. Thyroid disease requiring surgery significantly increases both the false positive and false negative rate of sestamibi scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/25\">",
"     25",
"    </a>",
"    ]. Falsely negative scans can also be caused by calcium channel blockers that interfere with the take up of the isotope by parathyroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/22\">",
"     22",
"    </a>",
"    ]. Other gland characteristics that can increase the likelihood of a negative scan include small size, superior position, and a paucity of oxyphil cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sestamibi scanning for parathyroid tissue can be enhanced by combination with three-dimensional imaging (SPECT), a subtraction thyroid scan, or fusion with computed tomography images (MIBI-SPECT-CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/17,26,27\">",
"     17,26,27",
"    </a>",
"    ]. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257607\">",
"    <span class=\"h3\">",
"     SPECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sestamibi-single photon emission computed tomography (SPECT or MIBI-SPECT) is a three-dimensional sestamibi scan that provides higher resolution imaging and improves the performance of sestamibi scanning (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50315 \" href=\"UTD.htm?1/20/1347\">",
"     image 1",
"    </a>",
"    ). The multidimensional images illustrate the depth of the parathyroid gland or glands in relation to the thyroid and improve detection of ectopic glands which facilitates minimally invasive parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/21,26,28,29\">",
"     21,26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In single institution comparison studies utilizing a variety of imaging protocols, the addition of SPECT improves the sensitivity for identifying abnormal parathyroid glands to 92 to 98 percent as compared with 71 to 79 percent for planar sestamibi scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/17,21,26,28,29\">",
"     17,21,26,28,29",
"    </a>",
"    ]. As an example, in a prospective study of 338 patients with primary hyperparathyroidism, SPECT imaging successfully detected 96 percent of solitary adenomas and 83 percent of double adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/17\">",
"     17",
"    </a>",
"    ]. However, only 45 percent of multiglandular hyperplasia was detected.",
"   </p>",
"   <p>",
"    SPECT imaging substantially reduces the likelihood of missing multiglandular disease compared to planar imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/4,30\">",
"     4,30",
"    </a>",
"    ]. However, even with imaging showing a clear, bright focus of increased update, multiglandular disease is still a possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/4,15,17,30\">",
"     4,15,17,30",
"    </a>",
"    ]. Because SPECT imaging has a high rate of missed multiglandular disease, a validated adjunct to exclude multiglandular disease such as intraoperative parathyroid hormone monitoring or four-gland parathyroid exploration should be routinely utilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257614\">",
"    <span class=\"h3\">",
"     SPECT and CT fusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;SPECT-CT adds the ability to discriminate parathyroid adenomas from other anatomic landmarks, which may facilitate the surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/7,30\">",
"     7,30",
"    </a>",
"    ]. CT alone has low sensitivity for parathyroid adenoma localization. In a study evaluating 30 patients with multiglandular disease, SPECT-CT predicted the location of all abnormal glands in 46 percent of cases compared with 37 and 13 percent for CT alone and SPECT alone, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6957677\">",
"    <span class=\"h3\">",
"     Subtraction thyroid scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even with the addition of SPECT, distinguishing abnormal parathyroid glands from thyroid pathology can be difficult. If necessary, a subtraction thyroid scan can be obtained by using two radiotracers (dual isotope scintigraphy). The use of technetium plus a second radiotracer such as 123I or 99mTc pertechnetate (thallium) permits selective imaging of the thyroid gland.",
"   </p>",
"   <p>",
"    Technetium-99m-methoxyisobutylisonitrile (99mTc-sestamibi or MIBI) shows the parathyroid glands, while thallium shows both the thyroid and parathyroid glands [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/31\">",
"     31",
"    </a>",
"    ]. The technetium image is then subtracted from the thallium image. The same technique can be performed using technetium and 123I [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267381\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck ultrasonography (US) is also often utilized for parathyroid localization (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71417 \" href=\"UTD.htm?31/26/32165\">",
"     image 2",
"    </a>",
"    ). Sonographic characteristics of parathyroid adenomas include homogeneous hypoechogenicity and an extrathyroidal feeding vessel with peripheral vascularity seen on color Doppler imaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62112 \" href=\"UTD.htm?27/14/27879\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    US is highly sensitive in experienced hands and is inexpensive, noninvasive, and reproducible in the operating room. In reoperative cases, intraoperative US can be used to localize the adenoma and facilitate surgery in a previously dissected and scarred field. However, the accuracy of ultrasound is operator-dependent, as the sensitivity of ultrasound for detecting enlarged parathyroid glands ranges from 72 to 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/11,33-35\">",
"     11,33-35",
"    </a>",
"    ]. It is advantageous for experienced endocrine surgeons to learn to perform neck ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/36\">",
"     36",
"    </a>",
"    ] and studies have shown comparable sensitivity for localizing parathyroid adenomas compared to radiologist performed ultrasound (77 to 87 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with sestamibi based techniques, the sensitivity of ultrasound for parathyroid adenoma localization is reduced in patients with thyroid nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/38\">",
"     38",
"    </a>",
"    ]. However, US is helpful for the characterization and evaluation of any thyroid pathology, facilitating operative planning. This is a common problem, since concurrent thyroid pathology is present in up to 30 percent of patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/39\">",
"     39",
"    </a>",
"    ]. Concurrent thyroid disease should be addressed preoperatively (eg with fine needle aspiration)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraoperatively (eg, with concurrent thyroidectomy.) In addition, US directed fine needle aspiration biopsy with analysis of PTH levels can be helpful for confirming suspected parathyroid lesions such as intrathyroidal adenomas or cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts in parathyroid surgery rely on both US and SPECT for preoperative localization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/42\">",
"     42",
"    </a>",
"    ]. Combining 99mTc-sestamibi scintigraphy with neck ultrasound provides the highest sensitivity (79 to 95 percent) for predicting the location of a single parathyroid adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/29,30,43\">",
"     29,30,43",
"    </a>",
"    ]. Neither technique, even in combination, accurately predicts multiglandular disease and a bilateral neck exploration should be strongly considered when the studies are discordant, equivocal, or negative [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/17,44\">",
"     17,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages to the use of US include decreased accuracy in patients with smaller parathyroid gland size, obesity, or mediastinal glands located behind the clavicles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6958652\">",
"    <span class=\"h2\">",
"     Four dimensional computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four-dimensional computed tomography scans (4D-CT) take advantage of the rapid contrast uptake and washout that is characteristic of parathyroid adenomas for precise anatomic localization (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82115 \" href=\"UTD.htm?3/0/3073\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    4D-CT is particularly useful in the reoperative setting when initial imaging with sestamibi is negative. In a study of 45 patients who had undergone previous neck exploration, 4D-CT had 88 percent sensitivity for abnormal parathyroid glands compared to sestamibi SPECT or neck US (54 and 21 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2891789\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid adenoma characteristics on magnetic resonance imaging (MRI) include intermediate to low signal intensity on T1 imaging and high intensity on T2 imaging. Cervical lymph nodes can also have similar imaging characteristics, which limits the accuracy of MRI.",
"   </p>",
"   <p>",
"    For reoperative surgery, MRI provides a useful noninvasive imaging modality to localize abnormal parathyroid tissue and does not require iodinated contrast or exposure to ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/47\">",
"     47",
"    </a>",
"    ]. The reported sensitivity of MRI for abnormal parathyroid tissue ranges from 40 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/3,48,49\">",
"     3,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4090120\">",
"    <span class=\"h2\">",
"     Positron emission tomography and CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of 11C-methionine positron emission tomography and computed tomography (MET-PET-CT) uses 11C-methionine as a radiotracer to identify pathologic parathyroid glands [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/50\">",
"     50",
"    </a>",
"    ]. Several small studies found MET-PET-CT to be highly sensitive and potentially useful in cases where conventional imaging techniques had failed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2891782\">",
"    <span class=\"h2\">",
"     Invasive localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive procedures, such as selective venous sampling or selective arteriography, are generally reserved for more definitive localization in patients who have had prior neck surgery and in whom noninvasive testing has been unrevealing. They may also be used in a primary operation for the patient in whom noninvasive techniques are equivocal or unrevealing, but enthusiasm for their use is tempered by risks associated with the procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Risks associated with invasive localization procedures include groin hematoma, anaphylaxis from the iodinated contrast, contrast-induced acute renal failure, and stroke. They are also expensive and require an experienced interventional radiologist to perform. Because of improvements in scanning and ultrasonography, as noted above, the necessity for invasive testing has declined substantially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6958819\">",
"    <span class=\"h3\">",
"     Selective venous sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective venous sampling is the most common invasive modality used for parathyroid localization. A 1.5 to 2-fold increase in parathyroid hormone levels obtained from representative cervical vein drainage locations (inferior, middle, superior thyroid, thymic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vertebral veins) compared to a peripheral location is considered an abnormal elevation. Selective venous sampling can identify hyperfunctioning parathyroid tissue when all other imaging modalities are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6958878\">",
"    <span class=\"h3\">",
"     Selective arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective arteriography is performed by combining selective trans-arterial hypocalcemic stimulation with nonselective venous sampling. Baseline and timed superior vena cava samplings are taken after injection with sodium citrate to induce hypocalcemia while simultaneous arteriography is performed. A positive localization is considered an increase in the parathyroid hormone level to 1.4 times the baseline or a blush seen on arteriography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709617\">",
"    <span class=\"h1\">",
"     NEGATIVE IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-localizing imaging studies should not preclude initial surgery for patients with biochemically confirmed primary hyperparathyroidism who meet operative criteria. In such patients, a single adenoma is still the most likely intraoperative finding (62 to 77 percent); however, multiglandular disease is also common (20 to 38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These patients require bilateral exploration by an experienced parathyroid surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/16,55\">",
"     16,55",
"    </a>",
"    ]. When compared to patients with localized studies, equivalent long-term biochemical cure rates can be achieved although more extensive surgery may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/22,35\">",
"     22,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the reoperative setting, negative sestamibi and ultrasound results usually lead to prompt use of additional noninvasive imaging modalities such as 4D-CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI. If these studies are also non-localizing, then invasive studies such as arteriography or selective venous sampling can be performed. Reoperation with negative imaging is associated with a high failure rate (up to 50 percent) and nonoperative medical management should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of primary hyperparathyroidism\", section on 'Alternatives to surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2892141\">",
"    <span class=\"h1\">",
"     ROLE OF PREOPERATIVE LOCALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies have no role in the diagnosis of primary hyperparathyroidism. Localization techniques were originally used primarily to identify an ectopic parathyroid gland in patients with recurrent or persistent hyperparathyroidism after unsuccessful neck exploration. With the growing acceptance of minimally invasive surgery, localization studies are used to determine whether or not patients are candidates for minimally invasive techniques and to facilitate a direct operative approach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Available radiologic expertise is an important factor in choosing the type of localization testing to be performed. Localization images should be displayed and available intraoperatively, since review during exploration often usefully guides successful surgery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Minimally invasive and unilateral parathyroidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative localization reduces operative time in unilateral parathyroid surgery and is required if a minimally invasive procedure is contemplated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/18,60,61\">",
"     18,60,61",
"    </a>",
"    ]. The success of a minimally invasive approach is highly dependent upon accurate imaging results, which allow limitation of the dissection and operative field to the region where the adenoma has been localized. Confirmation of successful parathyroidectomy can be obtained by intraoperative parathyroid hormone assay. In every parathyroid operation, the goal is cure of the biochemical condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466879#H10466879\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Intraoperative assessment tools'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reoperation for recurrent or persistent hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five to ten percent of patients undergoing surgery for hyperparathyroidism have recurrent or persistent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/53\">",
"     53",
"    </a>",
"    ]. In such cases, the diagnosis of primary hyperparathyroidism should be confirmed biochemically and indications for surgery reevaluated. Accurate localization studies are mandatory in patients undergoing reoperative surgery. Because of fibrosis from the previous surgery and alterations in parathyroid gland location, complications, such as recurrent laryngeal nerve injury, permanent hypoparathyroidism, and persistent disease, are typically higher [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/54,62-64\">",
"     54,62-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two or more concordant preoperative imaging studies such as sestamibi scans, sestamibi-SPECT, ultrasound, and 4D-CT should localize hyperfunctional parathyroid tissue to the same region before proceeding with re-exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The success rate of reoperative surgery without preoperative localization is only 60 percent. Several observational studies have reported success rates of 95 percent or more with the use of preoperative localization before reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/53,54,67\">",
"     53,54,67",
"    </a>",
"    ]. Almost 30 percent of patients undergoing reoperation have multiple gland disease. Thus, localization studies identifying an apparent single adenoma do not exclude the existence of abnormal parathyroid glands in other locations",
"   </p>",
"   <p>",
"    The best imaging study or combination of studies for persistent disease has not been determined. The two largest studies included 288 and 102 patients and compared sestamibi scans, thallium-technetium scans, MRI, CT, ultrasonography, and selective venous catheterization or other invasive tests [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Sestamibi scans detected 67 to 77 percent of the abnormal glands with few false positives; the other noninvasive studies detected slightly fewer lesions in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/54\">",
"     54",
"    </a>",
"    ] but 15 to 20 percent fewer in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound or CT guided fine needle aspiration of suspicious lesions for parathyroid hormone (PTH) assay can be performed to confirm that the lesion is parathyroid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In a study of 44 patients, fine needle aspiration with PTH assay had a specificity and sensitivity of 100 and 70 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/41\">",
"     41",
"    </a>",
"    ]. Selective arterial or venous angiography is usually the next localization modality used if multiple noninvasive imaging techniques do not identify an abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Algorithms for the evaluation of patients undergoing reoperation have been developed (",
"    <a class=\"graphic graphic_figure graphicRef78548 \" href=\"UTD.htm?13/18/13614\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/56,71\">",
"     56,71",
"    </a>",
"    ]. These algorithms, which are based upon clinical experience, suggest performing two noninvasive procedures prior to reoperation, one of which should be sestamibi imaging and the other is often ultrasonography. If the results of these studies are concordant, surgery is performed. If the results are discordant or inconclusive, the next step depends upon the expertise of the referral center and may include either surgery with intraoperative monitoring of PTH or additional testing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/56,71\">",
"     56,71",
"    </a>",
"    ]. Further testing includes additional imaging (CT, MRI) or possible invasive procedures (selective venous sampling). Several observational studies show that this approach allowed the identification of the offending parathyroid gland or glands in 92 to 97 percent of reoperated cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/56,67,71\">",
"     56,67,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329961\">",
"    <span class=\"h2\">",
"     Bilateral neck exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral parathyroid exploration should be planned when imaging studies are negative or show more than one focus of activity, in cases of secondary or tertiary hyperparathyroidism, suspected hereditary etiology, or when concurrent thyroid pathology is present and warrants surgery. Bilateral exploration should also be considered for male patients under 30 years of age because of the increased incidence of multiple endocrine neoplasia in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/72\">",
"     72",
"    </a>",
"    ]. In the hands of experienced surgeons, bilateral exploration has a high cure rate and low morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/73-79\">",
"     73-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466858#H10466858\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Bilateral parathyroid exploration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6958973\">",
"    <span class=\"h1\">",
"     STANDARDIZED NOMENCLATURE FOR ADENOMA LOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standardized nomenclature has been proposed to precisely describe the location of parathyroid adenomas based upon the embryology of parathyroid glands and regional cervical anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/80\">",
"     80",
"    </a>",
"    ]. This system uses the letters A through G to describe gland location:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type A ��� A",
"      </strong>",
"      dherent to the posterior thyroid parenchyma. An \"A\" gland is a superior gland posterior to the upper pole of the thyroid but not intrathyroidal and is the accepted location of a normal superior parathyroid gland.",
"     </li>",
"     <li>",
"      <strong>",
"       Type B",
"      </strong>",
"      ���",
"      <strong>",
"       B",
"      </strong>",
"      ehind the thyroid parenchyma. A \"B\" gland is a superior gland that lies in the tracheoesophageal groove and in the same cross-sectional plane as the superior portion of the of the thyroid. This category includes adenomas in retroesophageal, retropharyngeal, high lateral pharyngeal, and carotid sheath locations.",
"     </li>",
"     <li>",
"      <strong>",
"       Type C",
"      </strong>",
"      ���",
"      <strong>",
"       C",
"      </strong>",
"      audal to the thyroid parenchyma. A \"C\" gland is lies posteriorly in the tracheoesophageal groove and is located in the same cross-sectional plane as the inferior pole of the thyroid.",
"     </li>",
"     <li>",
"      <strong>",
"       Type D",
"      </strong>",
"      ���",
"      <strong>",
"       D",
"      </strong>",
"      irectly over the recurrent laryngeal nerve at the level of the inferior thyroid vessels. A \"D\" gland lies in the midregion of the posterior thyroid parenchyma, near the junction of the recurrent laryngeal nerve and inferior thyroid artery.",
"     </li>",
"     <li>",
"      <strong>",
"       Type E",
"      </strong>",
"      ���",
"      <strong>",
"       E",
"      </strong>",
"      asiest to resect. An \"E\" gland is an inferior gland superficial to the recurrent laryngeal nerve. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Type F",
"      </strong>",
"      ���",
"      <strong>",
"       F",
"      </strong>",
"      allen into the thyrothymic ligament, caudal to the inferior pole of the thyroid in a pretracheal plane. A type F gland is frequently referred to as an ectopic gland, and its resection usually involves transcervical delivery of the thyrothymic ligament or superior portion of the thymus.",
"     </li>",
"     <li>",
"      <strong>",
"       Type G",
"      </strong>",
"      ��� A \"G\" gland is a truly intrathyroidal parathyroid gland.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This system has not been universally adopted, but at some institutions, has produced a reliable means of communication between radiologists and surgeons, which facilitates surgical planning with respect to incision location, patient positioning, and the expected scope of the surgical procedure. Use of standardized nomenclature has proven to be especially useful in the reoperative setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18377/abstract/46,81\">",
"     46,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative parathyroid localization studies are useful for identifying patients who are candidates for a minimally invasive surgical approach. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localization studies should not be used to diagnose or confirm the diagnosis of primary hyperparathyroidism when positive, or to rule out the diagnosis when negative. The diagnosis of primary hyperparathyroidism should be based upon biochemical evaluation. Localization studies do not reliably exclude multiglandular parathyroid disease (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Results of localization studies, interpreted in conjunction with intraoperative parathyroid hormone testing, can guide incision placement, minimize the extent of surgical dissection, identify concurrent thyroid pathology, and locate ectopic parathyroid tissue in patients with recurrent or persistent hyperparathyroidism after unsuccessful parathyroid exploration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Minimally invasive and unilateral parathyroidectomy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For initial minimally invasive surgery, three-dimensional sestamibi scintigraphy (MIBI-SPECT imaging) and ultrasound together are often the localizing procedures of choice when available. Additional complementary techniques are sometimes needed for patients with",
"      <span class=\"nowrap\">",
"       persistent/recurrent",
"      </span>",
"      disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Imaging modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients undergoing reoperation, we recommend performing preoperative localization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest obtaining at least two imaging studies to assure concordance under these circumstances (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Reoperation for recurrent or persistent hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/1\">",
"      Kaplan EL, Yashiro T, Salti G. Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease. Ann Surg 1992; 215:300.",
"     </a>",
"    </li>",
"    <li>",
"     Smith, SL, Van, Heerden, J. Conventional parathyroidectomy for priimary hyperparathyroidism. In: Mastery of Surgery, I, Fischer, JE (Eds), Lippincott, Philadelphia 2007. p.430.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/3\">",
"      Udelsman R, Pasieka JL, Sturgeon C, et al. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/4\">",
"      Yip L, Pryma DA, Yim JH, et al. Can a lightbulb sestamibi SPECT accurately predict single-gland disease in sporadic primary hyperparathyroidism? World J Surg 2008; 32:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/5\">",
"      Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. Radiographics 2008; 28:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/6\">",
"      Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am 2009; 89:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/7\">",
"      Lavely WC, Goetze S, Friedman KP, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med 2007; 48:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/8\">",
"      Prommegger R, Wimmer G, Profanter C, et al. Virtual neck exploration: a new method for localizing abnormal parathyroid glands. Ann Surg 2009; 250:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/9\">",
"      Moure D, Larra&ntilde;aga E, Dom&iacute;nguez-Gadea L, et al. 99MTc-sestamibi as sole technique in selection of primary hyperparathyroidism patients for unilateral neck exploration. Surgery 2008; 144:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/10\">",
"      Lindqvist V, Jacobsson H, Chandanos E, et al. Preoperative 99Tc(m)-sestamibi scintigraphy with SPECT localizes most pathologic parathyroid glands. Langenbecks Arch Surg 2009; 394:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/11\">",
"      Gilat H, Cohen M, Feinmesser R, et al. Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography. J Clin Ultrasound 2005; 33:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/12\">",
"      Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery 2006; 140:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/13\">",
"      Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism--an evidence-based analysis. Langenbecks Arch Surg 2009; 394:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/14\">",
"      Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med 2005; 35:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/15\">",
"      Lal A, Chen H. The negative sestamibi scan: is a minimally invasive parathyroidectomy still possible? Ann Surg Oncol 2007; 14:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/16\">",
"      Chiu B, Sturgeon C, Angelos P. What is the link between nonlocalizing sestamibi scans, multigland disease, and persistent hypercalcemia? A study of 401 consecutive patients undergoing parathyroidectomy. Surgery 2006; 140:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/17\">",
"      Civelek AC, Ozalp E, Donovan P, Udelsman R. Prospective evaluation of delayed technetium-99m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery 2002; 131:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/18\">",
"      Hindi&eacute; E, Melli&egrave;re D, Perlemuter L, et al. Primary hyperparathyroidism: higher success rate of first surgery after preoperative Tc-99m sestamibi-I-123 subtraction scanning. Radiology 1997; 204:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/19\">",
"      Wheeler MH. Preoperative parathyroid scanning in secondary hyperparathyroidism. Lancet 1999; 353:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/20\">",
"      Mihai R, Gleeson F, Buley ID, et al. Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients. World J Surg 2006; 30:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/21\">",
"      Pappu S, Donovan P, Cheng D, Udelsman R. Sestamibi scans are not all created equally. Arch Surg 2005; 140:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/22\">",
"      Friedman K, Somervell H, Patel P, et al. Effect of calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery 2004; 136:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/23\">",
"      Mehta NY, Ruda JM, Kapadia S, et al. Relationship of technetium Tc 99m sestamibi scans to histopathological features of hyperfunctioning parathyroid tissue. Arch Otolaryngol Head Neck Surg 2005; 131:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/24\">",
"      Stephen AE, Roth SI, Fardo DW, et al. Predictors of an accurate preoperative sestamibi scan for single-gland parathyroid adenomas. Arch Surg 2007; 142:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/25\">",
"      G&oacute;mez-Ram&iacute;rez J, Sancho-Insenser JJ, Pereira JA, et al. Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism. Langenbecks Arch Surg 2010; 395:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/26\">",
"      Nichols KJ, Tomas MB, Tronco GG, et al. Preoperative parathyroid scintigraphic lesion localization: accuracy of various types of readings. Radiology 2008; 248:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/27\">",
"      Wimmer G, Profanter C, Kovacs P, et al. CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism. Langenbecks Arch Surg 2010; 395:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/28\">",
"      Schachter PP, Issa N, Shimonov M, et al. Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy. Arch Surg 2004; 139:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/29\">",
"      Spanu A, Falchi A, Manca A, et al. The usefulness of neck pinhole SPECT as a complementary tool to planar scintigraphy in primary and secondary hyperparathyroidism. J Nucl Med 2004; 45:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/30\">",
"      Sharma J, Mazzaglia P, Milas M, et al. Radionuclide imaging for hyperparathyroidism (HPT): which is the best technetium-99m sestamibi modality? Surgery 2006; 140:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/31\">",
"      Singh N, Krishna BA. Role of radionuclide scintigraphy in the detection of parathyroid adenoma. Indian J Cancer 2007; 44:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/32\">",
"      McBiles M, Lambert AT, Cote MG, Kim SY. Sestamibi parathyroid imaging. Semin Nucl Med 1995; 25:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/33\">",
"      Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clin Endocrinol (Oxf) 2002; 57:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/34\">",
"      Erbil Y, Barbaros U, T&uuml;kenmez M, et al. Impact of adenoma weight and ectopic location of parathyroid adenoma on localization study results. World J Surg 2008; 32:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/35\">",
"      Powell AC, Alexander HR, Chang R, et al. Reoperation for parathyroid adenoma: a contemporary experience. Surgery 2009; 146:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/36\">",
"      Solorzano CC, Carneiro-Pla DM, Irvin GL 3rd. Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism. J Am Coll Surg 2006; 202:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/37\">",
"      Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg 2008; 248:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/38\">",
"      Barbaros U, Erbil Y, Salmasho��lu A, et al. The characteristics of concomitant thyroid nodules cause false-positive ultrasonography results in primary hyperparathyroidism. Am J Otolaryngol 2009; 30:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/39\">",
"      Lever EG, Refetoff S, Straus FH 2nd, et al. Coexisting thyroid and parathyroid disease--are they related? Surgery 1983; 94:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/40\">",
"      Sacks BA, Pallotta JA, Cole A, Hurwitz J. Diagnosis of parathyroid adenomas: efficacy of measuring parathormone levels in needle aspirates of cervical masses. AJR Am J Roentgenol 1994; 163:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/41\">",
"      MacFarlane MP, Fraker DL, Shawker TH, et al. Use of preoperative fine-needle aspiration in patients undergoing reoperation for primary hyperparathyroidism. Surgery 1994; 116:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/42\">",
"      Elaraj DM, Sippel RS, Lindsay S, et al. Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results? Arch Surg 2010; 145:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/43\">",
"      Patel CN, Salahudeen HM, Lansdown M, Scarsbrook AF. Clinical utility of ultrasound and 99mTc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. Clin Radiol 2010; 65:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/44\">",
"      Haciyanli M, Lal G, Morita E, et al. Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma. J Am Coll Surg 2003; 197:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/45\">",
"      Berber E, Parikh RT, Ballem N, et al. Factors contributing to negative parathyroid localization: an analysis of 1000 patients. Surgery 2008; 144:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/46\">",
"      Mortenson MM, Evans DB, Lee JE, et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. J Am Coll Surg 2008; 206:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/47\">",
"      Gotway MB, Reddy GP, Webb WR, et al. Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology 2001; 218:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/48\">",
"      Wakamatsu H, Noguchi S, Yamashita H, et al. Parathyroid scintigraphy with 99mTc-MIBI and 123I subtraction: a comparison with magnetic resonance imaging and ultrasonography. Nucl Med Commun 2003; 24:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/49\">",
"      Lopez H&auml;nninen E, Vogl TJ, Steinm&uuml;ller T, et al. Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism. Invest Radiol 2000; 35:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/50\">",
"      Tang BN, Moreno-Reyes R, Blocklet D, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging 2008; 3:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/51\">",
"      Herrmann K, Takei T, Kanegae K, et al. Clinical value and limitations of [11C]-methionine PET for detection and localization of suspected parathyroid adenomas. Mol Imaging Biol 2009; 11:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/52\">",
"      Weber T, Cammerer G, Schick C, et al. C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res 2010; 42:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/53\">",
"      Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 1996; 224:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/54\">",
"      Shen W, D&uuml;ren M, Morita E, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg 1996; 131:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/55\">",
"      Chan RK, Ruan DT, Gawande AA, Moore FD Jr. Surgery for hyperparathyroidism in image-negative patients. Arch Surg 2008; 143:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/56\">",
"      Yen TW, Wang TS, Doffek KM, et al. Reoperative parathyroidectomy: an algorithm for imaging and monitoring of intraoperative parathyroid hormone levels that results in a successful focused approach. Surgery 2008; 144:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/57\">",
"      Carty SE, Worsey J, Virji MA, et al. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery 1997; 122:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/58\">",
"      Arici C, Cheah WK, Ituarte PH, et al. Can localization studies be used to direct focused parathyroid operations? Surgery 2001; 129:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/59\">",
"      Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002; 235:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/60\">",
"      Ryan JA Jr, Eisenberg B, Pado KM, Lee F. Efficacy of selective unilateral exploration in hyperparathyroidism based on localization tests. Arch Surg 1997; 132:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/61\">",
"      Martin RC 2nd, Greenwell D, Flynn MB. Initial neck exploration for untreated hyperparathyroidism. Am Surg 2000; 66:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/62\">",
"      Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery 1994; 116:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/63\">",
"      Wang CA. Parathyroid re-exploration. A clinical and pathological study of 112 cases. Ann Surg 1977; 186:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/64\">",
"      Lange, JR, Norton, JA. Surgery for persistent or recurrent primary hyperparathyroidism. Curr Pract Surg 1992; 4:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/65\">",
"      Henry JF. Reoperation for primary hyperparathyroidism: tips and tricks. Langenbecks Arch Surg 2010; 395:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/66\">",
"      Caron NR, Sturgeon C, Clark OH. Persistent and recurrent hyperparathyroidism. Curr Treat Options Oncol 2004; 5:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/67\">",
"      Udelsman R, Donovan PI. Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann Surg 2006; 244:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/68\">",
"      Levin KE, Gooding GA, Okerlund M, et al. Localizing studies in patients with persistent or recurrent hyperparathyroidism. Surgery 1987; 102:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/69\">",
"      Miller DL, Doppman JL, Krudy AG, et al. Localization of parathyroid adenomas in patients who have undergone surgery. Part II. Invasive procedures. Radiology 1987; 162:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/70\">",
"      Pallotta JA, Sacks BA, Moller DE, Eisenberg H. Arteriographic ablation of cervical parathyroid adenomas. J Clin Endocrinol Metab 1989; 69:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/71\">",
"      Alexander HR Jr, Chen CC, Shawker T, et al. Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/72\">",
"      Yip L, Ogilvie JB, Challinor SM, et al. Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. Surgery 2008; 144:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/73\">",
"      Mitchell BK, Kinder BK, Cornelius E, Stewart AF. Primary hyperparathyroidism: preoperative localization using technetium-sestamibi scanning. J Clin Endocrinol Metab 1995; 80:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/74\">",
"      Summers GW. Parathyroid exploration. A review of 125 cases. Arch Otolaryngol Head Neck Surg 1991; 117:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/75\">",
"      Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87:5353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/76\">",
"      Sosa JA, Powe NR, Levine MA, et al. Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab 1998; 83:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/77\">",
"      Russell CF, Edis AJ. Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient. Br J Surg 1982; 69:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/78\">",
"      Schell SR, Dudley NE. Clinical outcomes and fiscal consequences of bilateral neck exploration for primary idiopathic hyperparathyroidism without preoperative radionuclide imaging or minimally invasive techniques. Surgery 2003; 133:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/79\">",
"      Thompson NW. Localization studies in patients with primary hyperparathyroidism. Br J Surg 1988; 75:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/80\">",
"      Perrier ND, Edeiken B, Nunez R, et al. A novel nomenclature to classify parathyroid adenomas. World J Surg 2009; 33:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18377/abstract/81\">",
"      Silberfein EJ, Bao R, Lopez A, et al. Reoperative parathyroidectomy: location of missed glands based on a contemporary nomenclature system. Arch Surg 2010; 145:1065.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2069 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18377=[""].join("\n");
var outline_f17_60_18377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMAGING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2890373\">",
"      Sestamibi scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H257607\">",
"      - SPECT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H257614\">",
"      - SPECT and CT fusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6957677\">",
"      - Subtraction thyroid scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1267381\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6958652\">",
"      Four dimensional computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2891789\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4090120\">",
"      Positron emission tomography and CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2891782\">",
"      Invasive localization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6958819\">",
"      - Selective venous sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6958878\">",
"      - Selective arteriography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709617\">",
"      NEGATIVE IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2892141\">",
"      ROLE OF PREOPERATIVE LOCALIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Minimally invasive and unilateral parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reoperation for recurrent or persistent hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H329961\">",
"      Bilateral neck exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6958973\">",
"      STANDARDIZED NOMENCLATURE FOR ADENOMA LOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2069|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/20/1347\" title=\"diagnostic image 1\">",
"      MIBI SPECT images of parathyroid adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/26/32165\" title=\"diagnostic image 2\">",
"      Ultrasound of parathyroid adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/14/27879\" title=\"diagnostic image 3\">",
"      Sonographic characteristics of parathyroid adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/0/3073\" title=\"diagnostic image 4\">",
"      CT scan ectopic parathyroid adenoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2069|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/18/13614\" title=\"figure 1\">",
"      Algorithm for reoperation for primary hyperparathyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_60_18378="Management of childhood obesity in the primary care setting";
var content_f17_60_18378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of childhood obesity in the primary care setting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18378/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18378/contributors\">",
"     Joseph A Skelton, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18378/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18378/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18378/contributors\">",
"     Martin I Lorin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18378/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/60/18378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/60/18378/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/60/18378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11301228\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of mechanisms participate in weight regulation and the development of obesity in children, including genetics, developmental influences (&ldquo;metabolic programming&rdquo;, or epigenetics), and environmental factors. The relative importance of each of these mechanisms is the subject of ongoing research and probably varies considerably between individuals and populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H6#H6\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link\">",
"     \"Etiology and natural history of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these potential mechanisms, only environmental factors are potentially modifiable during infancy and childhood. Therefore, prevention and treatment of overweight and obesity in children in the primary care setting focuses on modifying behaviors that lead to excessive energy intake and insufficient energy expenditure. Experts who focus on cardiovascular health (rather than obesity per se) recommend very similar health behaviors, with a slightly different perspective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=see_link\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    This topic review will address interventions to prevent and treat childhood obesity in the primary care setting. The definitions, epidemiology, and comorbidities of childhood obesity are discussed in separate topic reviews. Surgical treatment of severe obesity in adolescents also is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16122?source=see_link\">",
"     \"Surgical management of severe obesity in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301285\">",
"    <span class=\"h1\">",
"     GUIDING PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few long-term randomized trials are available to determine which techniques to prevent or treat obesity are effective. Moreover, several of the techniques that have been addressed in clinical trials may not be practical for use in a clinical setting. Nonetheless, a number of approaches are recommended by expert consensus, based on clinical experience, inferences drawn from observing obesity-associated behaviors, and short-term evidence-based trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for primary care providers center on:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal measurement of body mass index (BMI) and plotting of results on a BMI chart to track changes over time",
"     </li>",
"     <li>",
"      Routine assessment of all children for obesity-related risk factors, to allow for early intervention",
"     </li>",
"     <li>",
"      Routine brief clinical interventions by the primary care provider, which include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Messages of obesity-focused education to all children and families",
"     </li>",
"     <li>",
"      Family-centered communication and interventions, rather than those focused on the child alone",
"     </li>",
"     <li>",
"      Emphasis on long-term changes in behaviors that are related to obesity risk, rather than relying on diets and exercise prescriptions, which tend to set short-term goals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Implementing a staged approach to weight management, to address obesity at different ages and levels of severity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8569783\">",
"    <span class=\"h2\">",
"     Staged approach to weight management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"    </strong>",
"    American Academy of Pediatrics (AAP) suggests a staged approach to pediatric weight management [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/4\">",
"     4",
"    </a>",
"    ]. A child&rsquo;s initial stage of treatment is determined by multiple factors, including the child&rsquo;s age, BMI percentile, and previous weight management history in other stages of treatment. The recommendations stipulate that all patients should receive counseling on obesity prevention, regardless of their BMI percentile, at each well-child visit. Additional intervention to address overweight or obesity is divided into stages representing escalating degrees of supervision, counseling, and intervention. An overview of care location, providers, and nutrition goals are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef54846 \" href=\"UTD.htm?12/51/13117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1: Prevention plus",
"     </li>",
"     <li>",
"      Stage 2: Structured weight management",
"     </li>",
"     <li>",
"      Stage 3: Comprehensive multidisciplinary evaluation",
"     </li>",
"     <li>",
"      Stage 4: Tertiary care intervention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At each treatment stage the clinician confronts a variety of barriers, which may include a lack of clinician time, knowledge and treatment skills, or lack of support services or of funding to get support services. Nonetheless, we feel that involvement of the primary care provider in the first two stages of management is both practical and important. (See",
"    <a class=\"local\" href=\"#H7827139\">",
"     'Brief clinical intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The third and fourth stages of the child&rsquo;s treatment typically require an intensive degree of care that is unlikely to be achieved in a primary care setting. For example, in adolescents with severe and refractory obesity, and particularly those with comorbidities, treatment options include weight loss surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16122?source=see_link\">",
"     \"Surgical management of severe obesity in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1807419\">",
"    <span class=\"h1\">",
"     RAISING THE SENSITIVE ISSUE OF WEIGHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most modern cultures of the developed world there is some bias against individuals with obesity, which presumes that obesity is a character flaw. Despite progress in understanding the complex origins of obesity, which include genetic, epigenetic, cultural, and environmental factors, this bias remains widespread. The bias is also present within the medical community [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/7\">",
"     7",
"    </a>",
"    ], where it often causes providers to take a blaming approach to individuals with obesity. Such an approach is rarely effective and often jeopardizes the therapeutic alliance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/8\">",
"     8",
"    </a>",
"    ]. Individuals with obesity have often absorbed the bias themselves, leading to self-criticism, low self-esteem, and hopelessness; these feelings are often barriers to behavior change.",
"   </p>",
"   <p>",
"    Because of this widespread cultural bias, many families with obesity are sensitive about discussing the issue. To form a therapeutic alliance and engage the family in addressing weight-related behaviors, the provider must carefully avoid a blaming approach. For these reasons, it is important for providers to understand and acknowledge the role of genetics and epigenetics in the development of obesity, even though their assessment and intervention will emphasize modifiable environmental factors. The genetic and epigenetic mechanisms help to explain why families of similar education and capabilities may have very different predispositions to obesity and different success in weight management. This perspective helps the provider take a supportive rather than blaming approach and also reduces provider frustration in the challenging endeavor of weight management.",
"   </p>",
"   <p>",
"    In our practice, we initiate the discussion of weight management by acknowledging that some individuals gain weight more easily than others, or are &ldquo;easy gainers.&rdquo; We then move on to say that such people may have to &ldquo;work extra-hard&rdquo; to keep a healthy body weight. This dual message avoids blaming a patient or family with obesity, while still strongly encouraging them to invest in lifestyle change. We generally use the words &ldquo;unhealthy weight&rdquo; or &ldquo;weight problem&rdquo; because these terms are perceived by parents as more motivating and less stigmatizing than the terms &ldquo;obese&rdquo; or &ldquo;fat&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also choose terms which focus on health and function, rather than appearance. For children who are already overweight or obese, we discuss the goal of &ldquo;growing into a healthy body weight,&rdquo; and being &ldquo;strong and fast.&rdquo; At least in the initial encounter, we try to avoid discussing an &ldquo;ideal weight&rdquo; for the child, both because this is a moving target for a growing child, but also because choosing a target ideal weight is often unrealistic and leads to discouragement, which tends to reduce patient adherence and chances of success. Appropriate weight goals are discussed later in this topic review. (See",
"    <a class=\"local\" href=\"#H11301668\">",
"     'Weight'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12510221\">",
"    <span class=\"h1\">",
"     THEORETICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for weight management counseling draw from framework of behavioral psychology that is outlined here. These ideas have been translated into a format that can be used for a brief clinical intervention, as described below. (See",
"    <a class=\"local\" href=\"#H7827139\">",
"     'Brief clinical intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5800378\">",
"    <span class=\"h2\">",
"     Behavioral strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simply providing patients with education on obesity related health risks, nutrition, and physical activity is insufficient to induce behavior change. Instead, nutrition and physical activity should be thought of as habitual behaviors. The best-established counseling techniques used for pediatric obesity treatment use a behavioral change model, which includes the following elements [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Self-monitoring",
"      </strong>",
"      of target behaviors (logs of food, activity, or other behaviors, recorded by patient or family). This process allows the patient and family to recognize which behaviors may be contributing to their weight gain. Clinician feedback throughout the self-monitoring process is essential to behavior change. A patient&rsquo;s food log may also identify other contributors to eating behaviors, such as meal-time environment, boredom, and level of hunger, all of which can be valuable in the evaluation of stimulus control.",
"     </li>",
"     <li>",
"      <strong>",
"       Stimulus control",
"      </strong>",
"      to reduce environmental cues that contribute to unhealthy behaviors. This includes reducing access to unhealthy behaviors (eg, removing some categories of food from the house or removing a television from the bedroom) and also efforts to establish new, healthier daily routines (such as making fruits and vegetables more accessible).",
"     </li>",
"     <li>",
"      <strong>",
"       Goal-setting",
"      </strong>",
"      for healthy behaviors rather than weight goals. Goal-setting is widely used for prompting behavior change. However, the process can be detrimental if goals are not realistic and maintainable. Appropriate goals are identified by the acronym &ldquo;SMART,&rdquo; where goals should be should",
"      <strong>",
"       S",
"      </strong>",
"      pecific,",
"      <strong>",
"       M",
"      </strong>",
"      easurable,",
"      <strong>",
"       A",
"      </strong>",
"      ttainable,",
"      <strong>",
"       R",
"      </strong>",
"      ealistic, and",
"      <strong>",
"       T",
"      </strong>",
"      imely.",
"     </li>",
"     <li>",
"      <strong>",
"       Contracting",
"      </strong>",
"      for selected nutrition or activity goals. Contracting is the explicit agreement to give a reward for the achievement of a specific goal. This helps children focus on specific behaviors and provides structure and incentives to their goal-setting process.",
"     </li>",
"     <li>",
"      <strong>",
"       Positive reinforcement",
"      </strong>",
"      of target behaviors. Positive reinforcement can be in the form of praise for healthy behaviors or in the form of rewards for achieving specific goals. The reward should be negotiated by the parent and the child, ideally facilitated by the provider to ensure that the rewards are appropriate. Rewards should be small activities or privileges that the child can participate in frequently, rather than monetary incentives or toys; food should not be used as a reward.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5800637\">",
"    <span class=\"h2\">",
"     Family-centered communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective approaches to behavior change are usually patient- or family-centered. In practice, this means that the process of behavior change should be collaborative rather than prescriptive. As an example, instead of dictating goals to the family, the clinician should engage the family in a conversation to select specific behaviors to change [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/1\">",
"     1",
"    </a>",
"    ]. The child should be directly involved in decision-making, as appropriate to his or her age. This process ensures that the family and patient have confidence that they can change a behavior and are invested in the process, which greatly enhances the chance of success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5800644\">",
"    <span class=\"h3\">",
"     Motivational interviewing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motivational interviewing is a patient-centered counseling technique that is increasingly used for obesity treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/1,4,16-18\">",
"     1,4,16-18",
"    </a>",
"    ]. Initially used for the treatment of addictions, this technique addresses a patient&rsquo;s ambivalence to change and focuses on his or her values as a means to resolve that ambivalence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/19\">",
"     19",
"    </a>",
"    ]. The clinician employs reflective listening to encourage patients to identify their own reasons for making a behavior change, as well as their own solutions. The tone of motivational interviewing is nonjudgmental, empathetic, and encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Clinicians should help the family focus on specific and achievable behavioral goals; which usually means selecting a few specific behaviors related to weight management and overall health, and not goals for weight loss itself.",
"   </p>",
"   <p>",
"    A clinical study of motivational interviewing used to treat overweight children in a primary care setting demonstrates that the technique is well accepted by parents and is effective for many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Formal assessment of a patient and family&rsquo;s motivation and self-efficacy has been successfully applied to a variety of health-related behaviors. Several approaches can be used to evaluate a patient&rsquo;s readiness to change (or stage of change) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/20\">",
"     20",
"    </a>",
"    ], including global assessment through interviewing questions, or use of a numerical or visual analog scale (eg, &ldquo;on a scale of 1 to 10, how ready are you to consider making this change [to diet or exercise]&rdquo;). This assessment may help a patient and clinician to recognize ambivalence, which is an important step in changing behaviors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5800652\">",
"    <span class=\"h2\">",
"     Scare tactics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician has a role in educating the family about the health risks associated with obesity. As an example, families may not accurately assess their child&rsquo;s weight status. In this case, it is appropriate to provide information to the family, such as reviewing the growth chart to show that the child&rsquo;s weight is in an unhealthy range and describing some of the health implications of overweight and obesity. However, the use of scare tactics (ie, conversation that emphasizes specific dire long-term risks) is not recommended. Scare tactics may garner short-term attention but are rarely effective in achieving long-term change, perhaps because most people do not think probabilistically or respond consistently to risk-based thinking [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/21\">",
"     21",
"    </a>",
"    ]. Instead, it is more effective to focus the discussion on health consequences that are less dire but more certain, such as persistence of obesity into adulthood, reduced mobility or athletic ability, and any personalized health concerns experienced by the patient and family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301293\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301301\">",
"    <span class=\"h2\">",
"     Body mass index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of body mass index (BMI) percentile for age and gender is the most practical tool for clinicians to identify and track overweight and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. A rapid increase in weight-for-height or BMI is an important predictor of future obesity even in children who are currently within a healthy weight category. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BMI percentiles are grouped into the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overweight: BMI 85",
"      <sup>",
"       th",
"      </sup>",
"      to 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"     <li>",
"      Obese: BMI &ge;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"     <li>",
"      Severe obesity: BMI &ge;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile, or &gt;120 percent of the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other methods for measuring adiposity include dual energy x-ray absorptiometry (DEXA) and air displacement plethysmography. These techniques measure fat mass directly but are too cumbersome and expensive for clinical use. Use of waist circumference and skin-fold thickness measurements is limited by discrepancies in normative data, and they are not accurate indices of body fat in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6760?source=see_link\">",
"     \"Measurement of body composition in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301333\">",
"    <span class=\"h2\">",
"     Assessment of comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the patient for comorbidities and for genetic causes of obesity is detailed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following are several tables highlighting key aspects of evaluating the obese child:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical findings to note in children with obesity, including review of linear growth (height velocity) and blood pressure (",
"      <a class=\"graphic graphic_table graphicRef73272 \" href=\"UTD.htm?6/51/6973\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Medical screening by weight category. Periodic measurement of a fasting lipid profile, hemoglobin A1c or fasting glucose level, and aminotransferase levels are suggested for children and adolescents with obesity (BMI &ge;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile), as outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef52069 \" href=\"UTD.htm?8/51/9020\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Review of systems (",
"      <a class=\"graphic graphic_table graphicRef67972 \" href=\"UTD.htm?2/53/2909\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Additional assessment may be required in selected children with symptoms or signs of weight-related comorbidities (",
"      <a class=\"graphic graphic_table graphicRef65547 \" href=\"UTD.htm?17/39/18045\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link\">",
"       \"Comorbidities and complications of obesity in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301510\">",
"    <span class=\"h2\">",
"     Nutritional assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed assessment of caloric intake is often impractical in the primary care setting, has low accuracy, and is not usually necessary to support a brief counseling intervention. Therefore, we suggest a problem-oriented approach, using a brief dietary assessment to identify a few key dietary habits which are most likely to be associated with obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301518\">",
"    <span class=\"h3\">",
"     Child&rsquo;s eating habits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child&rsquo;s eating habits can be briefly assessed by asking about the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequency of eating meals in restaurants (fast food, take-out, or service)",
"     </li>",
"     <li>",
"      Intake of calorie containing beverages (including juice and soft drinks)",
"     </li>",
"     <li>",
"      Frequency and portion size of energy-dense foods (such as cookies and other baked goods, chips, or ice cream)",
"     </li>",
"     <li>",
"      Servings of vegetables and fruits, and which of these are regularly offered and accepted. One serving equals one whole fruit, or &frac12; cup of vegetables.",
"     </li>",
"     <li>",
"      Number of meals each day, and frequency of skipping meals",
"     </li>",
"     <li>",
"      Typical snacking patterns (timing and foods consumed)",
"     </li>",
"     <li>",
"      School lunch (purchased or brought from home)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale and suggested approaches for making these inquiries are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef63820 \" href=\"UTD.htm?27/18/27950\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/1,2,4,25\">",
"     1,2,4,25",
"    </a>",
"    ]. Although this assessment is not comprehensive, it generally yields one or more appropriate targets for intervention, and is an efficient way to initiate counseling to improve nutritional status when the time available for clinical interaction is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301526\">",
"    <span class=\"h3\">",
"     Family factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity in a child&rsquo;s parents is an important predictor of the child&rsquo;s risk of persistent obesity; if both parents are obese the child&rsquo;s risk of being obese as an adult is increased 6- to 15-fold as compared with a child without obese parents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This is probably primarily due to genetic factors, but shared social and nutritional factors may also play a role. Therefore, we record the biological parents&rsquo; heights and weights, and calculate their body mass index (BMI).",
"   </p>",
"   <p>",
"    It is important to understand the child&rsquo;s nutrition patterns within the context of the family&rsquo;s nutritional patterns and finances. In our clinical evaluations, we evaluate the following aspects of family eating habits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shopping habits, including coupon use, meal planning, use of grocery list, food label reading, and purchasing habits for dairy (full-fat versus reduced-fat milk) and grains (white, wheat, whole grain)",
"     </li>",
"     <li>",
"      Frequency of family meals and who is present at meals",
"     </li>",
"     <li>",
"      Whether foods are served &ldquo;family style&rdquo; (self-serve) or served by parent or caregiver before bringing to the table",
"     </li>",
"     <li>",
"      Caregiver duties and communication regarding food (eg, who does shopping and who does cooking, whether food selection is discussed among family members, and whether meals are eaten together as a family)",
"     </li>",
"     <li>",
"      How child spends time after school, and who supervises this time",
"     </li>",
"     <li>",
"      Work schedules of parents or other caregivers",
"     </li>",
"     <li>",
"      Meal location (eg, at dining table, in bedroom, or on",
"      <span class=\"nowrap\">",
"       couch/",
"      </span>",
"      in living room) and emotional climate (especially arguments about food)",
"     </li>",
"     <li>",
"      Whether television or other media is used during meals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415354\">",
"    <span class=\"h3\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, economic or cultural factors may limit a family&rsquo;s ability or willingness to make changes in diet or physical activity. These obstacles can be addressed using a family-centered approach to counseling, in which families decide when to begin the change process and the intensity with which they are willing to pursue weight management. To initiate the discussion, the following factors should be assessed in selected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Economic challenges &ndash; Ask about food insecurity (do you sometimes run out of money for food?), about the family&rsquo;s living conditions (whether there is a working stove",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refrigerator), and the availability of income assistance such as food stamps.",
"     </li>",
"     <li>",
"      Cultural factors &ndash; Ask the parents and child what they think of the child&rsquo;s weight. Misperception of the child&rsquo;s weight status, such as a cultural preference for overweight in children, may affect a family&rsquo;s ability to effectively address the problem. Conversely, excessive anxiety about the child&rsquo;s weight status also can interfere with effective management. To address this issue, it is important to explore reasons for the anxiety in the parent or child. Reasons for excessive anxiety may include an overestimate of the child&rsquo;s risk for future obesity or a personal history of disordered eating in the parent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301562\">",
"    <span class=\"h2\">",
"     Activity assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the nutritional assessment of children, we suggest that clinicians do a brief qualitative assessment of physical activity and sedentary activity patterns in children. Both sedentary and active behaviors (structured and unstructured) should be assessed as outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef75838 \" href=\"UTD.htm?28/21/29019\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, assessment of the following social and environmental factors often helps to identify barriers to activity and opportunities for increasing physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Home &ndash; Television in bedroom [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/30\">",
"       30",
"      </a>",
"      ]; family physical activity routines [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/31\">",
"       31",
"      </a>",
"      ]; access to and frequency of free play [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]; access to and frequency of organized sports [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      School &ndash; Physical education classes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]; affordability of activities [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]; safety concerns [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lifestyle activity &ndash; Current habits that require walking or use of stairs [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combining a clinical assessment of baseline activity levels with the barriers to increased activity will provide the clinician with a basis with which to begin behavior changes. Reducing sedentary activities is a particularly important target for intervention and should be incorporated into any clinical approaches to obesity treatment and prevention.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H11301699\">",
"     'Sedentary activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7827786\">",
"    <span class=\"h1\">",
"     GOALS FOR WEIGHT MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301668\">",
"    <span class=\"h2\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;We find that discussion of specific weight loss targets with the patient and family is not usually helpful and sometimes causes the patient to become discouraged and to withdraw from weight control efforts. Instead of weight loss goals, we prefer to emphasize behavior goals for specific dietary habits and activities during discussions with the patient and family. Nonetheless, it is appropriate for the provider to keep weight targets in mind to ensure that a patient&rsquo;s weight trend is safe and realistic.",
"   </p>",
"   <p>",
"    Weight loss goals are a function of a patient&rsquo;s age and degree of overweight or obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/1,4,6\">",
"     1,4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children and adolescents who are overweight or mildly obese, the goal of maintaining current body weight is appropriate, because this will lead to a decrease in BMI as the child grows taller. If the child is in a phase of rapid linear growth, merely slowing weight gain is more realistic and often improves weight status.",
"     </li>",
"     <li>",
"      At higher degrees of obesity (BMI substantially above the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile, ie, at the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile), gradual weight loss is safe and appropriate, depending on the child&rsquo;s age and degree of obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children between two and eleven years old with obesity and comorbidities, a weight loss of up to one pound per month is safe and beneficial but may be difficult to achieve.",
"     </li>",
"     <li>",
"      For adolescents with obesity and comorbidities, it is safe to lose up to two pounds per week, although a weight loss of one to two pounds per month usually is more realistic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301683\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few clinical trials have evaluated structured dietary interventions for children with obesity, and even fewer have attempted to control for complex nutritional behaviors and the",
"    <span class=\"nowrap\">",
"     family/home",
"    </span>",
"    environment.",
"   </p>",
"   <p>",
"    As an example, a few clinical trials have shown modest efficacy of a glycemic index diet, which focuses on reducing those specific types of carbohydrates which produce a strong glycemic response (rise in blood sugar) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, overall findings from glycemic index research have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In addition, this type of highly structured diet is usually difficult to implement and sustain, so the results of a clinical study may not be generalizable to general clinical practice or to long-term outcomes. Diets that are low in carbohydrates are usually relatively low in glycemic index and may be simpler to teach and easier for patients to sustain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Unfortunately, these and other highly structured diets have poor adherence rates over long periods of time.",
"   </p>",
"   <p>",
"    Some semi-structured approaches to pediatric obesity treatment have been promising, particularly those which focus on encouraging families to select food groups of higher nutrient quality and lower energy-density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/10,43\">",
"     10,43",
"    </a>",
"    ]. As an example, clinicians can use the &ldquo;traffic light&rdquo; format as a teaching tool, grouping foods based on their nutrient quality and calorie density, and then explaining which foods should be eaten most often (red: eat rarely; yellow: eat less often; green: eat more often).",
"   </p>",
"   <p>",
"    For these reasons, we and others suggest that health care providers use semi-structured dietary goals, seeking long-term improvement in the quality and quantity of the fats and carbohydrates their patients consume. These goals are most likely to be achieved by focusing on eating behaviors, rather than by prescribing a specific structured diet. The following table outlines our approaches to common diet-related problems encountered in children (",
"    <a class=\"graphic graphic_table graphicRef80182 \" href=\"UTD.htm?0/47/766\">",
"     table 8",
"    </a>",
"    ). A dietitian can be helpful in providing this type of counseling, particularly if the emphasis and content are coordinated with and consistent with that of the primary care provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301691\">",
"    <span class=\"h2\">",
"     Activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling to improve physical activity should focus on reducing sedentary activities as well as increasing physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301699\">",
"    <span class=\"h3\">",
"     Sedentary activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence supports the importance of reducing sedentary activity as a means of preventing and treating obesity in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/3,44-46\">",
"     3,44-46",
"    </a>",
"    ]. Indeed, reducing sedentary activity may be more effective than increasing structured physical activity, perhaps because reducing sedentary activity has the secondary benefit of reducing caloric intake [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/45,47\">",
"     45,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries, sedentary activity is usually in the form of &ldquo;screen time&rdquo;: television, video games, internet and computer, and other media. According to national surveys in the United States, children between 8 and 18 years spend an average of",
"    <span class=\"nowrap\">",
"     7-1/2",
"    </span>",
"    hours daily viewing media, and those under age six spent nearly two hours daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/48\">",
"     48",
"    </a>",
"    ]. Television viewing is perhaps the best established environmental influence on the development of obesity during childhood. The association between obesity and use of other media is somewhat weaker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Environmental factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We and others recommend that television viewing and other &ldquo;screen time&rdquo; (other than homework) to be limited to less than two hours a day, and that children under age two avoid television altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/4,49\">",
"     4,49",
"    </a>",
"    ]. Because many children initially will be viewing substantially more than this target, the first step should be in decreasing their present amount. School-wide campaigns and messages [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/44\">",
"     44",
"    </a>",
"    ], and behavioral interventions using reinforcement and reward strategies have been effective in reducing television use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavioral treatment strategies, detailed above, such as self-monitoring, can be useful. Children and families should first monitor their present amount of media use and then set goals to decrease it. We ask families to set firm and consistent media limits for all family members including parents. Consistent with the policy statement from the American Academy of Pediatrics, we strongly encourage families to include all or most of the following components in their media rules [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No television set in child&rsquo;s bedroom",
"     </li>",
"     <li>",
"      No television viewing during meals",
"     </li>",
"     <li>",
"      Maximum time for television and media viewing (eg, no more than two hours daily, or some strategy that approximates that limit)",
"     </li>",
"     <li>",
"      No media viewing for children under two years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Substituting healthier behaviors and entertainment is helpful in achieving these goals. For younger children, this is through the use of &ldquo;active games&rdquo; such as tag, hula hooping, and obstacle courses. Quiet non-media activities such as reading aloud or playing board games are also acceptable substitutes, because they avoid television advertising and establish patterns of family interaction that may ultimately lead to active play. Taking activity breaks during television commercials both reduces exposure to advertising and establishes specific windows for activity; the average hour of television features approximately 20 minutes of commercials, and half of the advertisements are for food.",
"   </p>",
"   <p>",
"    Strategies to reduce media use for older children are more variable and are best addressed through a combination of self-monitoring, establishment of family media limits, and negotiation to identify substitute activities. Because both media and homework are often accessed through the computer, it can be difficult for a parent to monitor a child&rsquo;s actual media use. For these and other reasons, engagement of the child in the behavior-change process is essential, using the behavioral strategies outlined above. (See",
"    <a class=\"local\" href=\"#H12510221\">",
"     'Theoretical background'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301707\">",
"    <span class=\"h3\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite some discrepancy in study outcomes of increasing physical activity as a means to lower BMI, increasing child and family levels of physical activity is a key focus in obesity treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/46\">",
"     46",
"    </a>",
"    ]. It is generally recommended that children and adolescents participate in 60 minutes or more of physical activity a day [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/35,50,51\">",
"     35,50,51",
"    </a>",
"    ]; the American Academy of Pediatrics recommends at least 30 minutes of structured physical activity during the school day [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with nutrition goals, strategies for increasing physical activity are individualized. Clinicians should take into account the developmental stage of the child, family schedule, and personal preferences for activity, while being mindful of sedentary activity. Clinicians can support the change process by consistently advising patients and families to be physically active, suggesting options and encouraging goal-setting. In addition, clinicians can provide support for physical activity in the community by forming partnerships with local fitness centers and schools.",
"   </p>",
"   <p>",
"    To increase physical activity in children it is often helpful to consider a variety of options. Structured physical activity (organized sports or performance arts) may be team-based or individual, and competitive or non-competitive. Less structured activity includes recreational sports with peers or family, self-directed physical training, and lifestyle activity. Although these categories overlap, consideration of each allows for an expanded and diverse view of a child and family&rsquo;s opportunities for physical activity.",
"   </p>",
"   <p>",
"    For preschool-aged children, most physical activity will be unstructured; outdoor play is particularly helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/52\">",
"     52",
"    </a>",
"    ]. Providers can encourage physical activity in this age group by &ldquo;prescribing&rdquo; playground time and providing a list of local resources (playgrounds or other opportunities for active play), in addition to discouraging sedentary time (television use). The provider can also encourage parents to consider physical activity levels when they make choices among options for daycare and after-school programs.",
"   </p>",
"   <p>",
"    For older children, we prefer to encourage structured physical activity when possible (ie, participation in team or individual sports, or supervised exercise sessions). Patients are more likely to participate consistently in these activities because they are accountable to a coach or leader. However, whether a child is willing to engage in structured activities varies, particularly for adolescents. Some adolescents will enjoy engaging in sports or fitness centers, while others may not, due to lack of self-confidence or self-esteem. Directly engaging adolescents in choosing activities to replace sedentary time is helpful. We have found that a persistent trial-and-error approach often results in discovering activities that they enjoy.",
"   </p>",
"   <p>",
"    Non-competitive active games and lifestyle activities may be more appealing to some children, particularly those with more severe obesity. These activities provide moderate levels of physical activity, while also replacing sedentary time. Activities to consider are: a walking program (boosted by use of a pedometer or walking partner), trial memberships at local gyms (we find local fitness centers often provide trial memberships or passes to interested children and families), home fitness videos, and non-traditional sports such as yoga, tai chi, fencing, and martial arts.",
"   </p>",
"   <p>",
"    If a patient chooses to focus his or her activity on walking, we encourage them to use a pedometer to measure the number of steps that they take; we find that this improves motivation (at least initially) and accountability, and allows the patient to track progress. Typical goals in adults are to walk more than 10,000 steps a day to improve health. Step counts vary markedly among children, so the best strategy is to measure current step counts using the pedometer and then set a goal of increasing the number of steps by approximately 10 percent. Subsequent goal setting can be modified based on the patient&rsquo;s weight and other activities. A variety of devices are available (relative performance and costs are reviewed at",
"    <a class=\"external\" href=\"file://www.pedometers.com/\">",
"     www.pedometers.com",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Electronic gaming systems are now programmed to increase physical activity through interactive control devices, such as the Nintendo Wii&trade;. There is scant research but great interest in these systems to increase the physical activity level in children, and some have been used in school-based approaches. In general, the activity levels achieved while playing these games is modest, but certainly higher than sedentary activities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H9#H9\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Video games'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7827139\">",
"    <span class=\"h1\">",
"     BRIEF CLINICAL INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in the initial stages of obesity treatment (stages 1 and 2 above), we suggest that the provider of primary care perform a brief clinical intervention, using the behavioral strategies, nutritional goals, and exercise goals outlined above and summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef54846 \" href=\"UTD.htm?12/51/13117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Problems identified during the brief assessment are addressed in a brief problem-solving discussion. Even if many problems of lifestyle habits are identified, we suggest limiting the counseling to two or three problems that the family can agree are solvable. Other issues can be addressed in future sessions as needed. Consistent with the theoretical principles outlined above, the intervention should be focused on modifying lifestyle habits of the entire family, rather than focused exclusively on the identified child [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. In addition, the intervention should be tailored to the family&rsquo;s level of readiness (stage of change), and the tone of the interview should be nonjudgmental, empathetic, and encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/16\">",
"     16",
"    </a>",
"    ]. A guide to using these concepts for a",
"    <a class=\"external\" href=\"file://www.5210kitsap.net/healthcare/files/10-H-4-Time-Dependent-Office-Visit-Well-Child-Under-3-minutes-Tab-4.pdf\">",
"     brief clinical intervention",
"    </a>",
"    is available from the Maine Youth Overweight Collaborative [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12510221\">",
"     'Theoretical background'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The counseling session can be very brief (eg, three to five minutes) and use preprinted handouts. This brief format recognizes the time constraints that are usually present in the primary care setting, particularly because a substantial fraction of patients in most practices are overweight or obese and will require this intervention. Additional contact time is valuable if time permits or if an allied health care provider (eg, dietitian or nurse) is available to provide counseling. (See",
"    <a class=\"local\" href=\"#H5801051\">",
"     'Intensity of intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These brief counseling sessions are repeated at each subsequent follow-up visit. To provide continuity and reinforce the message, the provider should review the same concerns at a follow-up session. If progress has been made the provider should praise the family and encourage additional work; if no progress has been made the provider should engage in further problem-solving",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    work with the family to identify other goals that seem more achievable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4699424\">",
"    <span class=\"h2\">",
"     Early intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging evidence suggests that intervention during early- or mid-childhood can be effective. Although it is very difficult to directly compare the efficacy of interventions across different age groups through clinical studies, indirect comparisons suggest that early intervention may be more effective than intervention during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. If so, this advantage may be attributable to increased involvement of the family with younger age groups or to metabolic programming. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H14#H14\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Metabolic programming'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following studies illustrate the efficacy of early intervention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial in overweight or obese pre-school aged children in the United States consisted of 10 hours of group meetings over six months, supplemented by eight phone calls from a health &ldquo;coach&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/57\">",
"       57",
"      </a>",
"      ]. At the end of the intervention, significant effects were seen on child and parent body mass index (BMI).",
"     </li>",
"     <li>",
"      A randomized trial in overweight or obese pre-school aged children in the Netherlands consisted of 27 hours of provider contact over four months, including nutritional advice, supervised physical activity, and parent training [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/58\">",
"       58",
"      </a>",
"      ]. At the end of the four-month program, there were significant decreases in child BMI and in other anthropometric measures as compared with baseline and a &ldquo;usual care&rdquo; control group. Most of the improvements were sustained at 12 months follow-up.",
"     </li>",
"     <li>",
"      An observational study in Sweden evaluated predictors of success for a behaviorally based three-year treatment program for 643 children 6 to 16 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. Among participants with severe obesity, 58 percent of the younger children (six to nine years) experienced a clinically significant reduction in BMI Z-score (-0.5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      as compared with only 2 percent of adolescents (14 to 16 years). Among participants with moderate obesity, younger children also were more likely to be successful than older children.",
"     </li>",
"     <li>",
"      Several studies of lower-intensity interventions in young children report improvements in weight-related habits, such as television viewing, but did not achieve statistically significant improvements in BMI outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence base in this age group is still small, and the optimal type and timing of intervention remain unclear. Nonetheless, these findings call for further exploration of early interventions to prevent and treat obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/46,63\">",
"     46,63",
"    </a>",
"    ]. Research has not determined optimal intervention approaches based on child age groups, though it is believed that children should be increasingly included in the counseling dialogue and should be given autonomy in treatment decisions as they mature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5801051\">",
"    <span class=\"h2\">",
"     Intensity of intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most available data suggests that substantial hours of provider contact are necessary to improve a child&rsquo;s weight status. As an example, a systematic review concluded that behavioral interventions of moderate or high intensity (defined as 26 to 75 hours or &gt;75 hours of provider contact, respectively) are effective in achieving short-term (up to 12 months) weight improvements in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/5,18,64\">",
"     5,18,64",
"    </a>",
"    ]. Unfortunately, interventions at this level of intensity are usually impractical for use in a primary care setting, unless ample services from dietitians or other specialized counselors are readily available and funded.",
"   </p>",
"   <p>",
"    Low-intensity interventions (less than 25 hours of provider contact) are feasible in a primary care setting and are recommended by expert panels, although the evidence base to support this recommendation currently is weak. Clinical trials suggest that these low-intensity interventions for treatment of childhood obesity have weak or inconsistent effects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/5,65\">",
"     5,65",
"    </a>",
"    ]. It is likely that low-intensity interventions may have important effects on obesity and health behaviors in individual patients, even if they have little or no measureable effect on the study population as a whole. Moreover, meta-analyses suggest that lifestyle interventions to prevent and treat obesity in children are generally effective, even if some of the included studies are too small to show statistically significant changes in weight status [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/46,66\">",
"     46,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Environmental factors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Therefore, we and others recommend that providers of primary care consistently provide counseling to all patients to support healthy eating and activity behaviors in an effort to prevent obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, we recommend that providers engage in brief counseling interventions for their patients with obesity or those with significant risk factors for developing obesity (such as parental obesity) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who do not respond to a brief clinical intervention or for those with severe obesity, higher-intensity approaches are needed. These interventions are implemented in stages, and usually require referral to a dietitian or behavioral counselor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to specialized weight management programs or tertiary care centers. (See",
"    <a class=\"local\" href=\"#H8569783\">",
"     'Staged approach to weight management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415471\">",
"    <span class=\"h2\">",
"     Example and materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several groups have developed messaging to support this type of brief clinical intervention as outlined above. Materials to support patient education and practice process improvement are available at each of the following websites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.letsgo.org/\">",
"       5210 Let&rsquo;s go",
"      </a>",
"      (Maine Youth Overweight Collaborative)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nichq.org/childhood_obesity/index.html\">",
"       National Initiative for Children&rsquo;s Healthcare quality",
"      </a>",
"      (NICHQ)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.myeatsmartmovemore.com/SimpleTips.html\">",
"       Eat smart move more",
"      </a>",
"      (North Carolina)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www2.aap.org/obesity/index.html\">",
"       American Academy of Pediatrics",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These models have much in common and have not been directly compared. It is reasonable for providers to select materials with messaging that is best suited to their community.",
"   </p>",
"   <p>",
"    The Maine Youth Overweight Collaborative provides an example of a coordinated intervention that has been implemented in primary care practices across the state of Maine, using common approaches and messaging. The",
"    <a class=\"external\" href=\"file://www.letsgo.org/programs/healthcare/toolkits/\">",
"     Healthcare toolkit",
"    </a>",
"    includes extensive materials for patient education and improvement of practice processes, and is available to download free of charge or can be ordered in hard copy from the website. Some of these materials are translated into different languages. The program specifically seeks to evaluate outcomes using both qualitative and quantitative data. Initial analyses suggest substantial increases in clinician support for several obesity-related interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/67\">",
"     67",
"    </a>",
"    ]. The office-based initiative is closely integrated with initiatives in schools, after-school programs, and communities, and supported by community partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301723\">",
"    <span class=\"h1\">",
"     OFFICE SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing an effective and efficient approach to prevention and management of obesity in the primary care setting generally requires systems-level changes, including practice processes, training of staff and colleagues, and negotiating insurance reimbursement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/2,25\">",
"     2,25",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11301731\">",
"    <span class=\"h2\">",
"     Practice processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important practice process is to establish regular, accurate, and efficient BMI screening for all patients during routine health management visits. Despite the introduction of BMI growth charts over 10 years ago, many practices are not routinely calculating and plotting BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The first step is to identify the personnel responsible for measuring heights and weights, calculating BMI, and plotting the result. The calculation and plotting can be accomplished automatically by many electronic health records. Important steps in the practice improvement process are to set a clear goal for BMI charting and to objectively assess the practice&rsquo;s performance against the goal through chart audits.",
"   </p>",
"   <p>",
"    It is also important to integrate the results of BMI screening into the clinical and educational process of the health maintenance visit. Discussion of overweight and obesity with a patient and family can be challenging but is usually well accepted if approached in a nonjudgmental way (see",
"    <a class=\"local\" href=\"#H1807419\">",
"     'Raising the sensitive issue of weight'",
"    </a>",
"    above). The following office systems may facilitate a positive and efficient discussion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Educational materials &ndash; Having educational materials readily available in the office improves efficiency and communication. In our practice we have posters with health related messages on the wall of each clinic room alongside related educational handouts. The clinician can use the poster as a talking point in screening health behaviors. The proximity of the materials and displayed poster allow for efficient and focused discussion and also allows families to select materials that capture their interest.",
"     </li>",
"     <li>",
"      Community resources &ndash; To assist families in developing an action plan, the practice can collect and distribute information about resources in the local community, including options for physical activity, active after-school programs, nutrition counseling services, and sources of healthy food (eg, local sources of fresh produce).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415328\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, practices should have appropriate equipment to provide medical care to patients with obesity. This includes a wide range of blood pressure cuffs (including a &ldquo;large adult&rdquo; size) to ensure accurate measurements, and high-capacity scales (ideally up to 500 or 1000 lbs). In addition, it is helpful to have office furniture that is appropriate for large patients and their families, including sturdy armless chairs and lower examination tables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8569914\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing obesity in children should be a focus of every child healthcare provider. Prevention efforts are best focused on key behaviors associated with the development of obesity (",
"    <a class=\"graphic graphic_table graphicRef63820 \" href=\"UTD.htm?27/18/27950\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75838 \" href=\"UTD.htm?28/21/29019\">",
"     table 7",
"    </a>",
"    ), although other factors including genetics undoubtedly also contribute to the risk for obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is modest evidence to suggest that modification of the following factors may help to prevent the development of obesity. These issues are discussed in more detail in the linked topic reviews.",
"   </p>",
"   <p>",
"    <strong>",
"     Maternal factors",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal weight prior to conception and weight gain during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link\">",
"       \"Weight gain and loss in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H14#H14\">",
"       \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Metabolic programming'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Breastfeeding &ndash; Breastfeeding may have a weak protective effect on the development of obesity, but probably is not a major determinant of obesity risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H18#H18\">",
"       \"Infant benefits of breastfeeding\", section on 'Obesity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Psychosocial factors",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establishing a healthy feeding relationship early in life (avoiding overly restrictive and overly permissive feeding patterns). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=see_link&amp;anchor=H24#H24\">",
"       \"Introducing solid foods and vitamin and mineral supplementation during infancy\", section on 'Feeding environment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Encouraging a family to eat meals together. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H29#H29\">",
"       \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Eating environment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Dietary goals:",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H12#H12\">",
"     \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Dietary guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limiting consumption of sugar-sweetened beverages, including juice",
"     </li>",
"     <li>",
"      Encouraging a diet with ample servings of vegetables and fruits",
"     </li>",
"     <li>",
"      Limiting eating at restaurants, particularly fast-food restaurants",
"     </li>",
"     <li>",
"      Limiting portion size (which for young children often is less than a &ldquo;serving size&rdquo; as listed on a food label)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Activity goals",
"    </strong>",
"    : (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14298?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of physical activity and strength training in children and adolescents\", section on 'Physical activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Encouraging moderate to vigorous physical activity for one or more hours daily [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limiting television and other screen time &ndash; no screen time for children under two years of age; less than two hours daily after age two [",
"      <a class=\"abstract\" href=\"UTD.htm?17/60/18378/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5799548\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity during childhood is associated with long-term health consequences and is influenced by genetic, epigenetic, behavioral, and environmental factors. Among these, only behavioral and environmental factors are modifiable during childhood, so these are the focus of clinical interventions.",
"   </p>",
"   <p>",
"    We suggest the following practices among providers of primary care to children. These suggestions are based primarily on expert opinion; some are supported by clinical studies, usually with short-term outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal measurement of body mass index (BMI) and plotting of results on a BMI chart to track changes over time. (See",
"      <a class=\"local\" href=\"#H11301301\">",
"       'Body mass index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine assessment of all children for obesity-related risk factors, to allow for early intervention. This includes recording the obesity status (BMI) of the biological parents and assessing key nutritional and physical activity habits (",
"      <a class=\"graphic graphic_table graphicRef63820 \" href=\"UTD.htm?27/18/27950\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75838 \" href=\"UTD.htm?28/21/29019\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11301510\">",
"       'Nutritional assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11301562\">",
"       'Activity assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with obesity, weight-related comorbidities should be assessed through a focused review of systems (",
"      <a class=\"graphic graphic_table graphicRef67972 \" href=\"UTD.htm?2/53/2909\">",
"       table 4",
"      </a>",
"      ), physical examination (",
"      <a class=\"graphic graphic_table graphicRef73272 \" href=\"UTD.htm?6/51/6973\">",
"       table 2",
"      </a>",
"      ), and laboratory screening (",
"      <a class=\"graphic graphic_table graphicRef52069 \" href=\"UTD.htm?8/51/9020\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11301333\">",
"       'Assessment of comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all children and their families, routine health care should include obesity-focused education. Key goals to address are the common diet-related problems encountered in children (",
"      <a class=\"graphic graphic_table graphicRef80182 \" href=\"UTD.htm?0/47/766\">",
"       table 8",
"      </a>",
"      ), set firm limits on television and other media early in the child&rsquo;s life, and establish habits of frequent physical activity. (See",
"      <a class=\"local\" href=\"#H11301683\">",
"       'Diet'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11301699\">",
"       'Sedentary activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11301707\">",
"       'Physical activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children who are overweight or obese, we suggest a series of clinical counseling interventions in the primary care setting (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Each session can be brief (3 to 15 minutes); this brief format is most practical for the primary care setting and is supported by limited clinical evidence. Additional contact time is valuable if time permits or if an allied health care provider (eg, dietitian or registered nurse) is available to provide counseling. (See",
"      <a class=\"local\" href=\"#H7827139\">",
"       'Brief clinical intervention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5801051\">",
"       'Intensity of intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Educational materials are available from a variety of sources to facilitate the counseling. These materials have much in common and have not been directly compared; it is reasonable for providers to select materials with messaging that is best suited to their community. Options include a",
"      <a class=\"external\" href=\"file://www.letsgo.org/programs/healthcare/toolkits/\">",
"       Healthcare toolkit",
"      </a>",
"      and an outline for a",
"      <a class=\"external\" href=\"file://www.5210kitsap.net/healthcare/files/10-H-4-Time-Dependent-Office-Visit-Well-Child-Under-3-minutes-Tab-4.pdf\">",
"       brief clinical intervention",
"      </a>",
"      , which is based on the principles of motivational interviewing. (See",
"      <a class=\"local\" href=\"#H415471\">",
"       'Example and materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not respond to a brief clinical intervention or for those with severe obesity, higher-intensity approaches are needed. These interventions are implemented in stages (",
"      <a class=\"graphic graphic_table graphicRef54846 \" href=\"UTD.htm?12/51/13117\">",
"       table 1",
"      </a>",
"      ) and usually require referral to specialized weight management programs or tertiary care centers. (See",
"      <a class=\"local\" href=\"#H8569783\">",
"       'Staged approach to weight management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To establish a therapeutic relationship and enhance effectiveness, the communication and interventions should be supportive rather than blaming, and family-centered, rather than focused on the child alone. Long-term changes in behaviors that are related to obesity risk should be emphasized, rather than diets and exercise prescriptions, which tend to set short-term goals. (See",
"      <a class=\"local\" href=\"#H12510221\">",
"       'Theoretical background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To be effective in managing populations with obesity, primary care offices should develop an efficient office system for calculating and tracking BMI at each visit and have a wide range of blood pressure cuffs (including a \"large adult\" size) and high-capacity scales (ideally up to 500 or 1000 lbs). It is also helpful to have office furniture that is appropriate for large patients and their families, including sturdy armless chairs and low examination tables. (See",
"      <a class=\"local\" href=\"#H11301723\">",
"       'Office systems'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/1\">",
"      Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 Suppl 4:S164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/2\">",
"      Davis MM, Gance-Cleveland B, Hassink S, et al. Recommendations for prevention of childhood obesity. Pediatrics 2007; 120 Suppl 4:S229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/3\">",
"      Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in children. Cochrane Database Syst Rev 2009; :CD001872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/4\">",
"      Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/5\">",
"      Whitlock EP, O'Connor EA, Williams SB, et al. Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF. Pediatrics 2010; 125:e396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/6\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/7\">",
"      Majdan JF. Memoirs of an obese physician. Ann Intern Med 2010; 153:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/8\">",
"      Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health 2010; 100:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/9\">",
"      Puhl RM, Peterson JL, Luedicke J. Parental perceptions of weight terminology that providers use with youth. Pediatrics 2011; 128:e786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/10\">",
"      Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year outcomes of behavioral family-based treatment for childhood obesity. Health Psychol 1994; 13:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/11\">",
"      Epstein LH, Myers MD, Raynor HA, Saelens BE. Treatment of pediatric obesity. Pediatrics 1998; 101:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/12\">",
"      Ross MM, Kolbash S, Cohen GM, Skelton JA. Multidisciplinary treatment of pediatric obesity: nutrition evaluation and management. Nutr Clin Pract 2010; 25:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/13\">",
"      De Santis-Moniaci D, Altshuler L. Comprehensive behavioral treatment of overweight and the pediatric practice. Pediatr Ann 2007; 36:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/14\">",
"      Robinson TN. Behavioural treatment of childhood and adolescent obesity. Int J Obes Relat Metab Disord 1999; 23 Suppl 2:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/15\">",
"      Faith MS, Van Horn L, Appel LJ, et al. Evaluating parents and adult caregivers as \"agents of change\" for treating obese children: evidence for parent behavior change strategies and research gaps: a scientific statement from the American Heart Association. Circulation 2012; 125:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/16\">",
"      Schwartz RP, Hamre R, Dietz WH, et al. Office-based motivational interviewing to prevent childhood obesity: a feasibility study. Arch Pediatr Adolesc Med 2007; 161:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/17\">",
"      Irby M, Kaplan S, Garner-Edwards D, et al. Motivational interviewing in a family-based pediatric obesity program: a case study. Fam Syst Health 2010; 28:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/18\">",
"      Huang JS, Barlow SE, Quiros-Tejeira RE, et al. Consensus Statement: Childhood Obesity for Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/19\">",
"      Suarez M, Mullins S. Motivational interviewing and pediatric health behavior interventions. J Dev Behav Pediatr 2008; 29:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/20\">",
"      Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 1983; 51:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/21\">",
"      Hill D, Chapman S, Donovan R. The return of scare tactics. Tob Control 1998; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/22\">",
"      Freedman DS, Wang J, Ogden CL, et al. The prediction of body fatness by BMI and skinfold thicknesses among children and adolescents. Ann Hum Biol 2007; 34:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/23\">",
"      Freedman DS, Wang J, Thornton JC, et al. Classification of body fatness by body mass index-for-age categories among children. Arch Pediatr Adolesc Med 2009; 163:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/24\">",
"      Reilly JJ. Descriptive epidemiology and health consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab 2005; 19:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/25\">",
"      Krebs NF, Himes JH, Jacobson D, et al. Assessment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S193.",
"     </a>",
"    </li>",
"    <li>",
"     Lohman TG. Anthropometric assessment of fat-free body mass. Wile-Liss, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/27\">",
"      Sarr&iacute;a A, Moreno LA, Garc&iacute;a-Llop LA, et al. Body mass index, triceps skinfold and waist circumference in screening for adiposity in male children and adolescents. Acta Paediatr 2001; 90:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/28\">",
"      Whitaker RC, Wright JA, Pepe MS, et al. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997; 337:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/29\">",
"      Rudolf M. Predicting babies' risk of obesity. Arch Dis Child 2011; 96:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/30\">",
"      Dennison BA, Erb TA, Jenkins PL. Television viewing and television in bedroom associated with overweight risk among low-income preschool children. Pediatrics 2002; 109:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/31\">",
"      Kalakanis LE, Goldfield GS, Paluch RA, Epstein LH. Parental activity as a determinant of activity level and patterns of activity in obese children. Res Q Exerc Sport 2001; 72:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/32\">",
"      Fulton JE, Garg M, Galuska DA, et al. Public health and clinical recommendations for physical activity and physical fitness: special focus on overweight youth. Sports Med 2004; 34:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/33\">",
"      Kohl HW 3rd, Hobbs KE. Development of physical activity behaviors among children and adolescents. Pediatrics 1998; 101:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/34\">",
"      Dietz WH, Robinson TN. Clinical practice. Overweight children and adolescents. N Engl J Med 2005; 352:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). School health guidelines to promote healthy eating and physical activity. MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/36\">",
"      Ludwig DS. Clinical update: the low-glycaemic-index diet. Lancet 2007; 369:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/37\">",
"      Ebbeling CB, Leidig MM, Sinclair KB, et al. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003; 157:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/38\">",
"      Lean ME, Han TS, Prvan T, et al. Weight loss with high and low carbohydrate 1200 kcal diets in free living women. Eur J Clin Nutr 1997; 51:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/39\">",
"      Ebbeling CB, Leidig MM, Sinclair KB, et al. Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr 2005; 81:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/40\">",
"      Due A, Larsen TM, Mu H, et al. Comparison of 3 ad libitum diets for weight-loss maintenance, risk of cardiovascular disease, and diabetes: a 6-mo randomized, controlled trial. Am J Clin Nutr 2008; 88:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/41\">",
"      Sondike SB, Copperman N, Jacobson MS. Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factor in overweight adolescents. J Pediatr 2003; 142:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/42\">",
"      Demol S, Yackobovitch-Gavan M, Shalitin S, et al. Low-carbohydrate (low &amp; high-fat) versus high-carbohydrate low-fat diets in the treatment of obesity in adolescents. Acta Paediatr 2009; 98:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/43\">",
"      Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based treatment for obese children. JAMA 1990; 264:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/44\">",
"      Robinson TN. Reducing children's television viewing to prevent obesity: a randomized controlled trial. JAMA 1999; 282:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/45\">",
"      Epstein LH, Valoski AM, Vara LS, et al. Effects of decreasing sedentary behavior and increasing activity on weight change in obese children. Health Psychol 1995; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/46\">",
"      Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev 2011; :CD001871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/47\">",
"      Epstein LH, Roemmich JN, Paluch RA, Raynor HA. Influence of changes in sedentary behavior on energy and macronutrient intake in youth. Am J Clin Nutr 2005; 81:361.",
"     </a>",
"    </li>",
"    <li>",
"     Generation M2: Media in the lives of 8- to 18-year olds. The Kaiser Family Foundation. Available at: file://www.kff.org/entmedia/mh012010pkg.cfm. (Accessed on January 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/49\">",
"      Strasburger VC, American Academy of Pediatrics. Council on Communications and Media. Policy statement--children, adolescents, substance abuse, and the media. Pediatrics 2010; 126:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/50\">",
"      Physical fitness and activity in schools. American Academy of Pediatrics. Pediatrics 2000; 105:1156.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Agriculture, Center for Nutrition Policy and Promotion: Dietary guidelines for Americans, 2010. Available at: file://www.cnpp.usda.gov/dietaryguidelines.htm (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/52\">",
"      Burdette HL, Whitaker RC, Daniels SR. Parental report of outdoor playtime as a measure of physical activity in preschool-aged children. Arch Pediatr Adolesc Med 2004; 158:353.",
"     </a>",
"    </li>",
"    <li>",
"     Maine Youth Overweight Collaborative \"5210 Let's Go\" website. Available at: file://www.letsgo.org/resources/Healthcare_Professionals_Toolkit.php?id=greenHealth&amp;vid=v8 (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/54\">",
"      Reinehr T, Kleber M, Lass N, Toschke AM. Body mass index patterns over 5 y in obese children motivated to participate in a 1-y lifestyle intervention: age as a predictor of long-term success. Am J Clin Nutr 2010; 91:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/55\">",
"      de Silva-Sanigorski AM, Bell AC, Kremer P, et al. Reducing obesity in early childhood: results from Romp &amp; Chomp, an Australian community-wide intervention program. Am J Clin Nutr 2010; 91:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/56\">",
"      Baidal JA, Taveras EM. Childhood obesity: shifting the focus to early prevention. Arch Pediatr Adolesc Med 2012; 166:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/57\">",
"      Quattrin T, Roemmich JN, Paluch R, et al. Efficacy of family-based weight control program for preschool children in primary care. Pediatrics 2012; 130:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/58\">",
"      Bocca G, Corpeleijn E, Stolk RP, Sauer PJ. Results of a multidisciplinary treatment program in 3-year-old to 5-year-old overweight or obese children: a randomized controlled clinical trial. Arch Pediatr Adolesc Med 2012; 166:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/59\">",
"      Danielsson P, Kowalski J, Ekblom &Ouml;, Marcus C. Response of severely obese children and adolescents to behavioral treatment. Arch Pediatr Adolesc Med 2012; 166:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/60\">",
"      Danielsson P, Svensson V, Kowalski J, et al. Importance of age for 3-year continuous behavioral obesity treatment success and dropout rate. Obes Facts 2012; 5:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/61\">",
"      McCallum Z, Wake M, Gerner B, et al. Outcome data from the LEAP (Live, Eat and Play) trial: a randomized controlled trial of a primary care intervention for childhood overweight/mild obesity. Int J Obes (Lond) 2007; 31:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/62\">",
"      Taveras EM, Gortmaker SL, Hohman KH, et al. Randomized controlled trial to improve primary care to prevent and manage childhood obesity: the High Five for Kids study. Arch Pediatr Adolesc Med 2011; 165:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/63\">",
"      McGuire S. Institute of Medicine (IOM) Early Childhood Obesity Prevention Policies. Washington, DC: The National Academies Press; 2011. Adv Nutr 2012; 3:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/64\">",
"      DeBar LL, Stevens VJ, Perrin N, et al. A primary care-based, multicomponent lifestyle intervention for overweight adolescent females. Pediatrics 2012; 129:e611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/65\">",
"      Saelens BE, Sallis JF, Wilfley DE, et al. Behavioral weight control for overweight adolescents initiated in primary care. Obes Res 2002; 10:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/66\">",
"      Ho M, Garnett SP, Baur L, et al. Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis. Pediatrics 2012; 130:e1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/67\">",
"      Centers for Disease Control and Prevention (CDC). CDC grand rounds: childhood obesity in the United States. MMWR Morb Mortal Wkly Rep 2011; 60:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/68\">",
"      Klein JD, Sesselberg TS, Johnson MS, et al. Adoption of body mass index guidelines for screening and counseling in pediatric practice. Pediatrics 2010; 125:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/60/18378/abstract/69\">",
"      Sesselberg TS, Klein JD, O'Connor KG, Johnson MS. Screening and counseling for childhood obesity: results from a national survey. J Am Board Fam Med 2010; 23:334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15848 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18378=[""].join("\n");
var outline_f17_60_18378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5799548\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11301228\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11301285\">",
"      GUIDING PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8569783\">",
"      Staged approach to weight management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1807419\">",
"      RAISING THE SENSITIVE ISSUE OF WEIGHT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12510221\">",
"      THEORETICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5800378\">",
"      Behavioral strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5800637\">",
"      Family-centered communication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5800644\">",
"      - Motivational interviewing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5800652\">",
"      Scare tactics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11301293\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301301\">",
"      Body mass index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301333\">",
"      Assessment of comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301510\">",
"      Nutritional assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11301518\">",
"      - Child&rsquo;s eating habits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11301526\">",
"      - Family factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415354\">",
"      - Other considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301562\">",
"      Activity assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7827786\">",
"      GOALS FOR WEIGHT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301668\">",
"      Weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301683\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301691\">",
"      Activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11301699\">",
"      - Sedentary activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11301707\">",
"      - Physical activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7827139\">",
"      BRIEF CLINICAL INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4699424\">",
"      Early intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5801051\">",
"      Intensity of intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415471\">",
"      Example and materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11301723\">",
"      OFFICE SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11301731\">",
"      Practice processes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415328\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8569914\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5799548\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15848\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15848|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/51/13117\" title=\"table 1\">",
"      Staged treatment for childhood obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/51/6973\" title=\"table 2\">",
"      Physical findings in obese children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/51/9020\" title=\"table 3\">",
"      Medical screening by BMI category",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/53/2909\" title=\"table 4\">",
"      ROS overweight child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/39/18045\" title=\"table 5\">",
"      Assessment for weight-related comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/18/27950\" title=\"table 6\">",
"      Nutrition assessment in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/21/29019\" title=\"table 7\">",
"      Physical activity assessment in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/47/766\" title=\"table 8\">",
"      Dietary counseling tips",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=related_link\">",
"      Introducing solid foods and vitamin and mineral supplementation during infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6760?source=related_link\">",
"      Measurement of body composition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14298?source=related_link\">",
"      Overview of physical activity and strength training in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=related_link\">",
"      Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16122?source=related_link\">",
"      Surgical management of severe obesity in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_60_18379="ECG criteria for RBBB";
var content_f17_60_18379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ECG in RBBB",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        QRS duration",
"       </td>",
"       <td>",
"        &ge;0.12",
"sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Intrinsicoid deflection",
"       </td>",
"       <td>",
"        &gt;0.035 in V1 and V2 due to delayed R'",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Common pattern: Posterior mid-temporal forces",
"       </td>",
"       <td>",
"        qRS or qrS in I, V6; rsR' or qR in V1 -",
"Reflects anterior initial forces, anterior and rightward terminal forces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Atypical pattern: Anterior mid-temporal forces",
"       </td>",
"       <td>",
"        qRS, qrS, or RS in I, V6; rsR' or qR in V1 -",
"Reflects anterior mid-temporal right ventricular enlargement and left",
"anterior fascicular block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        ST-T waves",
"       </td>",
"       <td>",
"        ST depression and T inversion in right precordial",
"leads, upright in left precordial and limb leads - ST-T",
"vectors are discordant to terminal mean QRS spatial vector",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Major electrocardiographic characteristics of right bundle branch block.",
"     <span style=\"font-style:italic\">",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Willems JL, Demedina EO, Bernard R, et al. J Am Coll Cardiol 1985; 5:1261.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18379=[""].join("\n");
var outline_f17_60_18379=null;
var title_f17_60_18380="Prev CVP cath infection";
var content_f17_60_18380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of infection with central venous catheters*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement and relocation of",
"catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not routinely replace central venous catheters solely for the",
"purpose of reducing the incidence of infection (including",
"peripherally-inserted, nontunneled or tunneled catheters and",
"implantable devices).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of",
"catheter-site dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace dressing when the catheter is removed or replaced, the dressing",
"becomes damp, loosened, or soiled or inspection of the site is",
"necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace gauze dressing every two days and transparent dressings every",
"seven days on short-term catheters.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace dressing no more than once per week until the insertion site is",
"healed on long-term catheters. The necessity for dressing on",
"well-healed exit sites of long-term culled and tunneled CVC is an",
"unresolved issue.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of",
"administration sets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace administration sets, including secondary sets and add-on",
"devices, no more frequently than at 72-hour intervals, unless",
"clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace tubing used to administer blood, blood products, or lipid",
"emulsions within 24 hours of initiating the infusion.",
"        <strong>",
"         No recommendation&bull;",
"        </strong>",
"        for replacement of",
"tubing used for intermittent infusions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace tubing used to administer propofol infusions every 6 or 12",
"hours, depending on its use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hang time for",
"parenteral fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete infusion of lipids or lipid-containing parenteral nutrition",
"fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid.",
"When lipid emulsions are given alone, complete the infusion within 12",
"hours of hanging the emulsion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete infusion of blood or blood products within four hours of",
"hanging the blood.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No recommendation&bull;",
"        </strong>",
"        parenteral nutrition fluids.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes nontunneled catheters, tunneled catheters, and totally implanted devices.",
"     <br>",
"      &bull; No recommendation is made when there is insufficient data in the literature.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18380=[""].join("\n");
var outline_f17_60_18380=null;
var title_f17_60_18381="Psychodynamic defense mechanisms";
var content_f17_60_18381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F81648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F81648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psychodynamic defense mechanisms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Defense mechanisms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Primitive defenses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Splitting",
"       </td>",
"       <td>",
"        Compartmentalizing internal representations of self and others so that conflict is avoided and integration of these representations is not possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Projective identification",
"       </td>",
"       <td>",
"        A defense involving subtle interpersonal pressure so that the target of a projection takes on characteristics of either an aspect of the self or the internal object that is being projected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Projection",
"       </td>",
"       <td>",
"        Externalizing unacceptable inner impulses and their derivatives by attributing them to someone else",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Denial",
"       </td>",
"       <td>",
"        Avoiding awareness of aspects of external realities that are difficult to face by dismissing perceptions that are obvious to everyone else in the environment. What is not perceived is not real, and thus cannot cause pain. The unpleasant aspects that are denied may be replaced by a more pleasant internal fantasy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disavowal",
"       </td>",
"       <td>",
"        Dismissing or failing to acknowledge thoughts or feelings that are uncomfortable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schizoid fantasy",
"       </td>",
"       <td>",
"        Retreating into one's private, internal world to avoid anxiety about interpersonal situations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regression",
"       </td>",
"       <td>",
"        A partial or total return to earlier patterns of adaptation or behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conversion",
"       </td>",
"       <td>",
"        Development of symbolic physical symptoms and distortions involving the voluntary muscles or special sense organs; symptoms are not under voluntary control and cannot be explained by any physical disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Undoing",
"       </td>",
"       <td>",
"        Symbolically acting out in reverse something unacceptable that has already been done or against an impulse which the ego must defend itself",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Higher-level defenses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rationalization",
"       </td>",
"       <td>",
"        Justifying irrational or unacceptable behavior, motives, or feelings by making them appear rational and reasonable through belief in plausible explanations that are false",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Displacement",
"       </td>",
"       <td>",
"        Shifting unacceptable feelings associated with one idea or object to another that resembles the original in some way",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intellectualization",
"       </td>",
"       <td>",
"        Using excessive and abstract rational and logical reasoning to avoid difficult feelings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isolation of affect",
"       </td>",
"       <td>",
"        Separating an idea or impulse from its associated feeling or affect to avoid emotional turmoil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sexualization",
"       </td>",
"       <td>",
"        Endowing an object or behavior with sexual significance to turn a negative experience into an exciting and stimulating one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reaction formation",
"       </td>",
"       <td>",
"        Transforming an unacceptable wish or impulse into its opposite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sublimation",
"       </td>",
"       <td>",
"        Energy associated with unacceptable impulses or wishes is diverted into personally and socially acceptable channels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Humor",
"       </td>",
"       <td>",
"        Finding comic and/or ironic elements in difficult situations to reduce unpleasant affect and personal discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticipation",
"       </td>",
"       <td>",
"        Committing oneself to the needs of others over and above one's own needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suppression",
"       </td>",
"       <td>",
"        Consciously deciding not to attend to a particular feeling, state, or impulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Repression",
"       </td>",
"       <td>",
"        Expelling unacceptable ideas or impulses, thus blocking them from entering consciousness (repression is more closely linked with inner states, whereas denial involves external sensory data)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Gabbard, GO. Long-Term Psychodynamic Psychotherapy: a Basic Text, 2nd ed, American Psychiatric Publishing Arlington, VA 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18381=[""].join("\n");
var outline_f17_60_18381=null;
var title_f17_60_18382="Irbesartan in type 2 diabetes";
var content_f17_60_18382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Irbesartan slows progression of nephropathy in type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 309px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of irbesartan, amlodipine, and placebo on the course of hypertensive patients with nephropathy due to type 2 diabetes; the target blood pressure was similar in the three groups. Treatment with irbesartan was associated with a risk of the primary end point (doubling of the baseline serum creatinine, development of end-stage renal disease, or death from any cause) that was 20 percent lower than placebo and 23 percent lower than amlodipine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data published in: Lewis EJ, Hunsicker LG, Clarke WR, et al. N Engl J Med 2001; 345:851.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18382=[""].join("\n");
var outline_f17_60_18382=null;
var title_f17_60_18383="Esophageal adenocarcinoma retroflexed CPC";
var content_f17_60_18383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of an esophageal adenocarcinoma extending into the gastric cardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retroflexed endoscopic view of this esophageal adenocarcinoma mass extending into the gastric cardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_60_18383=[""].join("\n");
var outline_f17_60_18383=null;
